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Abstract 
Common variable immunedeficiency (CVID) is the most common symptomatic primary 
immunodeficiency. The cardinal manifestations are hypogammaglobulinaemia and 
recurrent infections. In fact, CVID is a heterogeneous cluster of disorders associated 
with not only infection but also autoimmune disease, sarcoidosis-like granulomatous 
inflammation, and neoplasia. In a minority of cases, CVID follows simple Mendelian 
inheritance, and in other cases, there is familial clustering, with CVID or autoimmunity, 
and in other cases, CVID is sporadic. The aim of this project was to investigate the 
genetic and cellular pathogenesis of cases of CVID.  
 
We established a large national cohort of patients with primary antibody deficiencies. 
First, we discovered a novel heterozygous mutation, S254R in TNFAIP3 (A20), from 
two patients with CVID and their family members. Biochemical analysis revealed that 
the S254R substitution in A20 impairs deubiquitination. Nevertheless, only one patient 
with the heterozygous (S254R) mutation in TNFAIP3 exhibited an activated NF-kB and 
apoptotic phenotype. This patient was also found to carry a mutation encoding an L307I 
substitution in TAX1BP1, an interacting partner of A20. We investigated this 
interaction and discovered biochemical evidence that TAX1BP1L307I enhances binding 
with A20S254R. Thus, the A20 phenotype is modified by a TAX1BP1 variant, consistent 
with non-allelic noncomplementation.  
 
Second, we describe three individuals with complete B cell deficiency within single 
kindred. We identified a novel heterozygous mutation in NFKB2 (encoding a D865G 
substitution) in each affected individual. Mutant p100 is poorly processed, after 
Novel NF-kB mutations in common variable immunodeficiency (CVID)  
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activation of the non-canonical NF-kB pathway with CD40L stimulation, both in vitro 
and in cells isolated from the proband. We discovered that the mutation inhibits p100 
phosphorylation. Remarkably, unprocessable p100 exhibits IkB like activity, which 
serves to sequester p65 in the cytoplasm. In other words, the immune deficiency appears 
to arise from disruption of both canonical and non-canonical NF-kB pathways.  
 
In summary we have described two novel forms of CVID, one arising from an 
autosomal dominant mutation in NFKB2, and the other resulting from a low penetrance 
mutation in TNFAIP3, where the phenotype appears to depend on epistatic interaction 
with TAX1BP1.  
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1 Introduction 
1.1 NF-kB pathway 
NF-kB was discovered by Sen and Baltimore in 1986 as an interacter with the enhancer 
of kappa light chain. Initially, it was reported that NF-kB was expressed only in the 
cells that expressed kappa light chains (Sen and Baltimore 1986) and it was therefore 
named nuclear factor kappa light chain enhance of activated B cells (NF-kB). NF-kB 
has since been identified in most cells in the immune system and plays a pivotal role in 
many aspects of immunity. NF-kB is in fact a transcription factor complex. In resting 
cells, NF-kB complexes are sequestered in cytoplasm in inactive forms by inhibitory 
proteins of NF-kB. Upon stimulation, NF-kB complexes are liberated from these 
inhibitory proteins and translocate to the nucleus where they induce gene expression. 
NF-kB was initially thought to be responsible for acute inflammation but subsequent 
work has identified many other functions of NF-kB in the immune system. NF-kB 
regulates expression of many genes including antimicrobial peptides, cytokines, 
chemokines, stress response proteins and antiapoptotic proteins. Analysis of mice 
deficient in different NF-kB family members as well as mice lacking different NF-kB 
inhibitors or IKK subunits demonstrated that proliferation, differentiation, survival and 
apoptosis of cells in immune responses as well as lymphoid organogenesis require NF-
kB. Close regulation of NF-kB appears to be crucial. Reduced NF-kB activation leads to 
immune deficiency whereas prolonged NF-kB activation leads to inflammation or 
malignancy associated with tissue damage or uncontrolled cell proliferation (Karin and 
Greten 2005).  
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The mammalian NF-kB family consists of 5 members; RELA (p65), c-REL, RELB, 
NF-kB1 (p50/p105), and NF-kB (p52/p100). Each protein contains conserved Rel-
homology domains (RHD) of approximately 300 amino acids length, and dimerization, 
nuclear-localization and DNA-binding domains (Figure 1.1). Each NF-kB protein can 
form heterodimers, and all except RELB can also form homodimers. RELA, c-REL and 
RELB contain a transcription activation domain (TAD), necessary for regulating 
transcription of target genes after binding to NF-kB binding sites in DNA (Ghosh and 
Karin 2002; Li and Verma 2002; Ruland 2011).  
 
Expression of some NF-kB subunits is confined to particular types of cells. For 
example, c-REL was reported to be restricted to haematopoietic cells and lymphocytes 
and RELB is specifically expressed in the thymus, lymph nodes and peyer’s patches. 
p52 has been reported to be found exclusively in B cells. However, p50 and p65 are 
expressed widely in various cell types (Li and Verma 2002). 
 
In order to regulate gene expression, p52 and p50 must associate with a TAD-
containing NF-kB family member or another protein capable of coactivator recruitment 
(Hayden and Ghosh 2008). Due to the lack of TAD, homodimers of p50 or p52 were 
suggested to be the suppressor of transcription (Li and Verma 2002).  
 
In resting cells, homo or heterodimer NF-kB complexes are associated with inhibitors of 
NF-kBs (IkBs) and sequestered in cytoplasm. They have 6 or 7 ankyrin repeats each 
containing a 33 amino acid motif, which mediate binding to NF-kB dimers (Figure 1.1). 
IkBs include IkBα, IkBβ, IkBƐ and BCL-3. p105 and p100, precursors of p50 and p52  
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Figure 1.1 Mammalian NF-kB and IkB family members Schematic diagram for different NF-kB 
members and IkB members are shown. Rel homology domain (RHD), transcription activation domain 
(TAD), leucine zipper motif (LZ), glycine-rich region (GRR), ankyrin repeats (ANK), nuclear 
locationzation (N) and phosphorylation site (P) are shown. 
 
respectively, also carry ankyrin repeats, therefore, they are also considered as IkB 
proteins (Li and Verma 2002). IkB maintains NF-kB proteins in the cytoplasm by 
masking nuclear localization sequences (NLSs). NLS on NF-kB subunits induces 
nuclear translocation (Ghosh and Karin 2002). Once NLS are unmasked, dimers can 
shuttle continuously between the nucleus and the cytoplasm. NF-kB dimers, with 
exposed NLS, are liberated to enter the nucleus and bind to kB sites to regulate 
transcription through the recruitment of coactivators and corepressors (Hayden and 
Ghosh 2008). A strong nuclear export signal (NES) is located at the amino terminus of 
IkBα. NF-kB complexes containing NES truncated IKBα are found in the nucleus.  
After stimulation, IKBα is degraded and therefore the NES no longer exists. As a result, 
when bound to IkBα, NF-kB-IkBa complexes are expelled from the nucleus and 
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therefore NF-kB–IkBα complexes are detected mainly in the cytoplasm (Lee and 
Hannink 2002). Various stimuli result in degradation of IkBs under the action of IkB 
kinase (Speliotes, Willer et al.) complex activation.  
 
There are two distinct NF-kB signalling pathways designated canonical (or classical) 
and non-canonical (or alternate) pathways.  
 
1.1.1 Canonical NF-kB pathway 
Canonical NF-kB pathway regulates both innate and adaptive immune responses and is 
activated rapidly in response to a wide range of stimuli such as pathogens, stress signals 
and pro-inflammatory cytokines. Receptors responsible for activating the canonical 
pathway include Tumour Necrosis Factor Receptor type 1 (TNFR1), IL-1 receptors (IL-
1R), Pattern Repeat Recognition (PRR) such as Toll-like receptors (TLR), NOD like 
receptor (NLRs) and lymphocyte receptor such as T cell receptors (TCR) and B cell 
receptors (BCR).  
 
The IkB kinase (Speliotes, Willer et al.) complex regulates the canonical pathway. IKK 
consists of two catalytically active subunits, IKKα, and IKKβ, and a regulatory subunit 
IKKγ (also known as regulatory subunit NF-kB essential modulator (NEMO)). While 
IKKα and IKKβ phosphorylate inhibitors of NF-kB such as IkBα, IkBβ and IkBƐ, IKKγ 
regulates IKK complex activation through protein-protein interaction mediated by helix-
loop-helix and leucine-zipper motifs (Vallabhapurapu and Karin 2009).  
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Analysis of Ikbkb-/- mice showed that IKKβ is a crucial regulator of the canonical NF-
kB pathway. Ikbkb deficient mice die prenatally due to TNF dependent liver apoptosis 
(Li, Chu et al. 1999). Surprisingly, NEMO deficiency is also embryonic lethal. Neither 
IKBα degradation nor NF-kB activation occurred in NEMO deficient murine embryonic 
fibroblasts (Romberg, Chamberlain et al.) even though NEMO does not have catalytic 
activity (Makris, Godfrey et al. 2000; Rudolph, Yeh et al. 2000). By contrast, after TNF 
or IL-1 stimulation, IKBα degradation and NF-kB activation was similar in IKKα-/- and 
wildtype MEF.  
 
 
Figure 1.2 Canonical NF-kB pathway. Activation of IKK complex triggers IkBα phosphorylation. 
Subsequent degradation results in rapid and transient nuclear translocation of the prototypical NF-kB 
heterodimer such as RelA/p50 
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These findings indicate that IKKα is dispensable for canonical NK-kB activation, 
although IKKα can compensate IKB kinase activity in the absence of IKKβ (Hu, Baud 
et al. 1999; Li, Chu et al. 1999). 
 
Upon stimulation, the IKK complex becomes activated and the IKK complex 
phosphorylates IkBs at phosphorylation sites (for instance, IKBα on serine 32 and 
serine 36). Then the Skp1, Cdc53/Cullin1, and F box protein (SCF) containing β 
transducin repeat containing protein (β-TrCP) E3 ubiquitin ligase complex attaches 
lysine 48-linked polyubiquitin chains to IKBα at the DSGXXS consensus sequence for 
ubiquitination. Ubiquitinated IkBs is then degraded by 26S proteosomes (Klionsky, 
Abdalla et al.). This liberates NF-kB subunits, which enter the nucleus to initiate 
transcription of NF-kB target genes (Figure 1.2).  
 
After activation by canonical NF-kB stimuli, IkBα is replenished by de novo synthesis 
of IKBα, which is positively regulated by canonical NF-kB signalling. This represents a 
negative feedback loop, which prevents prolonged NF-kB activation.  
 
1.1.1.1 A20 
Negative regulation of NF-kB regulator by A20 protein encoded by the TNFAIP3 gene 
provides another negative feedback loop. A20 was originally identified as a cytokine-
induced gene, since robust induction of A20 was seen in human umbilical vein 
endothelial cells after stimulation with the pro-inflammatory cytokine TNF (hence 
TNFα induced protein 3, TNFAIP3) (Opipari, Boguski et al. 1990). A20 was originally 
thought to protect cells from TNF-induced cytotoxicity (Opipari, Hu et al. 1992). More 
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recently, evidence has emerged that A20 is induced not only by TNF, but also by other 
stimuli including IL-1, CD40, pattern recognition receptors (PRRs), T cell receptors and 
B cell receptors (Boone 2004; Catrysse, Vereecke et al. 2014). 
 
Evidence from Tnfaip3-deficient mice suggests that the principal function of A20 is to 
terminate exaggerated NF-kB activity. A20 deficient mice died shortly after birth due to 
multi-organ inflammation and cachexia (Lee, Boone et al. 2000). Embryonic 
development appeared to be normal. Lee showed that Tnfaip3-/- mouse embryonic 
fibroblasts (Romberg, Chamberlain et al.) failed to terminate prolonged NF-kB activity 
and were hypersensitive to sublethal doses of TNF and LPS.  
 
  
Figure 1.3 Ubiquitination by stepwise ubiquitin enzymes Ubiquitin activating enzymes (E1s) activate 
ubiquitin in an ATP-Mg2+ dependent manner and form thioester linked complex between the catalytic 
cystein of the E1 and the C terminus of ubiquitin 96. Activated ubiquitin is then passed from the E1 to 
ubiquitin conjugating enzymes (E2s) by forming second thioester complex with E2 cysteine. E2s interact 
with ubiquitin ligases (E3s). E2s and E3s recruit substrates and modify substrates by addition of mono or 
poly ubiquitin chains. 
 
A20 regulates NF-kB activation by editing ubiquitination. Ubiquitination describes a 
post translational protein modification in which ubiquitin is covalently attached to a 
substrate. Ubiquitin is a 76 amino acid peptide (8.5 kDa), which contains 7 lysine 
residues (K6, K11, K27, K29, K33, K48 and K63). Mammalian ubiquitin is encoded by 
4 genes: UBA52, RPS27A, UBB and UBC.  
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Ubiquitination proceeds in three steps. E1 enzyme activates ubiquitin by adding ATP, 
E2 transfers ubiquitin to the substrate protein, and E3 ligase attaches ubiquitin to the 
substrate (Pickart 2001). Generally, the last amino acid of ubiquitin (glycine 76) binds 
to a lysine on the substrate protein. Lysine-63 (K63)-linked ubiquitination leads to a 
protein-protein interaction and consequently regulates signalling whereas K48 linked 
ubiquitination flags proteins for proteosomal degradation. This process can be reversed 
by deubiquitination (DUB).  
 
 
Figure 1.4 Schematic structure of A20 A20 consists of ovarian tumour domain (OTU) and zinc finger 
domain (ZnF). OTU domain is for deubiquitylating (DUB) activity and catalytic cysteine at position 103 
and catalytic histidine at position 256 were known to be critical for DUB activity. A20 contains. While 
ZnF domain is responsible for E3 ubiquitin ligase activity. Catalytically active ZnF4 introduce K48 linked 
ubiquitin chains to substrates. NF-kB activity through linear ubiquitin chain can be inhibited through 
ZnF7. 
  
A20 protein is encoded by the TNFAIP3 gene located at 6q23 in the human genome. 
A20 comprises 790 amino acids and weighs approximately 91KDa. A20 is an atypical 
ubiquitin enzyme (Wertz, O'Rourke et al. 2004). It contains two opposite functions: 
DUB and E3 ligase at the N- and C-termini, respectively (Shembade, Harhaj et al. 
2007). A20 can be located in either cytosol or lysosome membrane (Li, Hailey et al. 
2008). It contains an N-terminal ovarian tumour ubiquitin (OTU) domain (1-370aa) and 
seven zinc finger (ZnF) domains (371-790aa) (Hymowitz and Wertz 2010). The OTU 
domain has deubiquitylating (DUB) protease activity, which removes K63 linked 
ubiquitin chains from substrates. The A20 ZnF domain has E3 ligase function, which 
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catalyzes K48 linkage of ubiquitin chains to substrates, leading to proteasome-
dependent degradation (Shembade, Harhaj et al. 2007). DUB and E3 domains of A20 
downregulate NF-kB signalling in a two-step process. First K63- linked ubiquitin chains 
are removed from RIP1 by DUB and then E3 ligase attaches K48- linked ubiquitins to 
the same substrate (Wertz, O'Rourke et al. 2004).  
 
 
Figure 1.5 Dual functions of A20 modified from Hymowitx and Wertz (2010) Upon TNFa stimulation 
RIP1 becomes rapidly polyuniquitinated via K63 linkage. A20 then deubiquitinates substrates via OTU 
domain. RIP1 is then polyubiqutinated via K48 linkage by ZnF domain of A20. K48 linked ubiquitinated 
RIP1 is subjected to be degradated by proteosome 26S. 
 
The OTU domain contains two active sites, C103 and H256, and amino acid 
substitutions at either site impairs deubiquitination (Komander and Barford 2008). Even 
though K63 linked deubiquitinase has been demonstrated in vivo, the isolated OTU 
domain preferentially deubinquitinates proteins at K48 in vitro (Komander and Barford 
2008). This suggests that there are additional factors involved in K63 DUB activity.  
 
The seven cys2cys2
 
zinc finger domain located in the A20 C-terminal has E3 ligase 
activity. Genetic modification showed that ZnF4 is critical for K48 linked ubiquitin 
ligase catalytic activity (Wertz, O'Rourke et al. 2004). Recently, it was shown that this 
ZnF4 was also able to recognise K63 linked polyubiquitin chains (Bosanac, Wertz et al. 
A20 
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2010). In addition, recent evidence suggests that ZnF7 has ligase activity (Skaug, Chen 
et al. 2011). A20 ZnF7 was shown to inhibit TNF induced NF-kB activation through 
linear ubiquitin chain assembly complex (LUBAC). Since LUBAC is essential for IKK 
activation, this mechanism of negative regulation by A20 provides another important 
feedback loop for NF-kB activation (Tokunaga, Nishimasu et al. 2012; Verhelst, 
Carpentier et al. 2012).  
 
Recently, A20OTU and A20ZnF4 mutant mice, carrying one or two point mutations at 
active sites, were generated (Lu, Onizawa et al. 2013). These mouse models 
demonstrated that either DUB or E3 activity alone cannot account for all the functions 
of A20, since mice remained grossly normal until at least four months of age. Fibroblast 
from these mice showed decreased NF-kB signalling in response to TNF as compared to 
A20 deficient cells. Nevertheless, these mouse models demonstrated that OTU and 
ZnF4 are important motifs that regulate immune homeostasis in vivo, as mutant strains 
gradually developed splenomegaly and accumulated modestly increased numbers of 
myeloid cells and lymphocytes (Lu, Onizawa et al. 2013). 
  
1.1.1.2 A20 plays as a negative controller of NF-kB 
Canonical NF-kB signalling can be divided into three distinctive pathways according to 
their activating receptors: TNF, Toll/IL-1R (Speliotes, Willer et al.) and lymphocyte 
receptor. A20 inhibits NF-kB activation by cleaving K63 linked ubiquitin chains or 
adding K48 to substrates to block down regulation of signalling. Alternatively, A20 can 
interrupt NF-kB signalling via non catalytic mechanisms. A20 can interact with E2 
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enzymes to interrupt E2-E3 interactions which are very important for the down 
regulation of NF-kB signalling (Shembade, Ma et al. 2010).  
 
1.1.1.2.1 A20 targets canonical NF-kB pathway by TNFa 
TNF receptors 1 and 2 are expressed on a wide range of cells. TNFR1 engages with 
TNF-α and induces receptor trimerization and recruitment of the adapter protein, 
TNFR1-associated death domain protein (TRADD), to the cytoplasmic tail of the TNF 
receptor. TRAF2/5 and receptor interacting protein (RIP1) are then recruited and RIP1 
is K63 ubiquitinated by TRAF2 (Ea, Deng et al. 2006). Binding of IKKγ to K63- 
ubiquitinated RIP1 stabilizes IKK interactions with the receptor complex and triggers 
IKK activation. TRAF2-dependent polyubiquitination of RIP1 recruits transforming 
growth factor activated kinase 1 (TAK1) and its regulatory subunits TAK1-binding 
protein (TAB) 1, 2, and 3 to TNFR signalling complex. This results in TAK1 activation, 
which may phosphorylate the activation loops of the IKK catalytic subunits (Kanayama, 
Seth et al. 2004; Chen 2005). Mitogen-activated protein (MAP/extracellular signal-
regulated kinase (ERK) kinase kinase 3 (MEKK3)) is also recruited to the IKK complex 
via RIP1, and may be responsible for phophorylation of IKKα and IKKβ (Blonska, You 
et al. 2004). However, these two kinases are not unequivocally essential for IKK 
activation in immune cells. It remains possible that IKK activation is induced by 
autophosphoylation of the IKK complex through conformational change after the 
interaction between IKKγ and ubiquitinated RIP1 (Yang, Masters et al. 2001; Blonska, 
You et al. 2004; Vallabhapurapu and Karin 2009) . 
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K63-ubiquitylation is a pivotal step for IKK recruitment and consequently NF-kB 
activation. A20 cleaves the K63-linked ubiquitin chain of RIP1 to inhibit signalling and 
subsequently catalyses the K48-linked ubiquitin chain to RIPK1 to induce proteosomal 
degradation, which inhibits NF-kB activation (Wertz, O'Rourke et al. 2004). RIP1 is 
thought to be polyubiquitinated by TRAF2/5 and cIAP1/2. After TNFR ligation, A20 
interferes with the interaction between E2 ubiquitin conjugating enzyme, Ubc13, and 
both E3 ligases TRAF2/5 and cIAP1/2. A20 then catalyses K48 linked ubiquitin chain 
to Ubc13 and induces the E2 enzyme degradation (Shembade, Ma et al. 2010). 
 
Activation of the canonical NF-kB pathway is also controlled by linear ubiquitin chain 
assembly complex (LUBAC). LUBAC is composed of SHARPIN, HOIL-1 and HOIP 
and conjugates the C-terminal Gly76 of a distal ubiquitin moiety to the α-amino group 
of the N-terminal Met1 of a proximal ubiquitin moiety. NEMO and RIP1 are linearly 
ubiquitinated by LUBAC upon TNF stimulation. A20 appears to contribute to LUBAC-
mediated termination of NF-kB activation. A20 ZnF7 binds to LUBAC and dissociates 
LUBAC and NEMO to block downregulation of signaling via noncatalytic mechanism 
(Skaug, Chen et al. 2011; Tokunaga, Nishimasu et al. 2012; Verhelst, Carpentier et al. 
2012).  
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Figure 1.6 NF-kB inhibition by A20 in TNFα induced NF-kB activity Ligation of TNFR1 results in 
TRAF2/TRF5 and RIP1 recruitment in TRADD dependent manner. TRAF2 ubiquitinates RIP1 and IKK 
complex is recruited and activated. Activated IKK phosphorylate IKBα and E3 ligase ubiquitilate IKBa 
via K48 linkage. Proteosome mediated degradation of IkBα releases the NF-kB heterodimers and regulate 
gene expression. A20 deubiqutinates RIP1 and IKKr and ubiquitinate RIP1 for proteosomal degradation. 
A20 also target E2 enzymes by introducing K48 linked ubiquitin chains. 
 
1.1.1.2.2 A20 inhibits TLR and IL-1b induced NF-kB 
The cytoplasmic regions of the TLR/IL-1R family members share a common motif 
called the Toll/IL-1 receptor (Speliotes, Willer et al.) domain. TIR domain containing 
receptors lack intrinsic catalytic activity, therefore, signalling depends on recruitment of 
adaptor proteins, ubiquitin ligases, and protein kinases. Upon ligand binding, the 
conformation of TIR domain is altered, and this allows the TIR containing adaptors to 
interact with the TIR domain (Martin and Wesche 2002). Two major TIR domain 
containing adaptors are myeloid differentiation primary response 88 (MyD88) and TIR 
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domain containing adaptor-inducing IFN-β (TRIF). TIR containing adaptor proteins, 
MyD88 and TRIF, bind to the receptors either directly or via adaptors. Toll/IL-1 
receptor adaptor protein (TIRAP, also known as MAL) and TRIF-related adaptor 
molecule (TRAM) are adaptors for MyD88 and TRIP, respectively. These intermediary 
adapters are thought to be required for their physical interaction due to electrostatic 
surfaces. For example, the highly electropositive TIR domain of TLR4 requires 
electronegative TIRAP to bind highly electropositive TIR of MyD88. Mice deficient in 
any of these adaptors reveal that they are vital for recruitment of other adaptor proteins, 
and ubiquitination (Kawai and Akira 2007).  
 
Unlike other TLRs, TLR4 binds to two adaptors (MyD88 and TRIF) and their 
intermediary adaptors, TIRAP and TRAM, respectively. In the MyD88-dependent 
pathway, IRAK1, IRAK4 and TRAF6 are recruited, and MyD88 interacts with IRAKs 
via a death domain. Once IRAK1 and IRAK4 are phosphorylated, they dissociate from 
MyD88. Phosphorylated IRAK1 and IRAK4 then interact with TRAF6. TRAF6 is an 
E3 ubiquitin ligase, which polyubiquitinates itself with K63 ubiquitin chains. K63-
polyubiquitinated TRAF6, IRAK1, and IRAK4 recruit TAK1 and TAB1, TAB2, and 
TAB3. TAK1 plus TAB1, 2, and 3 are thought to be responsible for activating the IKK 
complex. In the TRIF dependent pathway, TRIF recruits TRAF6 by direct interaction, 
and TRAF6 interacts with Ubc13 and UbcH5c leading to the K63-linked 
polyubiquitination of TRAF6, and downstream TAK1 and IKK activation. RIP1 is also 
recruited by TRIF, and might cooperate with TRAF6 to facilitate TAK1 activation 
(Kawai and Akira 2007). 
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A20 inhibits NF-kB activation via TRIF pathway by preventing interactions between 
Ubc13 /UbcH5c and TRAF6. A20 DUB activity removes K63-linked ubiquitin chains 
from TRAF6 to inhibit NF-kB signaling. In addition, A20 E3 ligase activity catalyses 
K48 linked ubiquitin chain to Ubs13/ UbcH5c, which leads to their proteosomal 
degradation (Shembade, Ma et al. 2010). 
 
 
Figure 1.7 NF-kB inhibition by A20 in TLR induced NF-kB activity In TLR4 signalling NF-kB is 
activated activation via both TRIF and MyD88 dependent pathway with adaptor protein TRAM and 
TIRAP, respectively. These adoptor proteins recruit TRAF6. Either direct or indirectly with IRAK 
members, TRAF6 activates TAK1 and TAK1 directly phophorylates IKKβ to activate the IKK complex. 
A20 deubiquitinates TRAF6 to inhibit its downsignaling. E2 enzymes are targeted by A20 for 
proteosomal degration. 
 
Besides A20, other inhibitory molecules block TLR4-mediated NF-kB acvtivation. 
After LPS stimulation, de novo short MyD88 isoform (MyD88s) is generated by 
alternative splicing (Burns, Janssens et al. 2003; Janssens, Burns et al. 2003). 
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MyD88s serves as a decoy that inhibits interactions between MyD88 and TRAF6, since 
MyD88s lacks the intermediate domain essential for the interaction of MyD88 with 
IRAK4. Dissociation of this complex shuts down LPS induced NF-kB activations. 
Similarly, IRAK-M is the inactive form of IRAK and interferes with the interaction 
between IRAK and TRAF6 (Kobayashi, Hernandez et al. 2002) 
 
1.1.1.2.3 A20 inhibits TCR induced NF-kB 
 
 
Figure 1.8 NF-kB inhibition by A20 in TCR induce NF-kB activity Src and Fyn and Zap70 are 
recruited upon TCR stimulation. ZAP70 then pohsphorylates LAT and SLP-76. PLCg1 then becomes 
activated and leads to PKCc stimulation by generation of IP2, Ca2+ and DAG. PI3K becomes activated 
through TCR and CD28 signal and facilitates recruitment of PKCc to the immunological synapse. PI3K 
also phosphorylated phosphoinositides and leads to membrane recruitment of PDK1. Then PKCc 
becomes activated and recruit IKK and CARD11 into the signaling complex. Phosphorylation of CAR11 
then recruits BCL10 and MALT1 and form a stable CBM complex. This complex then activates IKK 
complex and lead to activation of NF-kB. A20 targets TRAF6 and MALT1 via DUB activity, however, 
active MALT1 can cleave A20 to terminate its inhibitory function in NF-kB activity. 
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The protein kinase C (PKC) isoform θ in T cells and β isoform in B cells link TCR and 
BCR signalling with NF-kB activation. Upon TCR stimulation, Src family kinase Lck, 
Fyn, and Syk family kinase ZAP70 are recruited and activated. Lck activates PI3K, 
which in turn activates phosphoinositol and subsequently PDK1. ZAP70 
phosphorylation also results in phosphorylation of adapter proteins LAT and SLP-76, 
which leads to assembly of a multimolecular complex containing phospholipase C 
gamma (PLCγ) and nucleotide exchange factor, Vav1. PLCγ is then activated resulting 
in production of inositol triphosphate (IP3), increased intracellular calcium 
concentration, and formation of diacylglycerol (DAG). DAG activates and translocates 
PKCθ to the immunological synapse. PKCθ recruitment to the membrane is enhanced 
by PDK1 after TCR and co-stimulation by CD28 ligation.  
 
PKCθ and PKCβ result in activation of canonical NF-kB signalling via the CARD11, 
BCL10, MALT1 (CBM) complex. Activation of CARD11 causes a conformational 
change that allows association with BCL10 and MALT1 (Schulze-Luehrmann and 
Ghosh 2006). The CBM complex then activates NF-kB via the IKK complex, although 
the precise mechanism of IKK activation in this pathway remains poorly defined. It has 
been suggested that TRAF6, an E3 ubiquitin ligase, results in K63 ubiquitylation of 
MALT1, resulting in activation of the IKK complex. The CBM complex is also thought 
to ubiquitinate IKKγ via TRAF6 and subsequently activate IKKβ (Sun, Deng et al. 
2004). A20 interacts with both MALT1 and TRAF6 to inhibit NF-kB activity by 
deubiquitylation of K63 from TRAF6 and IKKγ (Duwel, Welteke et al. 2009). 
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A20 expression is maintained at very low levels in most resting cells. A20 expression is 
induced when cells are activated by canonical NF-kB stimuli. By contrast, A20 
expression is constitutively high in lymphocytes so its NF-kB inhibitory function 
controls NF-kB activation (Duwel, Welteke et al. 2009). In order to activate NF-kB 
signalling in lymphocytes, A20 must be degraded or inactivated. In 2008, the Beyaert 
group discovered that after TCR activation, MALT1 has a specific proteolytic activity 
and mediates cleavage and inactivation of A20, optimising IKK activation (Coornaert, 
Baens et al. 2008; Rebeaud, Hailfinger et al. 2008). 
 
1.1.1.3 A20 inhibits apoptosis 
Apoptosis, or programmed cell death, is classified as either intrinsic and extrinsic. 
Intrinsic apoptosis is initiated by the apoptosome via mitochondrial signals, and leads 
ultimately to activation of caspase-9. Extrinsic apoptosis is initiated after extracellular 
signals lead to receptor-specific activation of signalling pathways involving tumour 
necrosis factor (TNF) superfamily members. Proapoptotic ligands include FasL and 
TRAIL, which ligate Fas and DR4/ DR5, respectively (Wagner, Punnoose et al. 2007). 
Fas recruits Fas-associated death domain (FADD) through homophilic interaction of 
death domains in the receptor and adaptor. FADD then recruits caspase 8 through a 
death effector domain (DED) and consequently forms a death inducing signal complex 
(DISC). DISC then leads to activation of caspase 8 and autocatalytic processing. 
Cleaved caspase 8 is liberated and moves to the cytosol to target executioner caspases 
such as caspase 3 and caspase7 to induce apoptosis (Lamkanfi, Festjens et al. 2007). 
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In 2009, Jin and colleagues reported that DR4 and DR5 simulation induces 
polyubiqutination of caspase 8 by cullin E3 ubiquitin enzyme. The ubiquitinated 
caspase 8 binds to the ubiquitin binding protein, p62, and leads to its aggregation and 
activation (Jin 2009). Polyubiqutination of caspase 8 can be reversed by 
deubiquitination. Intriguingly, A20 contributes to DISC formation, and physical 
interaction with DISC has been shown by co-immunoprocipitation (Jin 2009; Bellail, 
Olson et al. 2012). Apoptosis is inhibited by deubiquitination of caspase 8 and over 
expression of A20 inhibited apoptosis (Daniel, Arvelo et al. 2004), which is explained 
by the deubiquitin activity of A20, which can reverse polyubiquitination of caspase 8 
(Jin 2009). Further to this, A20 has been reported to inhibit apoptosis via c-Jun N-
terminal kinase (JNK) pathways. TNFα induced NF-kB activates JNK pathway through 
activation of apoptosis signal regulating kinase1 (ASK1) and persistent JNK activation 
contributes to TNF induced cell death. Interestingly, A20 binds to AKS1 and promotes 
K48 linked polyubiquitination of ASK1. Proteasomal degradation of ASK1 leads to 
suppression of JNK activation and eventually blockage of apoptosis (Won, Park et al. 
2010). 
 
A20 not only regulates apoptosis directly by actions on apoptotic pathways, but also 
indirectly, by regulating expression of antiapoptotic genes as a result of NF-kB 
inhibition. The antiapoptotic actions of A20 are to some extent cell type-specific. In 
pancreatic β cells, antiapoptotic A20 has been reported (Grey, Arvelo et al. 1999; 
Liuwantara, Elliot et al. 2006), but in other cell types, proapoptotic functions have been 
reported for A20, which arise as a consequence of downregulation of antiapoptotic 
genes through NF-kB inhibition (Tavares, Turer et al. 2010; Kool, van Loo et al. 2011).  
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Figure 1.9 Schematic extrinsic apoptotic pathway TRAIL-induced ligation of its cognate death 
receptors result in recruiting FADD and proactive caspase8 and consequently forming a death inducing 
signal complex (DISC). The DISC activates capase8 to cleave procaspase3 to become active capase3. 
Apoptosis is induced by active caspase 3. Pcap8, pro caspase8; Acap8, active caspase8  
 
1.1.1.4 A20 as a disease susceptibility gene 
Genome-wide association studies (GWAS) have identified single nucleotide variants in 
or near A20 that segregate with inflammatory autoimmune diseases including 
rheumatoid arthritis (RA), juvenile idiopathic arthritis, systemic lupus erythematosus 
(SLE), inflammatory bowel disease (IBD), coeliac disease, psoriasis, type 1 diabetes, 
Sjogren’s syndrome, systemic sclerosis, and Crohn’s disease (Plenge, Cotsapas et al. 
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2007; Graham, Cotsapas et al. 2008; Han, Zheng et al. 2009; Vereecke, Beyaert et al. 
2009; Matmati, Jacques et al. 2011; Ma and Malynn 2012). Two exonic 
nonsynonymous SNPs, encoding A125V and F127C, have been shown to confer 
reduced DUB activity of A20. An SNP at a putative 3’ enhancer was suggested to alter 
A20 expression. Taken together, these findings suggest that reduced expression or 
activation of A20 confers an increased risk of inflammatory and autoimmune diseases. 
Consistent with this proposition, mice with defects in A20 expression developed SLE or 
IBD-like phenotypes (Chu, Vahl et al. 2011; Hammer, Turer et al. 2011). 
  
In addition to germline genetic variants, many somatic variants in TNFAIP3 have been 
discovered in lymphomas. Biallelic somatic mutations in the coding sequence of 
TNFAIP3 that result in stop codons, frame shifts, amino acid changes or splicing 
alterations have been found in multiple B cell lymphomas, including MALT lymphoma, 
Hodgkin’s lymphoma, diffuse large B cell lymphoma (DLBCL) and follicular 
lymphoma. A20 acts as a tumour suppressor as reconstitution of A20 in tumour cells 
showed cell cycle arrest or apoptosis (Compagno 2009; Kato, Ishii et al. 2009). 
 
A20 is considered to be a tumour-promoting factor that supports tumour survival and 
growth (Vendrell, Ghayad et al. 2007; Hjelmeland, Wu et al. 2010). In addition, normal 
A20 may be a tumour suppressor (proapoptotic) or tumour enhancer (antiapoptotic) 
depending on cell type and tumour stage. In summary, loss or reduced A20 function or 
expression is directly linked to the pathogenesis of human lymphoma or susceptibility 
to inflammatory diseases such as SLE. A20 is regarded as a disease susceptibility gene 
and A20 can be a target for therapeutic approach in a broad human diseases.  
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1.1.1.5 A20 interacting proteins 
1.1.1.5.1  TAX1BP1  
A20 requires essential contributions from other proteins to exert its functions as a 
negative regulator of NF-kB. TAX1BP1 was discovered as an A20 interactor in a yeast 
two-hybrid screen (De Valck, Jin et al. 1999). Interference of TAX1BP1 expression by 
antisense RNAs attenuated termination of NF-kB activity and promoted apoptosis (De 
Valck, Jin et al. 1999).  
 
 
Figure 1.10 Schematic structure of TAX1BP1 It contains SKICH, coiled coil (CC) structures and 
ubiquitin binding zone (UBZ) domains. SKICH domain contains14-3-3 binding site (RGASTP). The 
central part contains two helix loop helix (HLH) regions which are responsible for homodimerisation. 
Two UBZ domains both contain binding motif (PPXY) for WW domain containing proteins. P; proline; 
X, any amino acid; Y, tyrosine 
 
TAX1BP1 is located at locus 7p15 in the human genome (Nagaraja and Kandpal, 2004). 
TAX1BP1 localizes in intranuclear speckles, at the Golgi complex, on cytoplasmic 
vesicles distributed throughout the cytoplasm and near focal adhesion sites in the 
plasma membrane (Morrison, Reiley et al. 2005; Ulrich, Seeber et al. 2007). Two 
isoforms of human TAX1BP1 have been reported, and 749 and 783 amino acids are 
expressed to 86KDa and 90KDa proteins respectively (De Valck, Jin et al. 1999). 
 
Novel NF-kB mutations in common variable immunodeficiency (CVID)  
23 
 
TAX1BP1 consists of a novel membrane binding domain, the SKIP carboxyl homology 
(SKICH) domain, three central coiled-coil regions and two zinc finger domains at the 
N-terminus. SKICH domains contain 14-3-3 binding sites (RGASTP) but the function 
of this region is not clear, although SKICH domains have been implicated in membrane 
localisation (Gurung, Tan et al. 2003). The central coiled-coil domain contains two 
helix-loop helix regions, and is thought to be responsible for homodimerization and 
other protein-protein interactions (Chun, Zhou et al. 2000; Ling and Goeddel 2000).  
 
The TAX1BP1 C-terminus contains two zinc finger domains that also bind ubiquitin 
(UBZ). Both UBZs contain highly conserved motifs PPXY (prolin-prolin-any amino 
acid-tyrosine), which is thought to bind to WW domain containing proteins (Sudol, 
Chen et al. 1995). Ubiquitinated substrates such as RIP1 and TRAF6 are thought to bind 
to TAX1BP1 via the UBZ2. A20 also binds to TAX1BP1 via the same region, 
suggesting the possibility of TAX1BP1 dimerisation (Iha, Peloponese et al. 2008). 
 
TAX1BP1 inhibits NF-kB induction. Upon TNFα stimulation, TAX1BP1 binds to K63 
ubiquitinated RIP1 to block the downstream signalling. Previously, TAX1BP1 was also 
called T6BP because it was independently discovered as a TRAF6 binding partner. 
Subsequent studies reveal that TAX1BP1 binds to TRAF6 after IL-1 or LPS stimulation 
and inhibits NF-kB activity (Shembade, Harhaj et al. 2007). TAX1BP1 lacks ubiquitin 
editing functions therefore it has been suggested that TAX1BP1 is a scaffold protein 
that recruits A20 to ubiquitinated substrates to terminate NF-KB signaling (Verstrepen, 
Verhelst et al. 2011). 
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Figure 1.11 Functions of TAX1BP1. (A) TAX1BP1 recognises RIP1 or TRAF6 then recruits A20 to 
them. A20 then removes K63 linked ubiquitine chains (blue arrow) and attach K48 linked ubiquitin chain 
(red arrow) for proteosomal degradation. ITCH and RNF11 also exhibit the uniquitin editing process. (B) 
TAX1BP1 binds to E3 emzyme to hinder the interaction with E2 enzyme. TAX1BP1 binds to E2 enzyme 
directly and recruit A20 to introduce K48 linked ubiquitin chains for proteosomal degradation. 
 
TAX1BP1 also disrupts the interaction between E2 and E3 enzymes. In TAX1BP1 
deficient cells, E2 ligases persist after TNF or IL-1 stimulation while they are degraded 
A 
B 
Novel NF-kB mutations in common variable immunodeficiency (CVID)  
25 
 
in wildtype cells. Thus, TAX1BP1 may also serve as a scaffold that supports 
interactions between A20 to the E2 enzymes (UBC13 and UBCH5C), either to permit 
normal E3 ligase activity or to facilitate K48-ubiquitination of E2s (Verstrepen, 
Verhelst et al. 2011). 
 
TAX1BP1 controls NF-kB activation by TAX1, a human T-lymphotropic virus type I 
(HTLV-I) oncogenic protein. Overexpression of TAX1BP1 was shown to inhibit NF-kB 
activation induced by Tax1, while deficiency of TAX1BP1 enhanced Tax1 induced NF-
kB activation. The underlying mechanism of this inhibition is yet to be elucidated, but 
recently it was demonstrated that Tax1 binds to TAX1BP1-A20 complexes and blocks 
its inhibitory function.  
 
Overexpression or antisense TAX1BP1 experiments demonstrate that TAX1BP1 has 
anti-apoptotic properties (De Valck, Jin et al. 1999). It was suggested that TAX1BP1 
recruits A20 to a K63 ubiquitylated protein that is involved in apoptotic signalling. 
Upon TNF related apoptosis inducing ligand (TRAIL) stimulation, Caspase 8 
ubiquitylation is an essential for activating ‘executioners’ Caspase 9 or Caspase 3, 
which lead to apoptosis. As mentioned previously, A20 is also recruited to this complex 
and inhibits TRAIL induced apoptosis by deubiquitylating Caspase 8 (De Valck, Jin et 
al. 1999; Jin 2009).  
 
Tax1bp1 deficiency in mice revealed its essential role in regulation of NF-kB mediated 
proinflammatory signalling. Tax1bp1-/- mice die prematurely from age-dependent 
hypertrophic cardiac valvulitis (Iha, Peloponese et al. 2008). They also exhibited 
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hypersensitivity to sublethal doses of TNF and IL-1, a phenotype also observed in 
Tnfaip3-/- mice. After TNF-α, IL-1 and LPS Tax1bp1-deficient MEFs show elevated and 
persistent NF-kB and JNK activation (Shembade, Harhaj et al. 2007). Interestingly, the 
phenotype of Tnfaip3-/- mice was more abnormal than that of Tax1bp1-/- mice. It was 
suggested that A20 might be also contribute to embryonic development independently 
of TAX1BP1.  
 
1.1.1.5.2 A20 ubiquitin editing complex 
A20 and TAX1BP1 also interact with ITCH and RNF11 within a complex that inhibits 
NF-kB signalling after TNFα, IL-1 or TLR4 stimulation. ITCH was found to 
coimmunoprecipitate with TAX1BP1 (Shembade, Harhaj et al. 2008; Venuprasad, Zeng 
et al. 2015). ITCH is a cytoplasmic E3 ubiquitin ligase. Unlike the majority of E3 
ubiquitin ligases, which contain really interesting new gene (RING) motifs, ITCH is one 
of 28 E3 ligases that contain a homology to the E6 associated protein carboxyl terminus 
(HECT) motif. ITCH contains four N-terminal WW domains, which consist of two 
conserved tryptophans separated by 20-22 amino acids. The HECT domain binds to E2 
and transfers ubiquitins to a substrate, and the WW domain binds PPXY motifs to 
mediate protein-protein interactions (Sudol, Chen et al. 1995). 
 
Itch-/- mice exhibit spontaneous inflammation of lung and stomach, hyperplasia of 
lymphoid and hematopoietic cell, altered coat colour, and constant scratching (Perry, 
Hustad et al. 1998; Fang, Elly et al. 2002). Immunological analysis revealed a severe 
bias to Th2 differentiation, and the majority of their T cells adopt an effector memory T 
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cell phenotype (CD44hi CD62lo) (Fang, Elly et al. 2002). Itch-/- cells showed constitutive 
activation of NF-kB.  
 
RNF11 is RING type E3 ligase of 154 amino acids that also contains an H2 finger 
domain in its C-terminus, which may facilitate protein-protein interactions (Li and Seth 
2004; Shembade, Parvatiyar et al. 2009). RNF11 contains a WW binding domain 
(PPXY) motif, is predicted to interact with ITCH through this motif, and form a A20 
ubiquitin editing complex. Rnf11-/- cells showed persistent NF-kB activation upon TNF, 
IL-1 or LPS stimulation, similar to the signalling defect seen in Tnfaip3-/- cells. RNF11 
may facilitate termination of NF-kB signalling by ubiquiting substrates, however, the 
exact function of RNF11 in the complex is yet to be elucidated (Shembade, Parvatiyar 
et al. 2009).  
 
In summary, A20 interacts with RNF11, ITCH and TAX1BP1, which form an A20 
ubiquiting editing complex after cell activation. A20 and substrates bind to TAX1BP1, 
which together with ITCH, are thought to bind to RNF11 via their WW domains 
(Hymowitz and Wertz 2010). The details of the physical interaction between TAX1BP1 
and ITCH are yet to be determined. TAX1BP1 has been proposed as the scaffold 
protein of the complex. Scaffolds are normally catalytically inactive but facilitate 
interactions crucial for efficient signalling. Recently, evidence emerged, however, that 
the complex depends on TAX1BP1 phosphorylation. After TNFα or IL-1 stimulation, 
IKKα phosphorylates TAX1BP1 at Serine 593 and Serine 624, promoting interaction 
among TAX1BP1, A20, ITCH and RNF11 (Shembade, Pujari et al. 2011). It is likely 
that phosphorylation triggers a conformational change in TAX1BP1, and that the zinc 
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fingers and PPXY motifs are rendered accessible for recruitment of ITCH, RNF, and 
A20 and their respective substrates.  
 
1.1.1.5.1 ABIN1 
A20 binding inhibitor of NF-kB 1 (ABIN1) was discovered as an A20 binding partner 
in a yeast two hybrid screen of mouse fibroblasts (A20 as bait) (Heyninck, De Valck et 
al. 1999). Human ABIN1 is located on chromosome 5q32. ABIN1 comprises four ABIN 
homology domains (AHDs), a UBAN domain, a leucine zipper (LZ) structure and a 
NEMO binding domain (NBD) at its C-terminus containing the YPPM (tyrosine-prolin-
prolin-methionine) Src kinase phosphorylation motif. ABIN1 contains four putative 
nuclear export signals and a nuclear localization, and constitutively shuttles between the 
cytosol and the nucleus in a Crm1 dependent way (Gupta, Ott et al. 2000). 
 
Overexpression of ABIN1 inhibits NF-kB activation(Verstrepen, Carpentier et al. 
2009), while antisense Tnfaip3 RNA was shown to perturb inhibition of NF-kB 
activation, leading to the conclusion that the inhibitory function of ABIN1 is mediated 
by A20. Abin1 deficient mice exhibit a more severe phenotype than Tnfaip3-/-mice, 
suggesting that ABIN1 might regulate NF-kB through additional pathways. ABIN1 is 
an essential regulator in embryonic development, which is dependent on TNF-induced 
NF-kB activity. ABIN1 specifically interacts with NEMO via its NBD domain, and 
facilitates recruitment of A20 to NEMO to exert its deubiqitination activity to the 
substrate. In addition, ABIN1 inhibits apoptosis by hindering caspase 8 recruitment to 
FADD.  
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1.1.1.5.2 CCDC50 
CCDC50 (Coiled-Coil Domain Containing 50; YMER) is another A20 interactor, 
identified by yeast two-hybrid screen (Bohgaki, Tsukiyama et al. 2008). Like other A20 
interactors, overexpression of CCDC50 results in termination of NF-kB signalling, 
whereas reduced expression enhances NF-kB activity. CCDC50 binds directly to its 
substrate without ubiquitin chains therefore is considered to regulate signalling as an 
adaptor protein, in a manner similar to NEMO (Bohgaki, Tsukiyama et al. 2008; 
Tsukiyama, Matsuda-Tsukiyama et al. 2012). 
 
1.1.2 Non-canonical pathway 
The non-canonical NF-kB pathway predominantly mediates the activation of RelB/p52. 
Activation of the canonical pathway is rapid and occurs independently of protein 
synthesis. By contrast, activation of the non-canonical NF-kB pathway is slow and 
depends on protein synthesis. Even though NF-kB have been intensively investigated 
for the past 30 years, the non-canonical pathway is yet to be understood completely, but 
gene deficient mice indicated that the non-canonical pathway is essential for B cell 
maturation, lymphoid organogenesis and osteoclastogenesis (Dejardin 2006; 
Gerondakis and Siebenlist 2010; Zhu and Fu 2010; Novack 2011).  
 
Non-canonical signalling proceeds via processing of p100 (NFKB2) to p52. Unlike 
constitutive processing of p105 in the canonical NF-kB pathway, p100 processing is 
tightly regulated by signal induction and is initiated by relatively few stimuli, most 
notably ligation of CD40, LTβR and BAFF-R.  
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1.1.2.1 NFKB2 
NFKB2 or p100 is a protein of 900 amino acids. Unlike other NF-kB subunits or IkBs, 
p100 contains both REL homology domain (RHD) and ankyrin repeat domains (ARD). 
ARDs are thought to inhibit nuclear translocation of transcription factors by covering 
nuclear localization sequences (NLS), which is located in RHD. ARD has been reported 
to interact with RHD in p100 and its tight three dimensional structure may prevent p100 
processing in unstimulated cells.  
 
 
Figure 1.12 Non canonical NF-kB pathway Upon noncanonical stimulation, NIK become stabilized and 
activated. NIK then activates IKKa and IKKa phosphorylates p100 at the phosphorylation sites. TrCP in 
SCF E3 liages binds to ubiquitin binding site and ubiquitinates p100 via K48 linkage. C terminal part of 
p100 is degraded and p52 containing heterodimers enter into the nucleus for gene expression. 
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The processing inhibitory domain (PID) and NIK responsive domains (NRD are 
downstream of ARD. The core region of the PID is a death domain (DD), demonstrated 
to be responsible for inhibition of constitutive p100 processing (Xiao, Harhaj et al. 
2001). DD and/or ARD were shown to be negative regulators of p100 processing, as a 
p100 truncated mutant lacking whole PID or partial ARD underwent constitutive p100 
processing (Liao and Sun 2003). The nuclear localization sequence is critical for 
constitutive p100 processing and location; truncated p100 is translocated into the 
nucleus. Interestingly, truncated p100 with additional mutations in NLS locate in the 
cytoplasm and constitutive p100 processing is inhibited, indicating that constitutive 
p100 processing is dependent on nuclear translocation. One possible explanation for this 
observation is that the E3 ligases responsible for p100 processing are more abundant in 
the nucleus (Liao and Sun 2003). 
 
 
Figure 1.13 Schematic structure of p100  p100 contains Rel homology domain (RHD), ankyrin repeat 
domain (ARD)  processing inhibitory domain (PID), and NIK responsive domain (NRD). PID contains 
the core inhibitory domain, death domain (DD). NRD is responsible for p100 inducible processing and it 
contains phorphoylation sites. These sites are phosphorylated by IKKα and bound by βTrCP of SCF E3 
ligase upon stimulation.  
 
The NRS is located at the C terminus and is pivotal for p100 processing under normal 
conditions. Deletion of NRS abolished phosphorylation of p100 and consequently 
inhibits p100 processing (Xiao, Harhaj et al. 2001). The NRS is phosphorylated by 
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IKKα in a NIK-dependent manner, tagging the protein for binding by ubiquitin ligase 
which is necessary for partial degradation in the proteosome.  
1.1.2.2 Phosphorylation of p100 
Xiao and colleagues discovered that NF-kB inducing kinase (NIK) regulates the 
processing of NFKB2 (Xiao, Harhaj et al. 2001). NIK is a MAP kinase kinase kinase 
(MEK3K) and can be activated by both canonical and non-canonical pathways. 
Originally, NIK was identified as a mediator of TNF/IL-1 induced canonical NF-kB 
signalling, however, aly mice (carrying spontaneous loss of function mutations in Nik) 
and Nik-/- mice showed that NIK was dispensable in the canonical pathway but essential 
for p100 processing (Shinkura, Kitada et al. 1999). 
 
NIK was initially thought to bind directly to p100 for p100 phosphorylation as a NIK 
complex isolated from mammalian cells was able to phosphorylate p100. Subsequent 
studies revealed that IKKα directly phosphorylates p100, and neither IKKβ nor IKKγ 
are required for p100 processing (Senftleben, Cao et al. 2001; Liang, Zhang et al. 2006). 
 
IKKα can be activated by both canonical and non-canonical stimulation, although in the 
absence of NIK activation, phosphorylation of IKKα via the canonical pathway fails to 
phosphorylate p100. This demonstrates that p100 processing depends on NIK through 
phosphorylation of IKKα. In the absence of NIK, p100 fails to associate with IKKα, 
which implies that NIK may contribute to this interaction as an adapter protein. 
Nevertheless, NIK may not simply act as a bridge because only low levels of NIK are 
required to form relatively high amounts of p100/IKKα complexes. It has been 
postulated that the three-dimensional conformational structure of p100, formed by both 
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the DD and the N-terminus, is modified by interactions with recycling NIK, leading to 
exposure of docking sites for IKKα on p100 (Senftleben, Cao et al. 2001; Xiao, Fong et 
al. 2004). Finally, IKKα phosphorylates both NIK and p100, which appears to provide a 
negative feedback loop.  
 
IKKα and NIK result in p100 phosphorylation at serine 866 and serine 870, and 
phosphorylation at both sites is necessary for p100 processing in vivo, although they 
appear to be dispensable for p100 phosphorylation by recombinant IKKα in vitro. 
Serine 872 was also discovered to be a critical phosphorylation site as substitution of 
this site abolished p100 phosphorylation in vitro (Liang, Zhang et al. 2006). 
 
1.1.2.3 Inhibitory molecules, TRAF2/TRAF3/cIAP1/2 complex 
Although NIK mRNA is relatively redundant and undergoes protein synthesis, NIK 
expression is undetectable in resting cells (Liao, Zhang et al. 2004). This appears to be 
because of proteasome mediated degradation of NIK mediated by the TRAF2, TFAR3 
and cIAP1/2 complex (Zarnegar, Wang et al. 2008). Each of these proteins contains one 
to three zinc-binding baculovirus IAP repeat (BIR) domain,  which has anti- apoptotic 
activity, and a carboxy-terminal RING domain with ubiquitin ligase activitiy (Salvesen 
and Duckett 2002; Liston, Fong et al. 2003; Vaux and Silke 2005). BIR domains 
interact with the N-terminal of TRAF2 (Rothe, Pan et al. 1995). The first two α-helices 
of the first BIR in the c-IAP1/2 complex are crucial for this interaction (Samuel, Welsh 
et al. 2006; Varfolomeev, Wayson et al. 2006).  
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TRAF molecules regulate both canonical and non-canonical pathways. TRAFs were 
originally identified as adaptor proteins but more recent studies reveal that they have 
enzymatic function as well. TRAF3/NIK interactions target NIK for continuous 
degradation by the proteasome. TRAF3 is recruited after different non-canonical 
stimuli, and is predicted to regulate NIK (Liao, Zhang et al. 2004). Indeed, TRAF3 has 
been shown to physically interact with NIK. This interaction and subsequent processing 
of NIK depends on a sequence motif ISIIAQA located between amino acids 78 and 84 
of NIK (Liao, Zhang et al. 2004).  
 
 
Figure 1.14 Schematic structure NIK It contains negative regulatory domain (NRD), kinase domain, 
and non-catalytic region (NCR). TRAF3 bins to N terminus of NIK via TRAF3 bindind motif (ISIIAQA) 
at 78-84 and IKKα and p100 bind to NIK via NCR 
 
Purified TRAF3, however, does not ubiquinate NIK, suggesting that there may be other 
regulators in the NIK degradation process. (Varfolomeev, Blankenship et al. 2007; 
Vince, Wong et al. 2007; Vallabhapurapu and Karin 2009). Subsequent evidence has 
emerged that TRAF2 and the cIAP1/2 complex also regulate NIK abundance.  
 
TRAF2 was originally discovered to be a component of TNFR complexes after TNF 
stimulation. Two TNFRs, TNFR1 and TNFR2, are present on most cell types and 
TRAF2 interacts with TNFR1 directly or with TNFR2 through the adaptor protein, 
TRADD. TRAF2 is itself an adaptor protein in NIK regulation that supports TRAF3 
and IAP1/2, yielding the TRAF3-TRAF2-IAP1/2 complex. TRAF2 consists of a highly 
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conserved TRAF-C domain and a coiled-coil TRAF-N domain. While the C-domain is 
required for TRAF2 recruitment to the receptor, the N-domain interacts with cIAP1/2 
through a baculovirus IAP repeat (BIR) domain (Vallabhapurapu, Matsuzawa et al. 
2008). It has been reported that TRAF2 has an anti-apoptotic function and is required to 
recruit IAPs (Gardam, Turner et al. 2011).   
 
Knock down of TRAF2, TRAF3 or cIAP2 in murine embryonic fibroblasts (Romberg, 
Chamberlain et al.) resulted in similar phenotypes, with  NIK accumulation and 
abundant p52 production (Grech, Amesbury et al. 2004; Liao, Zhang et al. 2004; He, 
Zarnegar et al. 2006; Xie, Stunz et al. 2007; Graham, Cotsapas et al. 2008; Gardam, 
Turner et al. 2011). Thus, it appears that TRAF2, TRAF3 and cIAP2 are all necessary  
 
 
 
Figure 1.15TRAF2/TRAF3/ cIAP1/2 complex in a resting cell In resting condition, NIK maintains at 
very low level. NIK is bound by TRAF3 and the cIAP1/2 ubiquitin ligases are recruited to via TRAF3 
dimerisation with TRAF2. cIAPs then ubiquitinate NIK via k48 linkage and consequently NIK.becomes 
degradation by proteosome. 
 
Novel NF-kB mutations in common variable immunodeficiency (CVID)  
36 
 
for normal suppression of p100 processing by NIK degradation. While TRAF3 and 
TRAF2 contribute as adaptor proteins, the cIAP1/2 complex functions mediates K48 
ubiquitination of NIK, which leads to its proteasomal degradation (Varfolomeev, 
Blankenship et al. 2007; Zarnegar, Yamazaki et al. 2008). 
 
1.1.2.4 Degradation of inhibitory molecules upon activation 
 
     
Figure 1.16 NIK activation and stabilization upon stimulation Upon stimulation, TRAF2/ TRAF3 
cIAP complex is recruited to the receptor and TRAF2 activate cIAPs to target TRAF2 and TRAF3 for 
K48 linked ubiquitination. Deradation ofTRAF3 allows NIK to be accumulated and stabilized. NIK then 
phosphorylates IKKα and IKKα phosphorylates p100 leading to p100 processing 
 
Receptor ligation activates TRAF2, which acts as an E3 ubiquitin ligase to attach K63 
to c-IAP1/2. Activated cIAP1/2 complexes are E3 ubiquitin ligases that attach K48 
linked ubiquitin chains to TRAF3 molecules, flagging it for proteasomal degradation. 
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After TRAF3 degradation, activated NIK accumulates. A detailed understanding of the 
relative preference of IAP1/2 for either TRAF3 or NIK has yet to be elucidated.  
 
1.1.2.5 Ubiquitination of p100 
Phosphorylation of the two serine residues at C-terminus of p100 leads to recruitment of 
the SCF complex E3 ligase. Phosphorylation creates a binding site for β-TrCP, a subunit 
of the SCF complex. β-TrCP binding site motif was reported as DSGxxxS, a motif that 
is also found in other proteins including IkBs, p105, β-cat and Vpu (Figure 1.17). β-
TrCP of SCF physically interacts with p100 following phosphorylation of serines 866 
and 870 in a NIK-dependent manner and stimulates ubiquitination.  
 
 
Figure 1.17 Binding sequences of β-TrCP in human proteins 
 
Physical interaction of β-TrCP with p100 is pivotal for the ubiquitination and 
processing of p100 (Fong and Sun 2002). The ubiquitin acceptor site of p100 (K856) is 
located upstream of the phosphorylation site (Amir, Haecker et al. 2004). 
Polyubiquitinated p100 is then subjected to partial degradation by the S26 proteosome.  
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Figure 1.18 SCF E3 ligase complex and binding site of p100 Phosphorylation at serine 866 and serine 
870 is a prerequisite for ubiquiting binding. Phosphorylation was thought to create binding docking site 
for β-TrCP and exhibit E3 ligase activity at K856 (Sun 2011) 
 
1.1.2.6 Degradation of p100 by proteasome S9 
The S26 proteasome complex is composed of two subcomplexes: 20S catalytic particle 
and 19S regulatory particle. S20 forms a cylindrical proteolytic chamber with four 
stacked heptameric rings. S19 particles are located at both sides and are thought to 
facilitate 20S by recognizing and recruiting ubiquitinated p100s, unfolding the substrate 
so that it can enter the proteolytic chamber of the 20S catalytic particle. 
 
The 19S particle is also composed of two subcomplexes: a base and a lid. While the 
base complex is composed of six AAA families of ATPases and three other proteins, the 
lid complex is composed of eight non-ATPase proteins. S9 is located in the lid of the 
19S subunit and interacts with p100 (Fong, Zhang et al. 2002). The death domain (DD) 
of p100 appears to be critical for 9S binding, as deletion of the DD of p100 abolished 
the interaction between DD and S9 (Fong, Zhang et al. 2002). NIK-induced 
ubiquitination of p100 is a prerequisite for the interaction, however, S9/DD interactions 
can also be induced in the absence of NIK when the sequences located downstream of 
the DD of p100 are deleted (Fong and Sun 2002). It was therefore proposed that 
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ubiquitination induced conformational changes of p100 and rendered DD accessible to 
S9.  
 
As mentioned above, DD is thought to be a negative regulator of p100 processing as a 
p100 truncated mutant lacking DD (p100∆DD) underwent constitutive p100 processing 
(Xiao, Harhaj et al. 2001). Partial degradation of p100 is required for its constitutive 
activation, however, it has also been demonstrated that constitutive processing of 
p100∆DD is regulated by different mechanism independently of NIK induced 
ubiquitination (Fong and Sun 2002). 
 
Ubiquitinated p100 binds to S9 and enters the proteolytic chamber of the 20S catalytic 
particle. P100 is cleaved at residue D415, yielding p52 by partial degradation (Qing, Qu 
et al. 2007). 
 
1.1.2.7 IKB like function 
p100 processing liberates not only p52 but also RELB. p100 /RELB complexes are 
commonly found in the cytoplasm, and p100 is thought to inhibit RELB translocation to 
the nucleus, therefore acting as an IkB. The IkB function of p100 is consistent with its 
structure, which includes an ankyrin repeat domain, commonly seen in other IKBs. The 
IkB action of p100 was discovered after it was observed that IkBα did not completely 
abolish retention of p65 in the cytoplasm (Sun, Ganchi et al. 1993; Sun, Ganchi et al. 
1994). Subsequent work revealed that p100 bound the p65 complex. (Novack, Yin et al. 
2003; Basak, Kim et al. 2007; Tucker, O'Donnell et al. 2007). As a result of this IkB 
action, p100 processing modulates transcription mediated by both RELB and p52.  
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More recently, Basak and his colleagues found that p100 interacts with RelA as well as 
RelB in wildtype MEF, thereby controlling the canonical pathway even in the absence 
of canonical NF-kB stimuli (Basak, Kim et al. 2007). In 2007, Tucker and colleagues 
revealed that an ENU strain, Lym1, harbours a point mutation in Nfkb2 that results in a 
p100 truncation mutant (Y868>X) proximal to the second serine phosphorylation site. 
In this strain, p100 processing is impaired, and the mice exhibit a more severe clinical 
phenotype than Nfkb2 knockout mice. They also showed that unprocessible p100 
interfered not only with p52 and RelB translocation, but also canonical NF-kB 
transcription factor RelA translocation by interacting with RelA (Tucker, O'Donnell et 
al. 2007). In summary, p100 processing has been demonstrated to control canonical and 
non-canonical NF-kB pathways. 
 
1.1.3 Crosstalk between canonical and noncanonincal NF-kB pathways 
In addition to regulation of canonical NF-kB by p100, other pathways of cross-talk 
between canonical and non-canonical pathways exist. NIK was originally discovered as 
a mediator in the TNFα induced canonical NF-kB pathway, however, it is now well 
known that NIK is an important element in non-canonical NF-kB pathway and 
accumulation of NIK predominately activates the non canonical pathway. NIK 
contributes to the activation of canonical pathway when NIK is present in excess.  Thus, 
NIK accumulation seen in TRAF3 deficient cells or in lymphomas resulted in activation 
of both canonical and non canonical pathways (Zarnegar, Yamazaki et al. 2008; 
Demchenko, Glebov et al. 2010; Pham, Fu et al. 2011).  
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RIP1 may be involved in inhibition of non-canonical pathway. RIP1 is an important 
adaptor protein in TNFR-induced canonical NF-kB pathway. As mentioned above 
TNFR1 activates the canonical NF-KB pathway. Surprisingly, TNFR1 has an intrinsic 
activity to activate the non-canonical pathway. However, the non-canonical NF-kB 
activation is not induced by TNFR1 under normal condition because RIP1 inhibits the 
non-canonical NF-kB activation by stabilizing TRAF2 and cIAP2 in a manner that the 
kinase activity of RIP1 is not required. Upon TNF stimulation RIP1 deficient cells 
induced p100 processing due to degradation of TRAF2 or and cAIP1 (Gentle, Wong et 
al. 2011; Kim, Morgan et al. 2011).  RIP1 may be also involved in inhibition of TRAF2 
recruitment to TNFR1.  
 
1.2 Functions of NF-kB signalling in immune system 
NF-kB was discovered as a key regulator of inducible gene expression (specifically 
kappa light chains) in the immune system. Subsequent work has identified many 
functions of NF-kB in the immune system. The analysis of mice deficient for different 
NF-kB family members as well as mice lacking different NF-kB inhibitors or IKK 
subunits demonstrated that they play a major role in differentiation, proliferation, 
apoptosis and lymphoid organogenesis in immune system (Table 1.1). 
 
NF-kB signalling is involved in primary lymphoid organ development (bone 
development and thymus architecture) and secondary lymphoid organogenesis (splenic 
architecture, B cell follicles, marginal zones, lymph nodes, Peyer’s patches and 
germinal centres) (Gerondakis and Siebenlist 2010; Hayden and Ghosh 2011). Several 
NF-kB knockout mouse models have shown that the non-canonical NF-kB pathway is 
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crucial for lymphoid organogenesis. These models include mice deficient in RelB or 
NIK or with compound deficiency in NFKB2 and Bcl-3 or harbouring inactivating 
mutations of IKKa or NIK (Matsushima, Kaisho et al. 2001; Senftleben, Cao et al. 2001; 
Weih, Yilmaz et al. 2001; Paxian, Merkle et al. 2002; Yilmaz, Weih et al. 2003; Zhang, 
Wang et al. 2007). NF-kB regulates lymphoid tissues by inducing mediators of 
lymphoid organogenesis such as CXCL12, CXCL13, CCL19, CCL21, MadCAM, 
TNFα and LTα1β2 (Ruddle and Akirav 2009; van de Pavert and Mebius 2010). FDCs 
produce CXCL13 to attract B cells to form B cell follicles, and abnormal non-canonical 
NF-kB pathway activation via LTbR inhibits normal formation of B cell follicles 
(Mebius and Kraal 2005). 
 
NF-kB signalling is also known to be pivotal in lymphocyte development. Pre-B cells or 
double negative stage IV T cells showed high levels of nuclear NF-kB activity and 
inhibition of NF-kB by IkB a super-repressor allele results in apoptosis of these cells 
due to the failure of induction of anti-apoptotic protein A1. In both cases, NF-kB is 
thought to confer cell survival due to signals that depend on the pre-lymphocyte 
receptor (Feng, Cheng et al. 2004; Jimi, Phillips et al. 2005). In later stages of T cell 
development, double positive T cells (CD4+ CD8+) undergo positive and negative 
selection to become single positive T cells (CD4+CD8- or CD8+ CD4-). In this 
compartment, NF-kB activity appears to be proportional to lymphocyte antigen receptor 
binding affinity(Kishimoto, Surh et al. 1998; Hettmann, DiDonato et al. 1999), which in 
turn contributes to proapoptotic or antiapoptotic responses. During positive selection, 
NF-kB activity confers survival factors, although NF-KB appears to sensitize 
thymocytes to apoptosis in negative selection (Kishimoto, Surh et al. 1998; Hettmann, 
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DiDonato et al. 1999). Genetically modified mouse models reveal that RelA is 
predominantly expressed in the thymus cortex while Relb and cRel were highly 
expressed in the medulla. Furthermore, RelB-/- mice showed severely impaired negative 
selection(Gerondakis, Grumont et al. 2006).  
 
During B cell development, negative selection eliminates B cells which bind to antigen 
with strong affinity. NF-kB contributes to this response, although by contrast with 
negative selection in the T cell compartment, NF-kB activity is reduced in during B cell 
negative selection (Wu, Lee et al. 1996). In mature B cells constitutive low grade 
nuclear expression of both canonical and non-canonical NF-kB was reported in resting 
cells and it was thought to be required for B cell survival (Gerondakis and Strasser, 
2003; Claudio et al., 2006). Pro- pre B cell maturation require RelA while late B cell 
maturation from T1to T2 stage of B cells requires BAFFR mediated non-canonical 
pathway (Klionsky, Abdalla et al.).  
 
NF-KB is also required in lymphocyte differentiation after stimulation by antigen. In the 
case of CD4+ T cells, TH0 cells differentiate into TH1, TH2, TH9, TH17, TH22 and 
inducible Treg, and this differentiation is regulated by transcription factors T-bet, 
GATA3, PU.1 RORγt and FOXP3, respectively. NF-kB was shown to be involved in 
induction of this transcription factors (Corn, Hunter et al. 2005). NF-kB allows 
lymphocytes to survive from antigen inducing cell death (AICD) by inducing anti 
apoptotic genes including A1 and BCL-XL. c-Rel deficient cells were rescued from 
apoptosis by transgene expression of antiapoptotic gene BCL2 (Grumont et al., 1998).  
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Furthermore, NF-kB plays an important role in myeloid differentiation. c-Rel and Rela 
were reported to be vital components in erythrocyte differentiation in vivo and 
monocyte differentiation in vitro (Grossmann, Metcalf et al. 1999; Gerondakis, 
Grumont et al. 2006). IKKb also negatively control neutrophils proliferation. Ikbkb-/- 
myleloid cells resulted in massive neutrophilia(Greten, Arkan et al. 2007). 
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Table 1.1 Phenotype of knockout mice for NF-kB signalling components 
Type Mutated gene Phenotype of Knockout mouse 
N
F-
kB
 
Si
n
gl
e 
RelA (p65) Died at E15.5-E16.5; TNF dependent liver apoptosis; defect in 
lymphocyte activation, sensitivity to TNF 
NFKB1 Survival to adult; defect in lymphocyte activation  
NFKB2 Survival to adult; disruption of splenic and lymph node 
architecture; defective T cell response  
RelB 
Died postnatally from multi organ imflammation: T cell 
infiltration of organs, skin inflammation;  required for dendritic 
cell development  
C-Rel No developmental defects; defects in lymphocyte and 
macrophage functions; impaired T cell and B cell activation  
D
o
u
bl
e 
RelA and 
NFKB1 
Died at E13.5-E14.5, defects in b LYMPHOPOIESIS 
RelA and c-Rel Died at E13-E13.5 early liver apoptosis; skin epidermus development  
NFKB1 and c-
Rel 
Decreased humoral immunity, lack of germinal centres 
NFkB1 and 
NFkB2 
Died postnatally; lack mature B cells and osteoblasts; reduced 
growth, craniofacial abnormalities  
NFkB1 and 
RelB 
Died postnatally owing to immune deficiency , B cell 
developmental defects 
Pa
rt
ia
l 
de
le
tio
n
 
NFKB1 ∆C 
Splenomegaly; enlarged lymph nodes; infiltrations of lyung and 
liver; susceptibilit to pathogens Die postnatally owing to immune 
deficiency  
NFkB2 ∆C Died postnatally owing to immune deficiency; multiple organ defects  
C-Rel ∆C Lymphoid cell hyperplasia  
IK
K
 
IKK1 
Defects in keratinocyte differentiation, bone and limb 
development and mammary epithelial proliferation, no mature B 
cells, impaired RANKL induced NF-kB activation and NIK 
induces p100 processing  
IKK2 Died at E13.5-E14.5 owing to TNF dependent liver apoptosis, impaired NF-kB activaton by IL-1, TNF and LPS  
NEMO Died at E11.5-E12.5 owing to TNF dependent live apoptosis, no induced NF-kB activation in MEFs  
N
F-
K
B
 
in
hi
bi
to
r 
IkBa Early neonatal lethal inflammatory dermatitis and granulocytosis; constitutive NF-kB activity increased in lymphocytes 
IkBe NO defect in NF-kB activation; lack severe immune defects; 
reduction in number of CD44-CD25+ T cells 
Bcl-3 Disrupted splenic architecture; defects in B and T cell responses to antigens 
A20 Died postnatally with multiorgan inflammation and chacasia 
TAX1BP1 Died postnatally with cardiac valvulitis 
                                                  ∆C, carboxy terminal deletion; E, embryonic day 
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1.3 Mutations in Human NF-kB 
In the past few years, several variants in NF-kB signalling have been identified in 
humans with various forms of pathology (Geha, Notarangelo et al. 2007). Many of these 
have been identified by whole exome sequencing.  
 
As described above (refer to 1.1.1.2.3), caspase recruitment domain (CARD) 11 gene 
encodes a protein that acts as a scaffold for NF-kB signalling downstream of TCR and 
BCR. Upon TCR activation, PKC θ phosphorylates CARD11 and BCL10 plus MALT1 
are recruited to form the CBM complex. Activation of the CBM complex induces IKK 
activation and consequently NF-kB activation. Five genetic variants (one deletion and 
four single nucleotide polymorphisms (SNPs)) have been reported in human CARD11. 
Deletion of exon 21 (1377 bp) of this gene and a truncation mutation (Q945X) resulted 
in complete protein deficiency, while the others were missense mutations in which 
protein levels were normal. G123D conferred loss-of-function (Greil, Rausch et al. 
2013; Stepensky, Keller et al. 2013) mutation while the others (E127G, G116S) 
conferred gain-of-function (GOF). CARD11 deficiency or LOF mutations result in 
reduced or no IKK activation due to failure to either form or properly activate the CBM 
complex. The phenotype of these mutations is reduced or absent T cell proliferation and 
differentiation.  On the other hand, the GOF mutations lead to constitutive NF-kB 
activation, and the phenotype is accumulation of terminally differentiated B cell (Snow, 
Xiao et al. 2012; Turvey, Durandy et al. 2014; Brohl, Stinson et al. 2015). 
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One loss of function germline mutation in BCL10 has been described, in a patient with 
a combined immunodeficiency. A homozygous splice site mutation affecting the 
invariant first nucleotide of intron 1 causes complete BCL10 deficiency and confers 
defects of both hematopoietic and non hematopoietic immunity (Lee, Shin et al. 1999; 
Willis, Jadayel et al. 1999; Torres, Martinez-Barricarte et al. 2014). Two missense 
MALT1 mutations have been reported. Deficiency of MALT1 results in combined 
immune deficiency with abnormal IkB a degradation and IL-2 production (Jabara, 
Ohsumi et al. 2013; McKinnon, Rozmus et al. 2014). 
 
A nonsense mutation (Q422X) in IKBKA has been reported, which causes IKK1 
deficiency and results in autosomal lethal Cocoon-like syndrome characterised by 
multiple fetal malformations. Two genetic variants were described in human IKBKB, a 
nucleotide addition at c.1292 and a nonsense mutation (R272X), which both confer 
complete IKK2 deficiency. Patients with IKK2 deficiency exhibited severe combined 
immune deficiency due to impaired responses to various stimuli (Pannicke et al., 2013; 
Nielsen et al., 2014). Numerous mutations have been described in human IKBKG 
(NEMO). In females, hemizygous IKBKG mutations cause incontimentia pigmenti. In 
males, different mutations result in immunodeficiency with or without ectodermal 
dysplasia (Lahtela, Nousiainen et al. 2010). 
 
LUBAC is a ubiquitin ligase complex comprising HOIL-1, HOIP and SHARPIN 
proteins (Gerlach, Cordier et al. 2011; Ikeda, Deribe et al. 2011; Tokunaga, Nishimasu 
et al. 2012). As described above, LUBAC is important for IKK activation and NEMO 
recruitment. Several mutations have been described in genes encoding the human 
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LUBAC complex. Eight genetic variants were discovered in HOIL-1 (Boisson, 
Laplantine et al. 2012; Boisson, Laplantine et al. 2015). 6 mutations were found in 
patients with glycogen storage myopathy without immunodeficiency and 2 mutations 
(Q185X, 2 nucleotides deletion in exon 3) were found in patients with 
immunodeficiency. Loss or reduced function of HOIL-1 resulted in defects in NF-kB 
activation. One mutation (L72P) has been reported in HOIP. Although functional 
analysis has not been reported, the mutation was predicted to cause loss of function 
(Nilsson, Schoser et al. 2013). ITCH is E3 ubiquitin ligase and a homozygous single 
nucleotide insertion at 394 in ITCH was identified in Amish patients from 
consanguineous families. This homozygous mutation results in ITCH deficiency and 
confers multisystem autoimmune disease with morphologic and developmental 
abnormalities. Physical growth, craniofacial morphology, muscle development and 
immune function were destructively affected in these patients (Lohr, Molleston et al. 
2010).  
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        Table 1.2 Phenotype of gene knockout comparison between humans and mice 
gene Phenotype of knockout mice Phenotype of loss or reduced function in 
humans 
CARD11 Healthy and fertile defective T cell 
B cell activation failed to produce 
specific antibody, IgM high B cells  
impairment of NF-kB Jnk activation 
Pneumonia due to Pneumocystis jirovecii 
infection, increased numbers of transitional b 
cells and decreased regulatory T cells, 
defective NF-kB signaling in lymphocytes 
upon activation 
MALT1 Defective in antigen receptor 
induced NF-kB activation, cytokine 
production, and proliferation 
Impaired degradation of the NF-KB inhibitor 
IkBa, decreased IL2, poor antibody response 
and decreased T cell proliferative responses 
to mitogens; impaired B cell differentiation, 
absent proliferation and blast formation in 
CD3+ cells, decreased phophorylation of 
p65,  
BCL10 Embryonic lethality, severe 
immunodeficiency defective in 
antigen receptor induced NF-kB 
activation reduction in follicular 
marginal zone B1 B cells 
Hypogammaglobulinemia and a profound 
deficiency of memory B cells and memory T 
cells with predominantly circulating naïve 
cells, impaired NF-kB signaling via TLR4 in 
fibroblasts, impaired development in B cells, 
and impaired proliferation in T cells 
IKBKA Defects in keratinocyte 
differentiation, bone and limb 
development and mammary 
epithelial proliferation, no mature B 
cells, impaired RANKL induced 
NF-kB activation and NIK induces 
p100 processing 
Abnormal cyst in the cranial region, a large 
defect in the craniofacial area, an 
omphalocele and immotile and hypoplastic 
limbs -Cocoon syndrome, the fetuses were 
terminated at14 and 13 weeks of gestation. 
IKBKB Die at E13.5-E14.5 owing to TNF 
dependent liver apoptosis, impaired 
NF-kB activaton by IL-1, TNF and 
LPS 
Hypo/agammaglobulinemia with relatively 
normal number s of circulating B and T cells. 
Impaired phosphorylation of IkBa with TNFa 
stimulation and flagellin via TLR5. B and T 
cells were of the naïve type and showed poor 
differentiation o mitogenic responses under 
certain conditions, impaired phosphorylation 
of p65 and proliferation of T cells 
IKBKG Die at E11.5-E12.5 owing to TNF 
dependent live apoptosis, no 
induced NF-kB activation in MEFs 
Ecdermal dysplasia, reduced TNFa and LPS 
induced NF-kB activation in preB and T 
lymphocytes 
Itch Inflammation of the lung and 
stomach, hyperplasia of lymphoid 
and hematopoietic cells and 
constant itching  
Multisystem autoimmune disease with facial 
dysmorphism 
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Human mutations presented are often similar but not identical to phenotypes of mice 
with engineered deficiencies of the same genes (Table 1.2). There are also some 
significant differences. For example, Ikbkb deficiency is embryonic lethal, whereas in 
humans, IKBKB deficiency, caused by a homozygous duplication (c.1292dupG) in exon 
13, showed more restricted functions (Pannicke, Baumann et al. 2013). Thus, analysis 
of rare human variant alleles provides unique insights into human immunity. 
 
1.4 Common variable immune deficiency  
Common variable immune deficiency (CVID) is the most common primary 
immunodeficiency with an incidence estimated at 1:10000 to 1:50000 (Salzer, Warnatz 
et al. 2012). CVID was firstly reported in 1953 by Janeway and his colleagues, when 
they described a 39 year old patient who had a history of recurrent sinopulmonary 
infections, bronchiectasis and Haemophilus influenzae meningitis. The diagnosis of 
CVID depends on three features: hypogammaglobulinaemia of two or more 
immunoglobulin isotypes (low IgG, IgA, or IgM), recurrent sinopulmonary infections, 
and impaired functional antibody responses (Park et al., 2008). The number of B cells in 
peripheral blood can be normal or reduced, and the proportion of class switched 
memory B cells is often reduced (Cunningham-Rundles 1989; Cunningham-Rundles 
and Bodian 1999). Reduction of class-switched memory B cells was shown to correlate 
with granulomatous disease, splenomegaly and autoimmune cytopenias (Wehr, Kivioja 
et al. 2008). 
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Functional abnormalities are often found in T cell compartments, particularly during in 
vitro analysis, and this is the reason for the inclusion of the combined in the name of the 
syndrome. In older literature, various abnormalities were reported, including abnormal 
cytokine production, and decreased T helper cell function (Baumert, Wolff-Vorbeck et 
al. 1992; Holm, Sivertsen et al. 2004). More recently, abnormalities of T cell function 
have been characterised more precisely in Mendelian version of CVID (Bateman, Ayers 
et al. 2012). Patients do not usually suffer with opportunistic infections typically seen in 
patients with T cell deficiency. 
 
The main goal of therapeutic management is to decrease the morbidity and mortality 
associated with recurrent infections. The low prevalence together with heterogeneous 
clinical presentations, and recurrent infection with pathogens also encountered in 
immune competent individuals means that the diagnosis of CVID is often delayed. In 
1999, Cunningham-Rundles revealed that the average age of diagnosis was 29 years for 
males and 33 years for females, while the the average age of onset of CVID was 23 
years and 28 years, respectively (Cunningham-Rundles and Bodian 1999).  
 
In addition to recurrent infection, CVID is also associated with an increased risk of 
autoimmune disease, and sarcoidosis-likev granulomatous inflammation, and neoplasia. 
Occasionally these complications were diagnosed prior to CVID. Approximately 25-
30% of patients with CVID have autoimmune diseases. The most common autoimmune 
manifestations are thrombocytopenia (ITP), autoimmune haemolytic anaemia 
(AIHA)(Hermaszewski and Webster 1993; Cunningham-Rundles and Bodian 1999; 
Cunningham-Rundles 2002). 
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Granulomas are less frequent, although their presence is harder to ascertain. The risk of 
non-Hodgkins lymphoma has been estimated to be 400 times greater in CVID pateints 
than in the general population (Cunningham-Rundles, Siegal et al. 1987).  
 
Intravenous immunoglobulin replacement therapy (IVIG) is effective and is currently 
the mainstay of therapy for CVID (Park, Lerou et al. 2008). IVIG reduces the 
incidences of pneumonia and serious recurrent bacterial infections and prevents chronic 
lung disease and enteroviral menigoencephalitis. However it is not a curative treatment 
and majority of patients with CVID require a lifelong treatment with Ig replacement. 
CVID patients with IVIG treatment experience side-effects ranging from minor adverse 
reactions including headache, nausea, malaise, myalgias, arthralgias, chills, anxiety, 
flushing, abdominal cramps, rash, low grade fever, and leukopenia to rare but serious 
reactions, which are anaphylaxis, acute renal failure, stroke, myocardial infarction deep 
venous thrombosis or pulmonary embolus and aseptic meningitis.  
Decades long usage of IVIG treatment may cause deleterious effects and furthermore it 
is a financial burden for patients. The identification of genetic factors will facilitate 
appropriate diagnosis and potentially lead to curative therapeutic development 
(Schaffer, Salzer et al. 2007) 
  
Novel NF-kB mutations in common variable immunodeficiency (CVID)  
53 
 
Table 1.3 Genetic defects in patients with CVID 
Protein Gene 
symbol 
OMIM 
Designat
ion 
Reference 
Inducible 
costimulator (ICOS) 
ICOS CVID1 (Grimbacher, Hutloff et al. 2003; Salzer, 
Maul-Pavicic et al. 2004) 
Transmembrane 
activator and CAML 
interactor (TACI) 
TNFRSF13B CVID2 (Salzer, Chapel et al. 2005; Castigli, Wilson 
et al. 2007; Garibyan, Lobito et al. 2007; 
Lee, Rauter et al. 2009) 
CD19 CD19 CVID3 (van Zelm, Reisli et al. 2006) 
BAFF receptor 
(BAFFR) 
TNFRSF13C CVID4 (Warnatz, Salzer et al. 2009) 
CD20 MS4A1 CVID5 (Kuijpers, Bende et al. 2010) 
CD81 CD81 CVID6 (van Zelm, Smet et al. 2010) 
CD21 CR2 CVID7 (Wu, Boackle et al. 2007; Thiel, Kimmig et 
al. 2012) 
LRBA LRBA CVID8 (Alangari, Alsultan et al. 2012; Lopez-
Herrera, Tampella et al. 2012; Charbonnier, 
Janssen et al. 2015) 
PRKCD PRKCD CVID9 (Belot, Kasher et al. 2013; Kuehn, Niemela 
et al. 2013; Salzer, Santos-Valente et al. 
2013) 
 
Nine patients with CVID from four unrelated families showed ICOS deficiency. The 
patients had few peripheral B cells and very few or no class-switched memory B cells 
and produced very little IL-10 which is important for terminal differentiation of B cells. 
ICOS mutations appear to be rare (Grimbacher, Hutloff et al. 2003; Salzer, Maul-
Pavicic et al. 2004). 
 
TNFRSF13B (TACI) was originally identified in approximately 10% of CVID patients. 
Several homozygous, heterozygous or compound genetic defects were identified, 
including mutations encoding Cys104Arg, Ala181Glu, and 204 insAla. Subsequent 
studies have demonstrated these variants within the healthy population, and also in 
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healthy relatives of patients with CVID, indicating that TNFRSF13B defects are likely 
to operate only in epistasis with other variants to confer the CVID phenotype (Salzer, 
Chapel et al. 2005; Castigli, Wilson et al. 2007; Garibyan, Lobito et al. 2007; Lee, 
Rauter et al. 2009) ( Patrick et al., 2011).  
 
BAFFR deficiency was described in one individual a two related individuals with 
CVID. A 24 base pair deletion was found from this patient. Reduction of both class 
switched and non class switched (or marginal zone) B cells, an increase in the 
transitional B cells and a decrease in plasmablasts were reported (Warnatz, Salzer et al. 
2009). 
 
CD19 deficiency was discovered in four patients with CVID from two unrelated 
families. Homozygous mutations in CD19 introduced a premature stop codon. CD20+ B 
cell numbers were normal in the patients but CD19 expression was low or undetectable. 
CD27+ memory B cells were found to be low.  
 
The CD19 complex is formed by three other proteins; CD21 CD81 and CD225. A 
single nucleotide insertion at a splicing site in CD81 was discovered from one patient 
with CVID resulting in a complete lack of CD81 expression. The patient also showed an 
absence of CD19 expression on B cells and reduced memory B cell numbers.  
Mutations in CR2 also showed normal B cells numbers with an absence of CD21 
expression and decreased memory B cell numbers (van Zelm, Reisli et al. 2006; Wu and 
Zhang 2007; van Zelm, Smet et al. 2010; Thiel, Kimmig et al. 2012).  
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MS4A1 genetic defect was found in a Turkish girl, born of consanguineous parents. 11-
bp insertion and 2-bp deletion homozygous mutation in intron 5 of the MS4A1 gene 
resulted in loss of CD20 surface expression on B cells. B cell numbers were normal but 
peripheral memory B cells were reduced ( Kuijpers, Bende et al. 2010). 
 
Six different homozygous mutations in the LRBA have been discovered from seven 
patients from six unrelated consanguineous families with CVID. Decreased numbers of 
switched memory B cells and a failure to differentiate into plasma cells were observed. 
An increased susceptibility to apoptosis was discovered (Alangari, Alsultan et al. 2012; 
Lopez-Herrera, Tampella et al. 2012; Charbonnier, Janssen et al. 2015). 
Three homozygous mutations in PRKCD were discovered in five patients with 
decreased functional PRKCD protein in patient cells. Hyperproliferation in response to 
stimulus was shown in the patient B cells. It demonstrated that PRKCD is a crucial 
factor in B cell tolerance (Belot, Kasher et al. 2013; Kuehn, Niemela et al. 2013; Salzer, 
Santos-Valente et al. 2013). 
 
In total, nine genetic defects have been identified to account for CVID (Table 1.3). 
Collectively, these account for 10-15 % of CVID cases. In other words, 85-90% of 
patients with CVID have no known genetic cause or explanation. The discovery of new 
genetic defects associated with CVID is required in order to classify the disease and to 
facilitate diagnosis and prognosis.  
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2 Methods and Materials 
2.1 Materials 
2.1.1 Biological materials 
2.1.1.1 Patients and participants 
The patients, relatives and healthy controls are part of a larger cohort of primary 
antibody deficiency kindreds enrolled and recruited through the Australian and New 
Zealand antibody deficiency allele (ANZADA) study. Consents were obtained from all 
participants. This study has been approved by human research ethics committees at each 
institution. Blood and saliva were collected according to standard operating procedures 
(SOP).  
 
The cord blood was obtained through Human Research Ethics committee (Klionsky, 
Abdalla et al.) approved donations given in the birthing suite of the Centenary Hospital, 
ACT Health services. Spleen and lymph nodes were donated at time of diagnostic 
biopsies and therapeutic removal of organ tissue as part of patient treatment plans, and 
after informed consent was obtained. 
 
2.1.1.2 Other biological materials 
HEK293 cell line was purchased from ATCC®.  HEK293T, Raji, Daudi and Ramos cell 
lines were kindly provided by Dr. Vinuesa. E. coli strains, JM103and DH5α were 
purchased from Invitrogen. 
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2.1.2 Antibodies 
The following antibodies were used for flow cytometry analysis; CD3(HIT3A, BD), 
CD4(SK3, BD), CD8(SK1, BD),  CD10 (H110a, BD), CD14 (MφP9,BD) CD19 
(SJ25C1, BD),  CD27 (L128, BD), CD21(B-ly4, BD), CD23 (EBV CS-5, Biolegend), 
CD24 (ML5, BD), CD25 (M-A251, BD), CD31(WM59 , BD) CD38 (HB7, BD), 
CD45RA (H110, BD), CD45RO (UCHL1, Biolegend),  CD57 (HNK-1, BD), CD62L 
(DREG-56, BD),  CD69  (FN50, BD), CD84 (H B15e, BD), CD86 (FM95, Miltenyi 
Biotec), CD127 (A019D5, eBioscience),  CCR6 (11A9, BD), CCR7 (3D12, BD), 
CXCR3(IC6/CXCR3, BD), CXCR5 (RF8B2, BD) FoxP3 (259D/C7, BD), ICOS (ISA3, 
eBioscience), IFN-γ (25723.11,  IL-4 (7A3-3, Miltenyi Biotec ), IL-10 (JES3-19F1, 
BD), IL-17 (SCPL1362, BD),  BD), IgA (G20-359, BD), IgD (IgD26, BD), IgG (G18-
145, BD), PD1 (J104, eBioscience),  7AAD (BD),  and streptavidin (streptavidin, BD) 
Anti Fas antibody (CH11, Millipore). 
 
The following antibodies were used for western blot; A20 (59A426, Santa Cruz Bio), 
TNFAIP3/A20 (clone: A-12, sc-166692, Santa Cruz), Ubiquitin (clone: P4D1, sc-8017, 
Santa Cruz), TAX1BP1 (Abcam), c-Myc (Milipore), Flag (Sigma), NFKB2 (C5, Santa 
Cruz Bio) NFKB2 p100/52 antibody (cell signaling), Phospho-NFKB2 p100 
(ser866/870) antibody (cell signaling),  NIK (Santa Cruz Bio),  TBP antibody (1TBP18, 
abcam), and goat anti-mouse IgG HRP antibody (Santa Cruz Bio), GAPDHα (6C5 
abcam),   Phospho-IKK/ (16A6, Cell signaling), IKB (Cell signaling), Phospho-
IKB (Cell signaling), TATA box (ab818, Abcam), sheep polyclonal anti-rabbit IgG 
(Abcam), goat anti-mouse IgG-HRP (Santa Cruz Bioch), and Anti rabbit IgG HRP-
linked antibody (Cell Signaling).  
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2.1.3 Plasmids 
2.1.3.1 pcDNA™3.1(-)/myc-His A, B, & C mammalian expressing vecotr 
 
 
          It was purchased from Invitrogen.  
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2.1.3.2 pcDNA™3.1(+)/Flag mammalian expressing vector 
 
 
It was kindly provided by Dr Keisuke Horikawa (John Curtin School of Medical 
Research, Australian National University). Flag gene was inserted between NheI and 
BamHI 
 
2.1.3.3 pDONR223-NIK vector 
 
 
 
NIK containing pDONR223vector was purchased from Addgene.  
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2.1.3.4 pX330 U6 chimeric DD CBh hSpCas9 plasmid  
 
 
It was kindly provided by Dr. Vicki Athanasopoulos (John Curtin School of Medical 
Research, Australian National University). 
 
 
2.1.4 Primers 
2.1.4.1 Primers for genotyping by Sanger sequencing 
 
Name Sequence (5’-3’) Temp* Size 
TNFAIP3gDNAF AGCCTTATGCCTTGGCTCCTGG 69°C 566bp TNFAIP3gDNAR CTGACAGGCGTTTACTTGCTCCA 
TAX1BP1gDNAF TGTTCTGCTCCTGCATGCTT 69°C 312bp TAX1BP1gDNAR ACATAACTGCAGCCTGCCAA 
NKFB2gDNAF CTTCTCAGCTGGCTGGCGGG 69°C 430bp NKFB2gDNAR CTGAGGGGTGGGTGTGGGGT 
TNFSF9gDNAF GCGCTGTGTCTTCCCGCAGT 69°C 585bp TNFSF9gDNAR CTCGTAGCGGGCGCAGGATG 
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2.1.4.2 cDNA primers for cloning 
Name Sequence (5’-3’) Temp* Size 
A20cDNAF NotI aaaGCGGCCGCGCCACCATGGCTGAACAAGTCCTTCC 59°C 2397bp 
A20cDNAR KpnI tttGGTACCcGCCATACATCTGCTTGAACTG 
TAX1BP1cDNA 
BamHI 
aaaGGATCCGCCACCATGACATCCTTTCAAGAAGTC
CCA 59°C 2241bp TAX1BP1cDNAR 
NotI 
tttGCGGCCGCCTAGTCAAAATTTAGAACATTCTGATC
AA 
NIKcDNAF NotI tcatGCGGCCGCGCCACCATGGCAGTGATGGAAATG 
59°C 2900bp NIKcDNAR 
BamHI tactGGATCCTTTAGGGCCTGTTCTCCAGCTG 
TNFAIP3 cDNAF1 TTGAATTCGCCACCATGGCTGAACAAGTCCTTCCTCAG   
TNFAIP3 cDNAR1 AAAACTCGAGTTAGCCATACATCTGCTTGAACTG   
TNFAIP3 cDNAF3 TTGGATCCGCTGAACAAGTCCTTCCTCAGG-3’   
TNFAIP3 DA1 AAAACTCGAGTTACTGGGCGTGCCCCTCTCTCCTC   
TNFAIP3 H256A 
F 
CTCGGCTATGACAGCCATGCCTTTGTACCCTTGGTG
ACCC   
TNFAIP3 H256A 
R 
GGGTCACCAAGGGTACAAAGGCATGGCTGTCATAG
CCGAG   
TNFAIP3 S254R 
F 
TGTTCTCGGCTATGACAGACATCATTTTGTACCCTT
G   
TNFAIP3 S254R 
R 
CAAGGGTACAAAATGATGTCTGTCATAGCCGAGAA
CA   
*Temp: optimal annealing temperature; low case: additional nucleotide; red upper case: restriction site 
sequence; blue upper case: Kozak sequence 
 
2.1.4.3 Primers for sanger sequencing 
 
Name Sequence (5’-3’) 
A20cDNA F1 ATGGCTGAACAAGTCCTTCC 
A20cDNA F2 AACTGGAATGATGAATGGGAC 
A20cDNA F3 GCCGCAAAGTTGGATGAAGCT 
A20cDNA F4 GGAAGTGCCAAGCCTGCCTC 
A20cDNA F5 CCCTTGGAAGCACCATGTTTG 
A20cDNA F6 CAGTTCAAGCAGATGTATGGC 
TAX1BP1cDNAF1 AAGTTGGGAGAATGGAAAGAGAAC 
TAX1BP1cDNAF2 GAGATTGGCAGGCTGCAGTT 
TAX1BP1cDNAF3 AAGCCATCACCTTCTGCAGCA 
TAX1BP1cDNAF CACAATGACATCCTTTCAAGAAGT 
TAX1BP1cDNAR CTCATAATAAAAAGTAACTAGTCAAAATT 
T7promoter AAATTAATACGACTCACTATAGG 
 
2.1.4.4 Guide RNA (sgRNA) primers: 
 
Name Sequence (5’-3’) 
sgA20_F2 caccgTGTCATAGCCGAGAACAA 
sgA20_R2 aaacTTGTTCTCGGCTATGACAc 
sgTAX1BP_F4 caccgATACCAAGCTTATGTCAG 
sgTAX1BP_R4 aaacCTGACATAAGCTTGGTATc 
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2.1.4.5 ssODN repair template  
 
Name Sequence (5’-3’) 
A20 S254R C-A Rev 
CTCACCAGGCCCACTGTCCTTCAGGGTCACCAAGGGTACAAAATG
ATGTCTGTCATAGCCGAGAACAATGGGGTATCTGTAGCATTCCTG
GGCAGGCCAG 
TAX1BP L307I T-A 
CAGAAATAGAAAATACCAAGCTTATGTCAGAGGTCCTAAAAAATAT
AGATGGGAACAAAGAAAGCGTGATTACTCATTTCAAAGAAGAGATT
GGC 
 
 
 
2.1.5 General reagents and commercial kits 
Ficoll-Paque plus™ and Amersham ECL ™ western blotting detection reagents were 
purchased from GE Healthcare. PBS solution, DMEM medium were purchased from 
GIBCO. RPMI medium 1640, pcDNA™3.1(-)/myc-His A, B, & C, Lipofectiamin LTX 
with plus reagent, Cell Trace CFSE proliferation kit , Cell Trace Violet cell proliferation 
kit and PureLink®HiPure Plasmid Filter Midiprep kit were purchased from Invitrogen.  
SOC medium, L-glutamin , tryptone, yeast extract, penicillin streptomycin solution, and 
NaCl2, HEPES buffer solution, Dimethyl sulfoxide, L grutamine, Ampicillin sodium 
salt, protein G agarose were purchased from Sigma Aldrich.  Halt Phosphatase inhibitor 
cocktail (Piercent), Leucosep tube (Greiner Bio One-interpath), Human IL-2 
recombinant protein (Thermo Scienctific), Type B CpG oligonucleotide-human TLR9 
ligand (ODN2006) (Invivogen), Phusion Hot Start II High-Fidelity DNA polymerase 
(Finnzymes), Recombinant human TNFα (Biolegend) Nuclease free water (Applied 
Biosystems),  Gel Red nucleic acid gel stain (Omar Bioscience), anti Ig F(ab)2 (Jackson 
Laborotory), ORAgene-DNA OG-500 kit (DNAgenoTek), Tris-Glycin Mini 12% Gel 
(Nusep), were purchased. β-mercaptoethanol, isopropanol, absolute ethanol, methanol 
were purchased from JCSMR store.  
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Heat inactivated fetal bovine serum, Lipofectamine™ LTX with Plus™ Reagent, Bolt 
system kit, Neon transfection system 100µl kit were purchased from life Technologies. 
Protease inhibitor cocktail set III EDTA free and MG-132 were purchased from 
Calbiochem. Human recombinant CD40 Ligand and Human BAFF were obtained from 
Peprotech. 
 
Phusion hotstart flex, 100bp DNA Ladder, 1kb DNA Ladder, 6X gel loading dye , 
Restriction enzyme, KpnI, NotI, BamHI, HindIII-HF, ligase enzyme T4 were purchased 
from New England Biolabs ®Inc. Human recombinant IL-4, lymphotoxin /  and 
human recombinant GM-CSF were purchased from RnD. Fix buffer I and 
Cytofix/cytoperm kit were purchased from BD. QIAprep spin miniprep  mini kit, 
QIAamp DNA blood mini kit, QIAquick gel extraction kit, RNeasy plus mini kit, 
Miscript reverse transcription kit  SyBr Green PCR Kit were purchased from Qiagen.  
T-cell activation and expansion beads, CD14 MicroBeads human, CD4 MicroBeads, 
human recombinant IL-21 and Human GM-CSF were purchased from Miltenyi Biotech 
Inc. StemSep™ human B cell enrichment kit was purchased from Stemcell™ 
technologies. Immune-blot PVDF membrane, Precision plus protein™ Dual color 
standards and Bio-Rad DC™ protein reagent were purchased from Bio-rad.  
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2.1.5.1 Solutions and media 
2.1.5.1.1 FACS wash 
2ml of FBS (GIBCO) and 1g of sodium azide (NaN3) were dissolved in ~ 97ml of PBS 
(1X). 
2.1.5.1.2 FACS sorting solution 
1ml of FBS was added aseptically in 99ml of sterile PBS (1X) 
2.1.5.1.3 Lysis buffer for co immunoprecipitation 
120mM NaCl, 50mM HEPES, 1mMEDTA, 0.1%NP40, were dissolved in 1L of dsH2O. 
Protease inhibitor and phosphotase inhibitor were added freshly. 
2.1.5.1.4 Amplicillin solution (50mg/ml) 
10g of amplicillin was added to a final volume of 200ml of dsH2O and sterilized using a 
0.2um filter. 
2.1.5.1.5 LB media 
10g of trypton, 5g of yeast extract and 5g of NaCl2 were dissoloved in a total volume of 
1L of H2O. the solution was adjusted to pH 7.5 and autoclaved at 121°C for 15 minutes. 
2.1.5.1.6 LB agar plate  
10g of trypton, 5g of yeast extract and 5g of NaCl2 were dissoloved in a total volume of 
1L of H2O. The solution was adjusted to pH 7.5 and 15g of agar was added and the 
solution was autoclaved at 121°C for 15 minutes. When the temperature of the solution 
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reached about 50°C 2ml of Ampicillin solution (50mg/ml) was added and the LB 
solution was poured into plates and dried overnight at room temperature 
2.1.5.1.7 TAE buffer (50X) 
TAE buffer was prepared by dissolving 96.8g of Tris base, 13.5g of EDTA and 22.8g of 
glacial acetic acid in 300 ml of ds H2O. The pH was adjusted to pH8.0 with glacial 
acetic acid, the solution was autoclaved at 121°C for 15minutes and stored at 4°C.  
2.1.5.1.8 Transfer buffer 
100ml of Transfer buffer (20X), 200ml of methanol and 1.7Lof ds water were added 
and chilled overnight at 4°C. 
2.1.5.1.9 TBST (10X) 
24.23g of Trizma -HCl, 80.06 g of  NaCl  were added in 1L of water and pH was 
adjusted  to 7.6. 
2.1.5.1.10 Blocking buffer (3-5% skim milk or BSA) 
3- 5g of skim milk powder or BSA was added in 100ml of TBST (1X) solution. This 
solution was freshly made. 
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2.1.6 Bioinformatics 
 
Table 2.1Gene information 
Gene 
  
Website address 
A20 
gDNA NCBI http://www.ncbi.nlm.nih.gov/nuccore/NG_032761.1 
cDNA ensembl http://asia.ensembl.org/Homo_sapiens/Transcript/Exons?db=core;g=ENSG00000118503;r=6:138188351-138204449;t=ENST00000237289 
gene 
uniprot http://www.uniprot.org/uniprot/P21580 
genecards 
http://www.genecards.org/cgi-
bin/carddisp.pl?gene=TNFAIP3&search=951aade0b0275b184c6fb29cb8
a8ca9f 
OMIM http://omim.org/entry/191163?search=a20&highlight=a20 
TAX1BP
1 
gDNA NCBI http://www.ncbi.nlm.nih.gov/nuccore/NG_029523.1 
cDNA ensembl http://asia.ensembl.org/Homo_sapiens/Transcript/Summary?db=core;g=ENSG00000106052;r=7:27778950-27880938;t=ENST00000265393 
gene 
uniprot http://www.uniprot.org/uniprot/Q86VP1 
genecards 
http://www.genecards.org/cgi-
bin/carddisp.pl?gene=TAX1BP1&search=951aade0b0275b184c6fb29cb8
a8ca9f 
OMIM http://omim.org/entry/605326?search=tax1bp1&highlight=tax1bp1 
NFKB2 
gDNA NCBI http://www.ncbi.nlm.nih.gov/nuccore/NG_033874.1 
cDNA ensembl http://asia.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000077150;r=10:104154229-104162281;t=ENST00000189444 
gene 
uniprot http://www.uniprot.org/uniprot/Q00653 
genecards 
http://www.genecards.org/cgi-
bin/carddisp.pl?gene=NFKB2&search=e58d9149c970d62be6cab37032b
d7e53 
OMIM http://omim.org/entry/164012?search=nfkb2&highlight=nfkb2 
NIK 
gDNA NCBI http://www.ncbi.nlm.nih.gov/nuccore/555290184 
cDNA ensembl http://asia.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000006062;r=17:45263121-45317040 
gene 
uniprot http://www.uniprot.org/uniprot/Q99558 
genecards 
http://www.genecards.org/cgi-
bin/carddisp.pl?gene=MAP3K14&search=77113177b98eaff56855e81a42
9fc8c7 
OMIM http://omim.org/entry/604655?search=nik&highlight=nik 
 
 
 
Table 2.2Predicting functional effect  
Name Website 
Polyphen 2 http://genetics.bwh.harvard.edu/pph2/ 
Mutation taster www.mutationtaster.org 
SIFT http://sift.jcvi.org 
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Table 2.3 Analysis tool 
Name Website 
Primer design http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome 
DNA alignment tool http://www.ebi.ac.uk/Tools/psa/emboss_matcher/nucleotide
.html 
Annealing temperature 
tool 
http://www.neb.com/nebecomm/tech_reference/TmCalc/De
fault.asp 
Reverse complementary http://www.bioinformatics.org/sms/rev_comp.html 
Restriction enzyme tool http://www.restrictionmapper.org/ 
Searching for overlap http://www.pangloss.com/seidel/Protocols/venn.cgi 
Interacting gene search http://string-db.org/, http://thebiogrid.org/ 
Tm Calculator http://tmcalculator.neb.com/#!/  
Gene expression http://www.immgen.org/index_content.html 
 
 
2.2 Methods 
2.2.1 Cellular phenotypes 
2.2.1.1 PBMC isolation from Blood 
Whole blood was collected into ACD tubes then  diluted with PBS in a 1: 1 ratio then 
layered onto Ficoll- Paque PLUS solution (GE healthcare, 17-1440-03) before 
centrifugation at 400g for 30 minutes at room temperature then decelerated without the 
brake. Buffy coats were separated and washed twice in tissue culture media . 2 x 106 
PBMCs were resuspended with 1ml of freezing medium, which consisted of RPMI, 
10% of FBS and 10% of DMSO, and then stored at -80°C overnight and transferred to 
liquid nitrogen. 
 
2.2.1.2 Cell culture  
Frozen PBMC samples were transferred into a 37°C water bath for quick thawing then  
cells were immediately washed with tissue culture media, followed by centrifugation at 
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1200rpm for 5 minutes. Cell numbers were counted by haemocytometer and desired cell 
numbers were maintained in complete RPMI at 37°C with 5% CO2.  
 
2.2.1.3 Flow cytometry analysis 
2.2.1.3.1 Surface staining 
PBMCs were thawed and washed with culture media and spun at 350g 4°C for 10 
minutes. PBMCs were then washed twice with FACS buffer containing 2% of FBS, 1% 
of NaN3 in PBS followed by spinning at 300G for 5 minutes at 4oC. 2X106cells per 
200µl were transferred into a well of a 96 well plate with round bottom and centrifuged 
again at 300g for 5 minutes at 4oC. 30µl of desired antibody cocktail (Appendix II) was 
added and incubated for 30 minutes on ice. The cells were washed twice with FACS 
wash then resuspended with 100µl of FACS wash for FACS acquisition. 
 
2.2.1.3.2 Intercellular stain 
Intercellular staining was performed after surface staining. Cells were washed with 
perm wash 1X (BD) twice, then fixed with cytofix solution (BD) for 20 minute on ice. 
Antibody cocktail (Appendix II), which was prepared with perm wash (1X), was added 
and incubated for 20 minutes on ice. The cells were washed with perm wash (1X) once 
and washed with FACS wash once. The cells were resuspended with 100µl of FACS 
wash for Flow cytometry acquisition. 
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2.2.1.3.3 Foxp3 staining 
Cells were stained with CD4 CD127 and CD25 antibodies by surface staining protocols 
(Appendix II) then permeabilized and fixed with a FoxP3 staining kit. Cells were 
stained with Cells were washed with FACS wash twice and fixed with 100µl of 1x 
human FoxP3 buffer A. After incubating at RT for 10 minutes in the dark, cells were 
centrifuged at 300g for 5 minutes and  washed with FACS wash. The pellet was 
resuspended with 100µl of 1x working solution of Human FoxP3 Buffer C and 
incubated at room temperature for 30 minutes in the dark. Cells were washed with 
FACS wash and incubated with Foxp3 antibody cocktail (Appendix II) for 30 minutes 
at RT in the dark. Cells were then washed with FACS wash twice and 100µl of FACS 
wash was added for Flow cytometry acquisition.  
 
2.2.1.4 Cell sorting by Flow cytometry, MACS or Stem cell technology 
The cells were washed twice with FACS wash at 350g, 4°C for 10 minutes. Up to 100 x 
106 cells were resuspended with 500µl of sorting antibody cocktail (Appendix II). Cells 
were incubated about 30 minutes in the dark on ice and cells were washed with PBS 
two times and cells were then flushed through strainers (2µm). Cells were then sorted 
using BD FACS Aria I into complete RPMI medium, then pelleted and resuspended in 
tissue culture media.  
 
For MACS sorting, cells were incubated with antibody conjugated MACS Microbeads, 
then loaded into the MACS column. The column was washed three times with washing 
buffer (PBS with 1% BSA), then cells were eluted with washing buffer. With Stem cell 
technology sorting, cells were stained with a stem cell antibody cocktail and the mixture 
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was added into a tube inserted into StemcellTM magnet. The mixture was incubated for 5 
minute at room temperature and unbound cells were removed by inverting the tube. 
Cells were then washed twice with culture media. 
 
2.2.1.5 T cell and B cell activation and apoptosis assays  
Cells were incubated with various stimuli for 24, 48 or 96 hours. Cells were then stained 
with the activation antibody cocktail or the apoptosis antibody cocktail (Appendix II). 
 
2.2.1.6 T cell / B cell proliferation   
Proliferation of cells was analysed using Cell TraceTM Violet (CTV) Cell Proliferation 
Kit or Cell TraceTM Carboxyfluorescein succinimidyl ester (CFSE) Cell Proliferation 
Kit (invitrogen) according to the manufacturer’s instructions.  Sorted cells or PBMCs 
were washed twice with PBS and 1x106 cells were resuspended in 1ml of PBS. 1µl of 
CTV or CFSE was added and cells were incubated at room temperature for 5 minutes 
and then labelling was quenched with cold complete RPMI on ice for 10 minutes. Cells 
were centrifuged at 400g for 5 minutes at 4°C and washed with complete RPMI.  
 
2.2.1.7 Plasmablast induction  
PBMCs were washed twice with complete RPMI and 1x106 cells per 1 ml of complete 
RPMI were added to each well of a 48 well plate. For plasmablast induction B cells 
were cultured with various combinations of IL-21 (50ng/ml) and CD40L (1µg/ml) or 
IL-21 (50ng/ml) and CpG (2µM) or IL-21 (50ng/ml) and CD40L transfectants L-cells 
for 4 or 5 day at 37°C with 5% CO2.  
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2.2.1.8 Monocyte derived human dendritic cell culture 
CD14+ cells were isolated from PBMCs using magnetic CD14 microbeads according to 
the manufacturer’s instructions (Miltenyi Biotech, Sydney). Isolated cells were then 
analysed with Flow cytometry for purity check. CD14+ cells (1x106 cells/ml) were 
cultured with GM-CSF (100ng/ml), IL-4 (30ng/ml) and 2-mercaptoethanol (50µM) in 
complete RPMI1640 for 7 days with replenishment of the media every 2-3 days. The 
morphology was checked by microscope. The monocyte derived dendritic cells 
(MDDC) were cultured with various stimuli for desired studies. 
 
2.2.2 Molecular analysis 
2.2.2.1 DNA isolation from saliva 
Genomic DNA was isolated from saliva using ORAgene-DNA OG-500 kit 
(DNAgenoTek) according to the manufacturer’s instructions. Briefly, saliva samples 
were mixed in the DNA genotek kit by inversion and gentle shaking for a few seconds. 
The sample was then incubated at 50°C for 1 hour and 500µl of the sample mix was 
transferred into a 1.5ml tube. PT-L2P was then added and mixed by vortexing for a few 
seconds. The sample was incubated on ice for 10 minutes and centrifuged at room 
temperature for 15 minutes at 13 000 rpm. The supernatant was then transferred into a 
new 1.5ml tube and 600µl of ?% ethanol was added and mixed. The sample was 
centrifuged at 13 000 rpm for 5 minutes and the supernatant was removed and 250µl of 
70% ethanol was added and incubated at room temperature for 1 minute and centrifuged 
at 13000 rpm for 5 minutes. The supernatant was then removed completely. 100µl of 
Novel NF-kB mutations in common variable immunodeficiency (CVID)  
72 
 
H2O solution was added and the pellet was dissolved by vortexing and pipetting. The 
DNA solution was stored at -20°C.  
 
2.2.2.2 Whole Exome capture sequencing 
The Illumina paired-end genomic DNA sample preparation kit (PE-102-1001, Illumina) 
was used for preparing the libraries including end repair, A-tailing and ligation of the 
Illumina adaptors. Each sample was prepared with an index using the Illumina 
multiplexing sample preparation oligonucleotide kit (PE-400-1001, Illumina) and then 
pooled in batches of six in equimolar amounts prior to exome enrichment. The Illumina 
TruSeq exome kit (FC-121-1008, Illumina) was used to capture the human exome for 
each sample pool. Each 6-plex exome enriched library was sequenced in two lanes of an 
Illumina HiSeq 2000 with version 2 chemistry as 100bp paired end reads. 
 
Sequence reads were mapped to the GRCh37 or GRCh38 assemblies of the reference 
human genome using the default parameters of the Burrows-Wheeler Aligner (BWA, 
bio-bwa.sourceforge.net) 21. Untrimmed reads were aligned allowing a maximum of two 
sequence mismatches and reads with multiple mappings to the reference genome were 
discarded along with PCR duplicates. Sequence variants were identified with SAMtools 
(samtools.sourceforge.net)(Li and Durbin 2010) and annotated using Annovar 
(www.openbioinformatics.org) (Wang, Li et al. 2010). A version of PolyPhen2 
(genetics.bwh.harvard.edu/pph2) (Adzhubei, Schmidt et al. 2010), was utilized for the 
calculation of variant effect. 
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2.2.2.3 Single Nucleotide Variants (SNVs) analysis 
SNVs were filtered with sequential parameters for selecting candidate SNVs. Rare or 
Novel SNVs were the first line of the filtering. The rare or novel alleles were filtered 
according to the sum of scores for mouse mutant phenotype in the homologous mouse 
gene, Mendelian disease associations (OMIM), pathway analysis (GO), immune system 
expression (Immgen) and polyphen2 score, according to the following scheme: mouse 
mutant phenotype: non-immune=0, nil=1, immune=2; OMIM, non-immune disease=-1, 
Nil=0, immune disease=1; Gene ontology, non-immune tissue-specific 
function=0.general cellular process=1, immune-related=2, proven T or B cell 
function=4; Immgen, high=3, medium=2, low=1, nil=0; Polyphen2 score.    
 
2.2.2.4 RNA extraction 
1x106 cells were washed twice with PBS at 300g for 5 minutes at 4°C. 1ml of Trizol 
was added to the cell pellet and mixed well by pipetting several times and incubated for 
5 minutes at room temperature. 0.2ml of chloroform was added and mixed well by 
shaking tubes vigorously by hand for 15 seconds. After 2-3 minutes incubation at room 
temperature, the mixture was centrifuged at 12000g for 15 minutes at 4°C and the 
aqueous phase was carefully transferred into a 1.5ml tube. 0.5ml of 100% isopropanol 
was added to the aqueous phase and incubated for 10 minutes at room temperature. It 
was centrifuged at 12000g for 10 minutes at 4C and supernatant was removed. The 
pellet was washed with 1 ml of 75% ethanol and mixed by vortexing and centrifuged at 
7500g for 5 minutes at 4°C. The wash was discarded and the pellet was air dried for 5-
10 minutes. The pellet was resuspended with 30µl of RNase free water and mixed by 
passing the solution up and down several times through a pipette tip. The solution was 
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incubated in 55-60°C heat block for 10 minutes. RNA concentration was measured by 
nano drop and RNA was stored at -80°C.  
 
2.2.2.5 Reverse Transcriptase PCR to cDNA 
Frozen RNA, 5X miScript RT buffer and RNAse free water were thawed at room 
temperature. The reverse transcription master mix was prepared on ice as blew. 
Component Volume 
miScript RT buffer 5X 4µl 
RNase-free water 15µl-RNA volume 
miScript Reverse transcriptase mix 1µl 
Template RNA 1µg 
Total volume 20µl 
 
The mixture then was incubated for 60 minutes at 37°C then further 5 minutes at 95°C 
to inactivate miScript Reverse Transcriptase Mix. The cDNA was then stored at -20°C. 
 
2.2.2.6 RT PCR 
Commercial primers were purchased from Promega and real time PCR was run with 
Sybr green. 10pmol of forward and reverse primers were added to cDNA and Sybr 
green master mix (Promega). The PCR was initiated at 94°C for two minutes for DNA 
denaturation, and ran 35 cycles of denaturation at 94°C for 30 seconds, primer 
annealing at 55-70°C for 30 seconds and extension at 72°C for 1minute. This was 
followed by the final extension step, 5 minutes of 72°C and PCR products were then 
stored at 4°C or -20°C. 
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2.2.2.7 PCR primer design 
Whole DNA sequences were obtained from DNA data base (NCBI). 1000bp of genomic 
DNA sequence surrounding mutations (500pb forward and 500bp backward) were 
subjected for Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi?LINK_LOC=BlastHome). The primer set was selected after analysis for 
possible off-target amplification (BLAST). 
 
2.2.2.8 PCR 
The standard PCR solution was prepared with 2X Arbiter master mix (TrendBio) with 
forward and reverse primers on ice. (Table 2.4)The PCR was initiated at 94°C for two 
minutes for DNA denaturation, and ran 35 cycles of denaturation at 94°C for 30 
seconds, primer annealing at 55-69°C for 30 seconds and extension at 72°C for 1minute. 
This was followed by the final extension step of 5 minutes of 72°C, and PCR products 
were then stored at 4°C or -20°C. 10µl of the products were loaded onto a 1.5% agarose 
gel with GelRed Nucleic Acid Gel Stain (Omar Bioscience) and electrophoresis was 
performed in 1XTAE buffer at 100 voltages for 30 minutes. The GelRed stained PCR 
products were visualised under UV light with Gel Doc XR+ system (Bio-Rad). The 
optimal annealing temperature was determined by gel photograph.  
Component Volume 
DNA (100ng/µl) 1µl 
Primers (10pmol) 1 µl 
Arbiter 2x Master mix® 10µl 
H2O 8µl 
Total volume 20µl 
Table 2.4 PCR set up 
The conditional PCR was prepared with Phusion hotstart Flex polymerase (NEB). 
10pmol of forward and reverse primers and 10-100ng of DNAs, 0.3µl DMSO and up to 
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20µl of ds H2O were added into a PCR tube. The PCR was initiated at 98°C for three 
minutes followed by 35 cycles of denaturation at 98°C for 10 seconds, primer annealing 
at optimal temperature (55°C -70°C) for 30 seconds, and extension at 72°C for 1~2 
minutes. The final extension step was 5 minutes of 72°C. Products were loaded onto a 
1~2% of agarose gel containing 1X GelRed and electrophoresis was performed in 
1XTAE buffer at 100V for 30 minutes. The gel red stained PCR products were 
visualised under UV light with Gel Doc XR+ system (Bio-Rad).   
 
2.2.2.9 Purification of PCR products- Gel extraction, Exo SAP 
The PCR products were purified using QIAquick Gel Extraction Kit (QIAGEN) to 
remove polymerases, dNTP and the germline DNA. Alternatively, primers were 
removed from PCR product by ExoSAP-IT (usb®).  5µl of PCR products were mixed 
with 2µl of ExoSAP-IT. The mixture was incubated at 37° C for 15 minutes and 80° C 
for 15 minutes by thermocycler.  
   
2.2.2.10 Sanger sequencing  
2pmol of primers and 30ng of PCR products were submitted to Biomolecular Resource 
Facility at John Curtin School of Medical research, Australian National University.  
 
2.2.2.11 Analysis of sequencing results 
The sequencing results were aligned with a reference DNA to identify mutations using 
http://www.ebi.ac.uk/Tools/psa/emboss_matcher/nucleotide.html.   Reference 
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sequences were obtained from NCBI or ensemble. Forward and reverse primers were 
used for conforming mutations. 
 
2.2.2.12 Microarray  
Naïve B cells were isolated by positive selection. Naïve B cells were CD19+, CD27-, 
CD10- and CD21high.  After sorting, the cells were incubated with anti Ig stimulus 
(5ug/ml) overnight at 37°C with 5% CO2. The activated naïve B cells were then used 
for RNA extraction. RNAs were extracted by either trizol method or RNA kit method. 
The RNA pellets were then resuspended with RNase free water and stored at-80°C for 
overnight. The RNA solution was then delivered to Ramaciotti Centre for Genomics 
(Sydney) for microarray analysis. Duplicate biological samples were prepared for the 
assay. The microarray was done in Affymetrix platform with gene array. The data were 
analysed by Partek analyser gene array was qualified for the assay.  
 
2.2.3 Biochemical analysis  
2.2.3.1 Gene expressing vector construction 
2.2.3.1.1 Design primers for desired genes 
In order to generate mammalian expressing vectors containing target genes, cDNA 
nucleotide sequences of the gene of interest were found through Ensembl and NCBI 
(Table 2.2). Using restriction enzyme mapper; http://www.restrictionmapper.org/;  
http://66.155.211.155/nebecomm/DoubleDigestCalculatorIntl.asp. We idenified 
appropriate restriction sites with the multicloning locus. 
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The primers contained approximately 15 nucleotides of the gene of interest and 
restriction site and additional nucleotides which were added for codon reading frame or 
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assistance of digestion. In forward primers Kozak sequence was added to help initiating 
transcription. 
 
      eg. A20cDNAF NotI 
         additional nucleotides   restriction sequence  
                                         5’  aaaGCGGCCGCGCCACCATGGCTGAACAAGTCCTTCC 3’ 
                                                    Kozak sequence       A20 cDNA               
 
2.2.3.1.2 Digestion of DNAs  
The genes of interest were amplified by polymerase chain reactions (2.2.2.2.).  The PCR 
products were visualized by DNA staining with GelRed after electrophoresis.  PCR 
products and vectors were set up with the following digestion enzyme reactions. The 
PCR product and vector were digested with restriction enzymes for 4 hours at 37°C.  
 
 
1. A20-pcDNA vector ( -c version) 
Name DNA DNA (1ug) 
NEBuf
fer2 KpnI NotI BSA water 
Total 
volume 
(µl) 
A20 
digestion 
A20 pcr 
product 42.5 5 1 1 0.5 - 50 
pcDNA 
digestion 
pcDNA 
(-c) 3.6 5 1 1 0.5 38.9 50 
+ control 
Single cut 
pcDNA 
(-c) 3.6 5 1 - 0.5 39.9 50 
+ control 
Single cut 
pcDNA 
(-c) 3.6 5 - 1 0.5 39.9 50 
-control 
No cut 
pcDNA 
(-c) 3.6 5 - - 0.5 40.9 50 
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2. TAX1BP1-Flag tagged pcDNA( +) 
Name DNA DNA (1ug) 
Buffer
3 
BamH
I NotI BSA water 
Total 
volum
e (µl) 
TAX1BP1 
digestion 
TAX1BP1 
Pcr product 42.5 5 1 1 0.5 - 50 
pcDNA 
digestion 
pcDNA-
Flag (+) 3 5 1 1 0.5 39.5 50 
+ control 
Single cut 
pcDNA-
Flag (+) 3 5 1 - 0.5 40.5 50 
+ control 
Single cut 
pcDNA-
Flag (+) 3 5 - 1 0.5 40.5 50 
-control 
No cut 
pcDNA-
Flag (+) 3 5 - - 0.5 41.5 50 
 
 
 
 
3. NIK-pcDNA vector (– c version) 
Name DNA DNA (1ug) 
NEBuf
fer3 BamHI NotI BSA water 
Total 
volume 
(µl) 
NIK 
digestion NIK 16.4 5 1 1 0.5 26.1 50 
pcDNA 
digestion 
pcDNA (-c) 3.6 5 1 1 0.5 38.9 50 
+ control 
Single cut  
pcDNA (-c) 3.6 5 1 - 0.5 39.9 50 
+ control 
Single cut 
pcDNA (-c) 3.6 5 - 1 0.5 39.9 50 
-control 
No cut 
pcDNA (-c) 3.6 5 - - 0.5 40.9 50 
 
2.2.3.1.3 Ligation of two products 
Digested products were purified by gel extraction (protocol 2.2.2.). The amount of PCR 
product was determined according to the following formula (Klionsky, Abdalla et al.).  
 
Molar size of insert×Concentration of vector                  (ng/µl)	×(ratio)= Conc of    
      Molar size of vector                                                                            insert (ng/µl)       
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1:3, 1:5, and 1:7 ratios were used for optimal results. The reactions were set up as 
below.  
 
 
 
The reactions were then mixed by pipetting and incubated overnight at 4°C. 
 
2.2.3.1.4 Transformation 
The ligation reactions were briefly centrifuged and 2µl of each ligation reaction was 
transferred to a new tube. 0.1ng of uncut plasmid was added to separate 1.5ml tubes and 
incubated with DH5α cells on ice for 20 minutes. The tubes were then warmed in a 
42°C heat block for 45 seconds and then immediately placed into an ice bath for a 
further 2 minutes. 950µl of SOC medium (sigma) was added into the tubes. The tubes 
were then incubated for 1.5 hours at 37°C with shaking at about 150rpm. 50µl or 100µl 
of each transformation culture was plated onto an LB agar plate containing Ampicillin 
 Standard 
reaction 
(1:3) 
Standard 
reaction 
(1:5) 
Standard 
reaction 
(1:7) 
Positive 
control 
Negative 
control 
5X rapid   T4 
ligation buffer 2µl 2µl 2µl 2µl 2µl 
Digested 
vector  (~5kb) 1µl (50ng) 1µl (50ng) 1µl (50ng) - 1µl 
Digested PCR 
product 
(~2kb) 
1.2µl 
(60ng) 2µl(100ng) 2.8 (140ng) - 1µl (60ng) 
Single cut 
vector - - - 1ug (50ng) - 
T4 DNA 
ligase 1µl 1µl 1µl 1µl - 
Deionized 
water 14.8µl 14µl 13.2µl 16µl 16µl 
Total 20µl 20µl 20µl 20µl 20µl 
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(100ug/ml). The plates were then incubated overnight (16-24hours) at 37°C and the 
number of colonies were recorded from each plate.  
2.2.3.1.5 Plasmid isolation 
A single colony was inoculated with 5ml of LB medium containing ampicillin 
(100ng/ml) and incubated at 37 °C overnight with shaking.  1ml of each culture was 
stored with glycerol to a final concentration of 20% at -80°C. QIAprep Spin Miniprep 
Kit (QIAGEN) was used to isolate plasmids. Briefly, bacterial cell pellets were obtained 
by centrifugation at 13000rpm for 5 minutes and were resuspended in the 
manufacturer’s lysis buffer (QIAGEN). Denatured and precipitated cellular components 
were removed by centrifugation (at 13000rpm, 1 minute) and filtration using the 
QIAprep columns. The columns were washed with PE buffer which contained 70% of 
EtOH and then were eluted with H2O by centrifugation at 13000rpm for 2 minutes and 
the plasmid concentration was measured by nanodrop and the DNA solution was stored 
at -20°C. 
 
2.2.3.2 Transfection 
2.2.3.2.1 Lipofectamine 
HEK293 or HEK293T cells were seeded at 1x106 cells per well in 6 well plates and 
incubated overnight at 37°C with 5% CO2. When cells were reached approximately 70-
90% confluence, transfection was performed using 2ug of mammalian expression 
vectors was added in 250 µl of incomplete RPMI with 2µl of PLUS™ reagent (Life 
technologies), incubated at room temperature for 5 minutes while 10µl of 
lipofectamine® LTX (Life technologies) was added in 250µl of incomplete RPMI and 
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incubated at room temperature for 5 minutes. Next, these two solutions were combined 
and incubated at room temperature for 30 minutes. The overnight culture media was 
replenished with 1.5ml of fresh complete media without antibiotics. 0.5ml of 
transfection solution was added dropwise onto the cell culture and mixed gently by 
rocking the plate. The transfected cells were incubated for an additional 1-2 days at 
37°C with 5% CO2. 
 
2.2.3.2.2 Neon Transfection 
Neon TM Transfection System was used for electroporation. Raji cells were washed with 
PBS and 1 x 106 cells were pelleted and mixed with 50µl of R buffer. 10µg of DNA 
mixer was separately prepared with 50µl of R buffer. The DNA mixed was mixed with 
the cell solution and aspirate d into NeonTM pipette. The pipette was inserted into Neon 
tube containing 3ml of Electrolytic buffer. The electroporation was completed by 
pressing start button with appropriated protocols. The sample was then added in 
prewarmed complete media without antibiotics and incubated at 37°C in humidified 
CO2 incubator. 
2.2.3.3 Bradford protein assay 
Total protein content was determined by serial dilution of the cell lysate in PBS, and 
addition of 20µl of Bradford regent (Sigma) was added to each wells and the plate was 
incubated for 30 minutes, then analysed for absorbance at 570nm, and compared to the 
standard curve. 
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2.2.3.4 Immunoblotting 
Cell lysates were prepared in RIPA buffer (Sigma) or CytoBuster ™ protein exraction 
reagent (Novagen) with protease inhibitor cocktail (Dong, Strome et al.) and Halt 
phosphatase inhibitor (Piercent) and the lysates were subjected to SDS-PAGE. After 
protein estimation, equal amounts of proteins were mixed with 2X SDS sample loading 
buffer containing 10% of β-mercaptoethanol freshly and boiled at 100°C for 5 minutes. 
The samples were then loaded in precast polyacrylamide gels with precision plus 
protein™ dual color standards (Bio-rad). The gel was run at 120V for 1 hour, then 
transferred to PVDF membrane by wet transfer method. 20X transfer buffer was diluted 
with H2O and chilled overnight. The transfer sandwiches were prepared with transfer 
buffer (- charge cassette- sponge- gel-PVDF membrane- sponge- cassette + charge), run 
at 120V for 2 hours. Membranes were blocked for 1 hour 3~5% of BSA in TBST or 5% 
of skim milk in TBST. Primary antibodies were added with blocking buffer and 
incubated at 4°C overnight with gentle shaking. The membranes were washed with 
washing buffer (TBST 1X) for 10 minutes three times. HRP-conjugated secondary 
antibodies were added with blocking buffer and incubated at 4°C for 1 hour. The 
membranes were washed with washing buffer for 10 minutes three times anf analysed 
using the Amersham ELC western blotting system (GE healthcare) and band intensity 
was quantified with Fujifilm multi gauge software and normalized to loading control. 
 
2.2.3.5 Immunofluorescence  
HEK293 cells were transfected with indicated constructs and treated with TNF or left 
unstimulated. Cytospins were fixed with 4% paraformaldehyde in phosphate buffered 
saline, and permeabilized with 1% Triton X, then blocked with 3% skim milk and 
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stained with primary antibodies at 4°C overnight. Slides were washed three times with 
PBST for 5 minutes each before secondary immunofluorescent antibodies were added. 
The slides were then washed another three times with PBST and mounted with anti fade 
mounting media containing Dapi. Images were acquired by Leica SP5 confocal 
microscope with a 63x oil immersion objective.   
 
2.2.3.6 Deubiquitination assay 
 
Human TNFAIP3 were amplified with AccuPrime Pfx DNA polymerase (Invitrogen) 
from cDNA pool obtained from human peripheral blood. The full-length coding 
sequence of TNFAIP3 was cloned into the pcDNA3.1+ vector and confirmed with 
sequencing. PCR-based mutagenesis was used to introduce the mutations (H256A and 
S254R) in this study. The OTU domains of human TNFAIP3 (encoding 2-370 residues) 
were cloned between BamHI and XhoI sites in pGEX-6P-1 vector (GE Healthcare). 
GST-fused TNFAIP3 OTU protein was expressed in E. coli BL21 (BIOLINE) cells at 
30ºC for 12-16 hrs with 200 µM IPTG. Cells were lysed by sonication in 50 mM Tris 
(pH8.0), 100 mM NaCl, and 1 mM EDTA, followed by the addition of Triton-X100 
(1% w/v). The lysates were cleared by centrifugation, and then incubated with 
glutathione agarose (SIGMA). Precipitated complex was washed three times with lysis 
buffer, followed by washing with Prescission buffer (50 mM Tris [pH 7.5], 150 mM 
NaCl, 1 mM EDTA, and 1 mM DTT). TNFAIP3OTU protein was excised with 
Prescission protease (GE Health) and collected from supernatant. The purified A20 
OTU domain was tested for hydrolysis of Lys 63 linked tetraubiquitin chains in a time 
course experiment in vitro. Purified TNFAIP3OTU proteins were incubated in 100 µl of 
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DUB buffer (25 mM HEPES [pH 8.0], 5 mM DTT, 5 mM MgCl2) containing 2.5 µg of 
K48- or K63- linked polyubiquitin chain (#UC-230, #UC-330 from BostonBiochem). 
At the indicated time, 20 µl of reaction mixture was collected and enzymatic reaction 
was stopped by the addition of SDS sample buffer. Negative control was known 
mutation A20 H256S, which contains an amino acid substitution at 256 from histidine 
to serine. 
 
2.2.3.7 Co Immunoprecipitation 
HEK293T cells were co-transfected with A20 and TAX1BP1 expressing vectors. Cells 
were washed with PBS and 250µl of lysis buffer was added to each well on a 6 well 
plate and incubated on ice for 30 minutes. Lysed cells were collected into 1.5ml tubes. 
A 50% protein G agarose slurry was prepared with lysis buffer. Lysed cells were spun 
down at 13000rpm for 15 minutes at 4°C. Total protein was measured in the 
supernatant. For preclearing, 50µl of 50% slurry protein G was added into the sample 
tube with an isotype control antibody (2µg). The mixture was incubated at 4oC 
overnight with gentle rotation. The mixture was spun down at 1300rpm for 1 minute at 
4oC, and the supernatant was transferred into 3 new tubes and anti Myc, anti Flag or anti 
Isotype antibody (2µg each) and 30µl of protein G agarose slurry were added. The 
mixture was incubated at 4°C for 2 hours with gentle rotation. The protein agarose 
slurry was spun down and supernatant was discarded. Approximately 1ml of lysis buffer 
was added and the slurry was washed 3 times at 1300rpm, 4°C. 30µl of 2XSDS sample 
buffer was added and the protein solution was boiled at 100°C for 5 minutes. The 
denatured samples were stored at -20°C for further immunoblotting experiments. Anti 
c-Myc and anti FLAG antibodies were used for western blot. 
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2.2.3.8 CRISPR CAS9 
pX330 U6 chimeric DD CBh hSpCas9 plasmid was obtained from Addgene. 
Guide RNA containing target cutting site (CCG) was constructed.  In order to introduce 
desired mutations, DNA repair template was also synthesized (approximately 100bp). 
Cells were then transfected with these nucleotides by either Neon transfection or 
Lipofectimine transfection. Cells were then incubated at 37°C for 24 hours in 
humidified with Co2 incubator. The following day single cells were isolated by reporter 
gene expression such as GFP and mCherry and the single cells were cultured for 3-4 
weeks. Sanger sequencing and western blot were conducted to confirm knockout of the 
gene of interest. 
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3 Pedigree I 
3.1 Results 
3.1.1 Discovery of rare mutations in patients with CVID 
This chapter describes results from two kindreds recruited to the Australian and New 
Zealand Antibody Deficiency Allele (ANZADA) study. So far, more than 150 
individuals have been investigated by whole exome sequencing (WES) to identify 
causative genetic variants. Analysis of this dataset has revealed that mutations within 
the same gene is exceptionally uncommon in CVID, once variants in known CVID-
associated genes have been excluded. For our discovery programme, we hypothesized 
that a subset of CVID is caused by rare, highly penetrant genetic variants within the 
coding region of the genome. 
 
 
Figure 3.1 Pedigree of the family. Two affected individuals and their relatives were recruited 
through part of the ANZADA study. Circles represent female subjects and squares represent male 
subjects. Colour filled symbols denote clinical features; Black, common variable immune deficiency 
(CVID); blue, IgA deficiency syndrome (IgAD); yellow, multiple sclerosis (MS); green, Erosive Arthritis 
(EA). * denotes A20 S254R carrier. 
 
First, we analysed novel mutations and then filtered the mutant genes according to 
immune relatedness. After this analysis, only one specific novel mutation was identified 
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in more than one pedigree, a missense mutation in TNFAIP3. TNFAIP3 encodes the 
deubiquitinase A20, which is already known to be an important immune regulator. 
 
3.1.2 A20 mutations and functional analysis 
3.1.2.1 TNFAIP3 sanger sequencing results 
   
   
 
 
 
Figure 3.2 S254R TNFAIP3 mutation A. Sanger sequencing of S254R TNFAIP3 heterozygous 
mutation. B. The position of the missense mutation. C. Schematic representation of human A20 structure 
contains ovarian tumour (OTU) domain and seven zinc finger (ZF) domain. The mutation S254R in OTU 
domain is denoted. D. Conservation of amino acid at the residue. * denotes A20 S254R and A shows 
active site. 
 
cDNA Protein  
Position  Allele change  Position  Residue change  
828 AGC ⇒ AGA  254  S [Ser] ⇒  R [Arg]  
 
Human  IYLPLHWPAQECYRYPIVLGYDSHHFVPLVTLKDSGPE 
Mouse  IYLPLHWPAQECYRYPIVLGYDSQHFVPLVTLKDSGPE 
Macaca IYLPLHWPAQECYRYPIVLGYDSHHFVPLVTLKDSGPE 
Bovine IYLPLHWPAQECYRYPIVLGYDSQHFVPLVTMKDSGPE 
Horse  IYLPLHWPAQECCRYPIVLGYDSHHFVPLVTLKDSGPE 
Opossum IYLPLHWPAQECYKYPIVLGYDSQHFAPLVTLKDSGPE 
Platypu   IYLPLHWPAHECYRYPIVLGYDSQHFVPLVTLKDSGPE 
Xenopus   IYLPLHWPAKECYKYPVVLGYDSQHFAPLVTMKDSGPE 
Danio  IYLPLHWPPGECYKYPIVLGYDSQHFAPLITIKDSGPE
  
OTU ZF ZF ZF ZF ZF ZF ZF AA * 
 
 G A C A G A C A T C A T 
  R/S     H    H     D 
 
 G A C A G C C A T C A T 
     S     H    H     D 
A.II.1 A.I.1 
* 
  * 
 G A C A G A C A T C A T  G A C A G C C A T C A T 
     S     H    H     D     R/ S    H    H     D 
B.II.1 B.I.2 
B A 
C 
D * 
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Using WES, we identified an identical missense mutation (g.8910C>A) in probands 
from two separate unrelated kindreds (A.II.1, A.II.2 and A.I.2, Figure 3.1). In each case, 
the TNFAIP3 mutation was confirmed by Sanger sequencing. We went on to genotype 
other members of each kindred. We concluded that the mutation in family A may have 
been transmitted from the proband’s deceased maternal grandfather (Figure 3.3).  
 
 
 
 
Figure 3.3 Pedigree of Family A Sanger sequencing of TNFAIP3 heterozygous mutation. Circles 
represent female subjects and squares represent male subjects. Subjects with bold lines were Sanger 
sequenced. CVID, common variable immune deficiency; AIHA, autoimmune haemolytic anemia; ITP, 
immune thrombocytopenic purpura; IgAD, IgA deficiency syndrome (IgAD); MS, multiple sclerosis, 
IBD, inflammatory bowel disease; green. * denotes A20 S254R carrier.  
 
 
In family B, B.II.1 and his father B.I.1 were carriers of the mutation. Genomic DNA 
from both saliva and lymphocytes was tested and yielded similar findings. The 
heterozygous mutation (C→A) encodes an amino acid substitution of serine with 
arginine. This mutation remains novel according to 1000 genomes, dbSNP, and the 
Exome aggregate consortium (ExAC). Three major mutation prediction algorithms, 
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Polyphen2, MutationTaster and SIFT, predicted that it is a damaging mutation. S254 is 
conserved from human to danio.  
 
 
 
 
Figure 3.4 Crystal structure of A20 and location of S254R residue. C103 and His256 are active sites 
in DUB. Asp70 is a supporter of the active sites.S254R is adjacent to the active sites 
 
 
Crystal structures of A20 predict that the mutation disrupts the catalytic triad preventing 
nucleophilic hydrolysis or steric hindrance of substrate (Figure 3.4) Figure 3.2C shows 
the structure of A20. It has an ovarian tumour domain (OTU) at its C terminal and a 
zinc finger domain at the N terminal. In the DUB region there are two residues critical 
to function (103 and 256); substitutions of either of these amino acids leads to loss of its 
DUB function. Thus, the S254R mutation is located two amino acids away from one of 
the residues thought to be critical for DUB activity. Taken together, these findings led 
us to hypothesize that S254R alters the conformational structure to alter A20 function. 
 
C103 
Asp70 
His256 
Ser254 
C 
N 
C103 
Asp70 
His256 
Ser254 
C 
N 
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3.1.2.2 In vitro A20 ubiquitination assay 
 
Figure 3.5 Catalytic activity of the mutation. Wildtype or R254S A20 OTU domain was incubated with 
K48 linked polyubiquitin. At indicated times, enzyme reaction was stopped and hydrolysis of 
polyubiquitin chains was examined by immunoblotting ubiquitin chains. SR-OTU domain contains amino 
acid substitution at 254 from serine to arginine; HS-OTU domain contains an amino acid substitution at 
256 from histidine to serine; Ub-Ub8, monomeric to heptameric ubiquitin chains 
 
We began by testing the deubiquination activity of the mutant protein. Wild type or 
mutant versions of the A20 OTU domain were expressed in E.coli and purified by the 
GST fusion system from GE healthcare. GST fusion proteins containing the A20 OTU 
domain were precipitated with glutathione agarose (SIGMA) followed by cleavage of 
the GST proteins bound to glutathione sepharose. Purified OTU domains were tested for 
their capacity to hydrolyse Lys48-linked heptameric ubiquitin chains in an in vitro time 
course experiment. Polyubiquitin chains were incubated with either wild type OTU 
domain, a catalytically inactive OTU domain (His256>Ala), or the S254R OTU 
domain. Polyubiquitin chains were detected by western blotting using anti-ubiquitin 
antibodies. The mutant S254R OTU domain showed reduced catalytic activity 
compared to the wildtype polypeptide (Figure 3.5). After 30 minutes incubation, 
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wildtype A20 OTU cleaved most of the polyubiquitin chains and generated dimeric or 
monomeric ubiquitin chains, whereas mutant S254R OTU domain cleaved only 
octameric and heptameric ubiquitin chains, similar to catalytically inactive H256A 
OTU. After 60 minutes, S254R OTU failed to lyse tetrameric ubiquitin chains while 
wild type OTU cleaved most of the polyubiquitin chains and resulted in monomeric 
ubiquitin chains. Thus, the catalytic activity of S254R appears to be intermediate 
between H256A and wildtype OTU. At the 2 hour incubation time point, S254R 
produced di- or mono-meric ubiquitin chains while H256A resulted in UB5 and UB6 
chains. 
 
3.1.2.3 pIKBα activation 
                         
                         
Figure 3.6 Immunoblot analysis for phosphorylated IKBα A. Constructs for wildtype or S254R A20 
were transfected into HEK293T. pIKBα was analysed at 0, 3, 5, 10 minute after TNFα stimulation. β-
actin was assessed as a housekeeping gene. A20 S254R, A20 containing an amino acid substitution at 254 
from serine to arginine; B. Summary plot. 
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A20 is a negative regulator of the NF-kB pathway that acts on many target proteins. We 
examined NF-kB activation in the presence of mutant A20. We expressed wildtype or 
S254R mutant A20 by transient transfection in HEK293T, then cells were stimulated 
with TNFα for various times (as shown). Cell lysates were analysed by western blot for 
pIKBα. We observed that A20S254R resulted in enhanced and prolonged pIkBα activity 
compared to wildtype (Figure 3.6). This difference was evident at 3 minutes after the 
stimulation, and persisted at 5 minutes after the stimulation. By 20 minutes, pIKBα was 
similar in both mutant and WT transfectants, and to baseline. These findings indicated 
that A20S254R exhibits robust and prolonged NF-kB activity compared to its wildtype. 
DUB and IkB activation assays demonstrated that the S254R mutation results in loss of 
function. 
 
3.1.3 Summary of clinical phenotypes 
A.II.1 is a 41 year old male who was diagnosed with CVID after presenting with 
autoimmune thrombocytopenic purpura and panhypogammaglobulinaemia at age 19 
years. As a result of refractory thrombocytopenia (platelets 2 x 109/L) he underwent a 
splenectomy at age 20. At age 30 he was diagnosed with autoimmune haemolytic 
anaemia (AIHA). He has a history of recurrent sinopulmonary infection, campylobacter 
enteritis, and intestinal giardiasis. He was commenced on intravenous immunoglobulin 
replacement after the diagnosis of hypogammaglobulinaemia was made. He suffered 
several further bouts of AIHA, which were managed with high-dose corticosteroids. He 
continued to suffer with recurrent bacterial sinusitis despite adequate antibody 
replacement. He has developed symptoms of colitis, with diarrhoea, weight loss, 
abdominal pain and abdominal lymphadenopathy.  
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The proband (A.II.1) is the son of a healthy father (A.I.1). His mother (A.I.2) reports a 
history of multiple sclerosis, although she is currently well in the absence of immune 
modulating medication. A.II.1 (sister (A.II.2) of the proband) has IgA deficiency. She 
gives no history of recurrent infection. 
 
 
                                                                                                    
Figure 3.7 Pedigree of Family B Sanger sequencing of TNFAIP3 heterozygous mutation. Circles 
represent female subjects and squares represent male subjects. * denotes A20 S254R carrier. TED, thyroid 
eye disease; T2D, type 2 diabetes 
 
The proband (B.II.1) presented with recurrent bacterial respiratory tract infections in the 
first decade of life and was diagnosed with hypogammaglobulinaemia at age 8 years. He 
was commenced on intravenous immunoglobulin replacement therapy. He has one 
sibling, who has been diagnosed with autistic spectrum disorder. B.II.1 gives no history 
of autoimmune disease. The proband’s father has refractory seronegative arthritis with 
joint erosions. He failed to respond to methotrexate or sulfasalazine, but made an 
excellent response to TNF antagonist (etanercept).   
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3.1.4 Cellular phenotype 
3.1.4.1 B cell phenotype  
 
 
 
 
 
 
 
 
Figure 3.8 Flow cytometric analysis of B cells. A. CD19+ cells were analysed for CD21 and CD27 
expression. Memory cells (CD27+, CD38+) and CD21lo B cells were identified. A representative sample 
from an unrelated splenectomised patient is shown. B. Summary plot of CD21lo cells and memory B cells. 
Coloured symbols indicate S254R carriers. Clinical phenotypes are indicated. CVID, common variable 
immune deficiency; IgAD, Immunoglobulin A deficiency; MS, multiple sclerosis; RA, rheumatoid 
arthritis. Square presents family A and circle presents family B. 
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Figure 3.9 Flow cytometric analysis of B cells CD19+ CD3- cells were analysed for CD24 and CD38 
expression. Naïve B cells (CD24+, CD38+), transitional stage 1 B cells (CD24+++, CD38+++), transitional 
stage 2 B cells (CD24++, CD38++), memory B cells (CD24++, CD38+), anergic B cells (CD24-, CD38-), 
and plasma cells (CD24-CD38+++) were identified. Healthy individual and a patient that underwent a 
splenetomy were used as controls. B. Summary plot of naïve, T1, T2, and anergic B cells (CD24-, CD38-
). T1 B, transitional stage 1 B cells; T2 B, transitional stage 2 B cells; PB, plasmablast/plasma cells. 
A20S254R carriers are identified by coloured symbols. Clinical diagnoses are shown. Squares indicate 
family A and circles indicate family B. 
 
A 
B 
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Initial flow cytometric analysis of circulating B lymphocytes showed that A.II.1 has 
normal numbers of CD19+ cells but very few memory B cells (1%), and little evidence 
of either class-switched or non-switched memory B cells (CD19+CD27+). CD21 and 
CD27 expression analysis showed that approximately 40% of CD19+ cells of A.II.1 
were CD21lo B cells (Figure 3.8). He is therefore classified as Freiburg class Ia, defined 
as < 0.4% of class switched memory B cells and more than 20% of CD21lo B cells 
(Warnatz, 2009). 
 
B cell analysis by CD24 and CD38 expression reveals that A.II.1 has a deficiency of 
mature naïve B cells (CD24++, CD38++) compared to healthy controls (Figure 3.9). In 
addition, A.II.1 showed abnormally high proportions of transitional T1 (CD24+++, 
CD38+++) and T2 B cells (CD24+, CD38++), which was confirmed by CD10 analysis. 
Approximately 30% of his B cell compartment was CD10+, which represents a 5-fold 
increase relative to controls (Appendix IV). We also identified a prominent population 
of B cells that are CD24- CD38- in A.II.1. In contrast, the other A20 carrier A.I.2 
showed a normal range of memory, naïve and transitional B cells. CD21lo B cells 
accounted for approximately 5% of CD19+ cells. A.II.2 showed that slight deficiency in 
memory B cells and increase in transitional B cells.  
 
Since A.II.1 underwent a splenectomy we also analysed B cells from several individuals 
who had undergone splenectomies for autoimmune thrombocytopenia (ITP) in the 
absence of hypogammaglobulinaemia. None of those individuals had a similar B cells 
phenotype to that of A.II.1. A representative flow cytometric plot is shown in Figure 
3.9, and this individual showed reduced memory B cells but normal naive, transitional 
Novel NF-kB mutations in common variable immunodeficiency (CVID)  
99 
 
and CD24-CD38- B cells. Thus, the B cell profile of A.II.1 is not obviously accounted 
for by splenectomy. In conclusion, A.II.1 exhibits a B cell phenotype that is quite 
different from both healthy controls and other A20S254R mutation carriers. 
 
 
 
 
Figure 3.10 Analysis of lymph node from the proband A.II.1. A. Photomicrographs of lymph node 
analysied by Haematoxylin and Eosin staining, or by immunohistochemistry with indicated antibodies. B. 
Flow cytometric analysis of B cells from lymph node biopsy. CD38 and IgD or CD27 and IgD were 
analysed on CD19+ cells. Analysis of tonsil from an unrelated donor is shown for comparison. GC, 
Germinal centre B cells; PB, plasmablast cells. 
 
A 
B 
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B.I.1 and B.II.1 carry the identical TNFAIP3 S254R mutation. Both have high 
proportions of mature naïve B cells (approximately 70%) with slightly reduced memory 
B cells (CD24+++, CD38+). Nonetheless, we found no evidence of expansion of the 
CD24- CD38- population or increased CD21low B cells. 
 
At age 39, A.II.1 underwent a diagnostic mesenteric lymph node biopsy, as part of 
investigation for diarrhoea, weight loss and intra-abdominal lymphadenopathy on 
imaging. By haematoxylin and eosin staining, the architecture of the node was 
preserved, except for the absence of plasma cells. Immunohistochemical analysis 
revealed germinal centres CD10+, CD20+ and CD21+ cells (Figure 3.10), which were 
also Bcl6+. Consistent with these findings, flow cytometric analysis revealed that GC B 
cells accounted for approximately 31% of his CD19+ cells. Remarkably, despite 
abundant GC B cells, neither memory B cells nor plasmablasts were identified.  
 
3.1.4.2 T cell phenotype 
Analysis of circulating T cells (Figure 3.11) revealed that the majority of CD4 T cells in 
A.II.1 adopted an effector memory phenotype (CD45RA-, CCR7+). Strikingly, there 
were very few naïve T cells (CD45RA+, CCR7+) (Figure 1.7). By contrast, the majority 
of CD4 T cells in A.I.2, B.I.1, A.II.2 and B.II.1 were naïve (CCR7+, CD45RA+), and 
their effector memory T cells (CD45RA-, CCR7+) were comparable to healthy controls. 
In A.II.1, CD8+ T cell analysis revealed a skewing to effector memory cell formation 
(TEM, CD45RA-, CCR7-) or CD45+ effector memory T cells (TEMRA, CD45RA+, 
CCR7-) with very few naïve T cells.  
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Figure 3.11 Flow cytometric analysis of T cell distribution. A. CD45RA and CCR7 expression were 
analysed for CD45+ effector memory T cells (CD45RA+, CCR7-), naïve T cells (CD45RA+, CCR7+), 
central memory T cells (CD45RA-, CCR7-), and effector memory T cells (CD45RA-, CCR7+). B. 
Summary plot, A20S254R carriers are shown with coloured symbols. TEMRA, CD45RA+ effector memory 
T cells; TCM, central memory T cells;TEM, effector memory T cells 
 
Next, effector CD4 T cells subsets were examined for chemokine receptor expression 
(Figure 3.12). The majority of effector helper T cells in A.II.1, A.I.2 and A.II.2 adopted 
a Th2 phenotype (CXCR3-, CCR6-). By contrast, effector T cells 
 
A 
B 
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Figure 3.12 CD4+ T cell subsets. A. Flow cytometric plots of CCR6 and CXCR3 expression. TH1 
(CXCR3- CCR6+), TH2 (CXCR3- CCR6-), TH17 (CXCR3+ CCR6-) were shown. B. Intercellular 
expression of cytokine IFN-g, IL-4, and IL-17 were analysed and represent TH1, TH2 and TH17 
respectively. 
 
from B.I.1 and B.II.1 were evenly distributed into effector subsets according to 
chemokine receptor expression. The proportion of Th1 (CXCR3+, CCR6-) in A.II.1 and 
A.I.2 were reduced compared to controls, whereas they were increased in B.I.1 and 
B.II.1. The relative proportion of Th17 cells (CXCR3-, CCR6+) in A.II.1 was reduced, 
whereas in B.I.1, B.II.1 and A.II.2 Th17 cells were increased compared to controls 
(Figure 3.12 B).  
B 
A 
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Figure 3.13 Exhaustion markers. CD57 and PD1 were used as exhaustion markers on CD4+cells. 
Tonsils are shown for comparison. A. Flow cytometric dot plots and B. summary plot of CD4 T cells C. 
CD8 + cells. black filled circle, healthy control; black filled square, tonsil; red triangle, A.II.1 
B 
C 
A 
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Figure 3.14 Flow cytometric analysis of circulating follicular helper T cells CXCR5 and CD45RA 
were analysed on CD3+CD4+ cells. CXCR5 CD45RA- cells represent cTfhs. A. Dot plot B. Summary plot 
C. PD1 and CCR7 expressions were analysed on cTfhs and active (CCR7lo PD1hi) and resting effector 
cells (CCR7hi PDlo) are shown  
 
In view of the large number of TEM and TEMRA cells, we proceded to further analysis 
for evidence of T cell exhaustion according to expression of CD57 and PD1 (Figure 
3.13). This revealed expansion of CD57 and PD1+ CD4+ T cells in A.II.1 (80% of CD4+ 
T cells were PD1+, and 22% were CD57+). This is abnormal when compared with 
peripheral blood from healthy controls, but similar to the distribution of T cells 
observed in human tonsil (Figure 3.13C). Two A20S254R carriers, A.II.2 and B.I.1 
showed slightly increased CD57 expression. CD8+ T cell compartment, where 
approximately 65% were CD57+, which represents a 7-fold increase relative to controls. 
 
Memory T cells can be further subdivided according to CXCR5 expression. CXCR5+ 
CD4 T cells are often referred to as circulating Tfh cells (cTfh) (Fazilleau, Mark et al. 
2009). A.II.1 exhibits a relative reduction of cTfh (cTfh: 3.96% of CD4+ CXCR5+ 
CD45RA-), approximately 2.5 fold decrease relative to controls. B.II.1 presents a 
relative reduction of cTfh (5.51%, 1.8 fold decrease). By contrast, B.I.1 exhibits a 1.6 
fold increase relative to controls.  
 
PD1 and CCR7 expression was used for further analysis to distinguish effector (CCR7lo 
PD1hi) and memory Tfh cells (CCR7hi, PD1lo) (Ye et al, Immunity). A.II.1 exhibits a 3-
fold increase in CCR7lo, PD1hi cells and a 4 fold decrease in CCR7hi, PD1lo cells (Figure 
3.14). B.II.1 exhibits a 1.8-fold increase in effector phenotype (CCR7lo, PD1hi) and a 
1.3-fold decrease in resting phenotype (CCR7hi, PD1lo) Tfh cells. B.I.1 shows a 1.1-fold 
increase and a 1.9-fold decrease in CCR7lo, PD1hi cells and CCR7hi, PD1lo, respectively.  
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Figure 3.15 Flow cytometric analysis of regulatory T cells A. CD127 and CD25 expression was 
analysed on CD4+ CD3+ cells. Potential regulatory T cells are shown in the region. B. Foxp3 expression 
of the populations from region shown in A. Grey line represents controls and red line represents the 
proband. C. Summary plot of Tregs with a mean (4.6%). A20S254R carriers are indicated with coloured 
symbols. Clinical diagnoses are shown. Squares, family A; Circles, family B. 
 
Analysis of regulatory T cells revealed A.II.2, B.II.1 and B.I.1 have a slight reduction of 
putative regulatory T cells (CD25+ CD127- cells) compared to controls (from 0.96 and 
3.65%). However, A.II.1 has a deficiency of regulatory T cells. Normally, the CD25+ 
CD127lo phenotype identifies FOXP3+ regulatory T cells, however, approximately 40% 
A 
B C 
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of putative regulatory T cells from A.II.1 were Foxp3 negative. Thus, he exhibits a 
relative deficiency of regulatory T cells (approximately 9-fold decrease) compared to 
the mean (4.6%) of controls.  
 
 
Figure 3.16 Flow cytometric analysis of recent thymic emigrants (RTE) CD31 and CD45RA 
expressions were analysed on CD4+ CD3+ cells. CD31+ CD45RA+ cells represents recent thymic 
emigrants A. Flow cytometric dot plot B. summary plot for RTET cells in CD4+ CD3+ cells inverted red 
triangle, A.II.1; open circle, A.I.1; black filled circle, healthy controls 
 
 
Finally we enumerated recent thymic emigrant cells according to expression of CD31 
and CD45RA (Figure 3.16). 5% of CD4+ cells were recent thymic emigrant (CD31+, 
CD45RA+) T cells, compared with a mean of 18.5% in healthy controls. 
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3.1.5 Functional phenotypes 
3.1.5.1 Plasmablast induction  
 
 
A 
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Figure 3.17 Flow cytometric analysis of plasmablast induction in vitro A. PBMCs were cultured with 
CD40L transfectant cells (1:50 ratio) and IL-21 (50ug/ml) for 5 days. Plasmablasts are CD27++ CD19lo 
cells. B. Summary plot shows PB proportion out of B cells PB. 
 
 
Analysis of a lymph node isolated from A.II.1 was noteworthy for the absence of 
plasma cells. We proceeded to analysis of plasmablast induction in vitro to investigate 
that the absence of plasma cells resulted from an intrinsic B cell defect.  
 
PBMC were stimulated with CD40L + IL-21 for 5 days and plasmablast (PB) induction 
was examined according to CD19 downregulation and high level expression of CD27. 
We observed a consistent and significant defect in plasmablast formation in B cells 
from A.II.1, relative to controls and the other A20S254R carrier (Figure 3.17). 
Plasmablasts expressed as a percentage of CD19 cells show a significant deficit in 
plasmablast formation in A.II.1. This result was expected, since AII.1 has very few 
memory B cells, and we observed no plasmablasts in vivo (LN biopsy). Interestingly, 
B.II.1 also exhibited relative reduction in plasmablast formation in vitro. We observed 
approximately 2-fold and 4-fold reductions in plasmablast induction in B.II.1 (4.2%) 
and B.I.1 (2.2%), respectively, when compared to healthy controls (Figure 3.17B).  
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3.1.5.2 B cell activation 
          
Figure 3.18 B cell activation PBMCs were activated with a range of anti Ig F(ab)2 for 24 hours and cell 
activation marker, CD69 was analysed. Percentage was out of CD19+ cells. 
 
We examined B cells for expression of NF-kB-dependent activation marker, CD69 as a 
control for activation after stimulation in vitro (Figure 3.18). B cells were stimulated 
with anti-Ig F(ab)2 for 24 hours. We observed a reduction in expression of CD69 by B 
cells from A.II.1 across the dose range of anti-Ig F(ab)2. 40~50% of the B cells from 
A.II.1 became CD69 positive while 70%~80% of the B cells from controls became 
CD69 positive. Interestingly, approximately 25% of B cells expressed CD69 in the 
absence of simulation although he has massive transitional and anergic B cells and very 
few memory B cells. These data suggest a possible B cell intrinsic defect in activation.  
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3.1.5.3 T cell activation 
 
Figure 3.19 Flow cytometric analysis of CD25 and CD69 expression in response to T cell activation 
beads. Naive T cells (CD4+, CD3+, CD45RA+, CCR7+) and TEM (CD4+, CD3+, CD45RA-   CCR7-) were 
purified and incubated with T cell activation beads (Miltenyi Biotec) according to the manufacture’s 
instruction. After 24h of incubation, CD25 and CD69 expressions were analysed. This is representative of 
two separate experiments. 
 
Next we examined T cell activation in vitro. Naïve (CD3+, CD4+, CD45RA+, CCR7-) or 
effector memory (CD3+, CD4+, CD45RA-, CCR7-) T cells were positively sorted (BD 
FACSAria™) and stimulated in vitro with T cell activation beads containing anti 
CD2/CD3/CD28 antibodies (Miltenyi Biotec) for 24 hours. We examined up regulation 
of T cell activation markers CD69 and CD25 in the presence or absence of T cell 
activation beads. Unexpectedly, approximately 18% of A.II.1’s naïve T cells were 
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CD69 positive cells in the absence of in vitro stimulation, which represents a significant 
difference from controls (p<0.0001) (Figure 3.20). This suggests that naïve T cells from 
A.II.1 were activated in vivo. By contrast, after stimulation in vitro, A.II.1 exhibited 
impaired activation of naïve CD4+ T cells. In this experiment (representative of two), 
54.4% of CD4 naïve T cells remained negative for CD69 and CD25 (p=0.0125, 
p=0.0142 respectively, n= 8).  
 
 
           
Figure 3.20 Summary of CD69 and CD25 expression on naïve CD4+ T cells and effector memory 
CD4+ T cells. Percentage was obtained from live CD4+ T cells and A. the experiment is representative of 
two separate experiments. B. Statistical analysis was done with two tailed T-tests. 
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It is noteworthy that these findings are very similar to those described in caIKKβ mice, 
where a gain-of-function mutation in IKKβ results in constitutive activity of the IKK 
complex (Krishna, 2012), a similar biochemical defect to that expected and observed as 
a result of a defect in A20. As in A.II.1, caIKKβ exhibit spontaneous CD4+ T cell 
activation even in the absence of TCR crosslinking in vitro, while T cell activation is 
impaired after stimulation in vitro.  
 
 
3.1.5.4  B Proliferation 
We also examined B cell proliferation in vitro after 5 days incubation with CD40L 
transfectant cells (1:50 ratio) and IL-21 (50ng/ml). A.II.1 and A.I.2 showed obvious 
defects in B cell proliferation (Figure 1.16.A). B.II.1, B.I.1 and B.II.1 showed relatively 
normal proliferation compared to controls after 5 days activation (Figure1.21). We 
observed a significant reduction in live B cells in the A.II.1 cultures during the 
proliferation assay (Figure 3.21), suggesting increased apoptosis within the B cell 
compartment as well as the T cell compartment.  
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Figure 3.21 Proliferation of B cells in response to CD40L. PBMCs were labelled with cell trace violet 
(CTV) and incubated with CD40L transfected cells for 5 days. Viable B lymphocytes were gated and 
analysed according to CTV expression.  
 
 
3.1.5.5 T cell proliferation and T cell survival 
We also examined T cell proliferation in vitro (Figure 3.22). Both PBMCs and sorted 
naïve T cells were examined for proliferation, determined by dilution of CFSE or CTV 
label, respectively, after 5 days incubation with T cell activation beads. CD4+ T cells  
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Figure 3.22 Proliferation of T cells in response to T cell activation. PBMCs or sorted T cells were 
labelled with CFSE or cell trace violet (CTV) and incubated with T cell activation beads (Milteni 
Biotech) for 5 days. Viable lymphocytes were analysed according to CTV or CFSE. 
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from A.II.1 showed a defect in proliferation. Both unfractionated PBMCs and sorted T 
cells divided less than cells from healthy controls. In PBMC cultures, the majority of 
A.II.1’s T cells remained undivided. Sorted T cells also showed similar results: ~60% of 
naïve T cells and ~70% of memory T cells remained undivided. 
 
3.1.5.6 Cell survival 
 
 
Figure 3.23 Position of live cells in forward and side scatter flow cytometry data with 7AAD 
staining. A. Forward and side scatter dot plot. B. 7AAD profile from 3 populations. PBMCs from healthy 
controls were used for this experiment. 
 
In addition to an abnormality of proliferation, we observed a consistent reduction in the 
total number of cells remaining in culture of PBMCs from A.II.1, raising the possibility 
of increased cell death. We proceeded to more formal analysis of cell survival using 
7AAD to identify apoptotic cells. In Figure 3.23, population 1 is 7ADDhigh, which are 
late apoptotic cells. Population 2 contained both 7AADhigh and 7AADintermediate cells, 
indicating both late and early apoptotic cells. Population 3 contained only 7AADnegative 
(viable) cells. These results demonstrate concordance with cell viability determined by 
forward and side scatter. 
 
A. B. 
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Survival of the sorted T cells was then analysed by forward and side scatter and this 
revealed a significant loss of viable cells (approximately 70%) from A.II.1 culture of 
after 24 hours without stimulation. By contrast, approximately 80% of naïve T cells 
from healthy control and his family members remained viable. After stimulation, 
approximately 40% of cells remained viable in cultures of naïve T cells from healthy 
controls. In cultures of naïve T cells purified from A.II.1, less than 
 
.   
Figure 3.24 Viability of sorted T cells with T cell activation beads for 24 hours. Live cells were 
measured using viable cell gating (population 3) from Figure 3.23. Proportions of live cells were analysed 
with or without the stimulation. A.II.1, red filled square symbol; controls, black filled triangle symbol; 
A.I.1, black filled square symbol; A.I.2, blue filled square symbol. 
 
5% of cells survived in the presence of TCR stimulation. Analysis of effector memory T 
cells (TEM) also showed similar results. Approximately 30% of TEMs from A.II.1 
survived after a 24-hour incubation in the absence of simulation, whereas approximately 
70% of TEMs from controls survived. After stimulation, the survival percentage was 
similar in A.II.1 and controls. Two separate experiments showed very similar results. In 
other words, the survival of unstimulated naïve T cells from A.II.1 was similar to that 
observed after in vitro stimulation of control naïve T cells, and in vitro survival of naïve 
and memory T cells from A.II.1 was similar as well. We considered the possibility that 
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naïve T cells from A.II.1 are partially activated (in vivo) to explain this propensity to 
apoptosis. This had been suggested by our earlier observation of increased CD69 
expression at baseline. Furthermore, a similar in vitro survival defect has been reported 
in T cells from caIKKβ mice (S2012). 
 
We also re-examined the proliferation assay to investigate further T cell survival. First, 
live cells were identified according to forward and side scatter plot then a cell trace 
violet histogram graph was used to analyse proliferation in each subset. After 5 days of 
activation, cells had undergone up to 8 cell divisions. The total cell number from each 
cell division was divided by the 2 to the power of cell division number to obtain the 
proliferation precursor frequency. All the precursor cell numbers were combined and 
 
 
 
 
 
 
         
Figure 3.25 Viability of precursor cells after 5 days with T cell activation beads. Live cells were 
measured using viable cell gating (population 3) from Figure 3.23. A. Live cells on forward and side 
scatter dot plot. B. CTV analysis on live cells. C. Viability of precursor cells after 5 days stimulation. 
B 
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the total live precursor cells then were divided by total cell number to get the proportion 
of survival. In both memory and naïve T cells cultures, there was significant cell loss by 
apoptosis without stimulation. Less than 5% of memory T cells from A.II.1 survived, 
compared with control memory T cells, this represents a >8-fold deficit (Figure 3.25). 
While this experiment suggests that apoptosis is enhanced even in naïve T cells, one 
caveat of this experiment is that naïve cells were positively sorted using CD3 and CD4. 
 
 
3.1.5.7 Apoptosis 
 
 
A 
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Figure 3.26 Analysis of cell survival after various stimuli. PBMCs were stimulated with LAC, TNFα 
or nil for 24 hours. A. Family A. B. Family B  C. PBMCs were stimulated with a range dosage of TAB 
and live cells were analysed. LAC, lymphocyte activation cocktail; TAB, T cell activation beads. 
 
Next, we examined apoptosis in response to various additional stimuli. First, T cells 
were stimulated with either TNF or a lymphocyte activation cocktail (LAC) containing 
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PMA, ionomycin and brefeldin A. The most substantial defect in survival was observed 
after 24 hours stimulation with LAC. 5.4% of total patient cells remained viable 
compared with 25% from the control (Figure 3.26). In this experiment, we did not 
observe apoptosis in unstimulated cultures. The discrepancy between this result and that 
described above (1.1.5.6) may be explained by a difference in the absence of positive 
selection in this experiment.  
 
In PBMC cultures, we did not observe evidence of apoptosis after T cell activation 
beads. To exclude insufficient stimulation, the experiment was repeated with increasing 
amounts of T cell activation beads. Figure 3.26C shows that apoptosis was induced in a 
T cell activation bead dose-dependent manner while the there was no induction of 
apoptosis in control cultures, even with the highest doses of T cell activation beads 
(2.5ul/1M cells). Remarkably, the enhanced apoptosis observed with A.II.1 was 
stimulus-specific, and was not seen after stimulation with either anti-FAS or TNFα. 
This specificity provided us with a possible clue about the underlying defect.  
 
3.1.5.8 Gene expression signature  
3.1.5.8.1 B cells 
So far, we have established that the defect in A.II.1 consists of baseline activation of T 
cells, reduced proliferation in vitro, increased T cell exhaustion, and enhanced apoptosis 
in vitro in response to TCR ligation, and PMA/ionomycin. These findings would be 
consistent with a defect in NF-kB conferred by a mutation in TNFAIP3. To explore this 
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possibility further, we examined global gene expression in lymphocytes isolated from 
A.II.1 and controls.   
 
Naïve B cells were sorted according to CD21+, CD19+, CD10-, CD27- and were 
stimulated with anti Ig F(ab)2 for 24 hours, and global gene expression was determined 
by microarray. One patient and one control with two technical replicates were used for 
B cell gene expression Approximately 20000 transcripts were identified by Partek 
analysis software.  
 
 
 
 
Figure 3.27 Gene expression of control vs. the proband from Microarray gene analysis A. total gene 
expression of the proband vs. age matched healthy control. B. BTK related gene expression of the 
proband vs. age matched healthy control C.NF-kB target gene expression of the proband vs. age matched 
healthy control. 
A B 
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Overall gene expression was similar between patient and control (Figure 3.27A), but we 
observed a bias towards overexpression of NF-kB target genes in A.II.1 (Figure 3.27C). 
For comparison, we analysed target gene expression downstream of the BTK pathway 
and found no difference between proband and control (Figure 3.27B). 
 
Heat map projections of approximately 120 genes are shown in Figure 3.27A. Overall, 
higher expression of signature NF-kB target gene transcripts was found in the patient’s 
B cells compared to the control (Figure 3.27C).38 NF-kB target genes were upregulated 
or downregulated >2-fold (p<0.05). 33 were upregulated in A.II.1 (Figure 3.28). 
 
 
 
 
 
       
 
 
      
 
Figure 3.28 NF-kB target gene expression of stimulated naïve B cells by microarray. A. Heat map 
projection of 120 selected NF-kB target genes are shown. B. 38 genes which have more than 2 fold 
different from control are listed with their relative expression to control .33 genes were upregulated and 5 
genes were downregulated. 
 
-10
-5
0
5
10
15
20
C
D
3
8
A
B
C
B
4
P
R
K
A
C
A
C
T
S
B
M
A
P
4
K
1
P
R
K
C
D
T
N
IP
1
B
A
X
G
A
D
D
4
5
B
T
R
E
M
1
C
D
3
G
C
T
S
L1
C
C
L5
H
LA
-BFo
ld
 c
h
a
n
g
e
 v
s.
 c
o
n
tr
o
l NFkB target gene expression in TCH083
7
~
Regulation 
(fold change) 
Gene 
no. 
Gene no. 
(p<0.05) 
Up (>2) 48 33 
Down (<2) 5 5 
B A 
Novel NF-kB mutations in common variable immunodeficiency (CVID)  
124 
 
Genes whose expression differed most were IL8 and CCL2 (8-fold and a 61-fold 
increase, respectively). Recently it has been demonstrated that apoptotic cells secrete 
soluble factors which promote chemotaxis of phagocytotic cells toward dying cells 
(Gregory and Pound, 2011; Ravichandran, 2011). Both IL-8 (CXCL8) and MCP1 
(CCL2) are chemokines and it has been found that they are produced from Fas or TNF 
induced apoptotic cells to guide phagocytes to apoptotic cells (Cullen et al., 2013). The 
gene expression signature would therefore be consistent with the observation that B and 
T cells from A.II.1 exhibit an increased propensity to apoptosis. 
 
3.1.5.8.2 T cells 
Since naïve T cells showed an active phenotype in an absence of stimulation, we 
performed an independent analysis of T cell gene expression. Naïve T cells 
(CD3+CD4+ CD45- cells) were sorted by positive selection and RNA was prepared for 
gene expression in the absence of stimulation. RNAseq data were analysed by voom 
after normalisation by sequencing depth.  
 
Hierarchical cluster analysis shows that the two controls clustered closely together 
indicating that their expression profiles are similar, and significantly different from the 
expression signature observed in T cells from the proband. As in the B cell 
compartment, heat map projections reveal higher expression of signature NF-kB target 
gene transcripts from the patient’s naïve T cells compared to the controls (Figure 3.29). 
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Figure 3.29 NF-kB target gene expression of naïve T cells by RNAseq. A. Hierachical cluster analysis 
of RNA-Seq and Heat map projection of 100 selected NF-kB target genes are shown. B. 31 genes were 
upregulated and 4 genes were downregulated with p<0.05. one patient and two aged matched control with 
two technical  replicate were used for T cell gene expression.   
 
 
 
Thus, independent gene expression analyses reveal concordance for results obtained 
from T and B cells. Specifically, we observed upregulation of NF-kB regulated genes in 
both compartments. 35 NF-kB regulated genes were either upregulated or 
downregulated at least 2-fold (p<0.05). 31 genes (88.6%) were shown to be upregulated 
in A.II.1 relative to controls. Remarkably, IL-8 and CCL2 were most highly expressed 
in both naïve T cells and naïve B cells. Taken together analysis of global gene 
expression in both T and B cell compartments points to aberrant over-activity of NF-kB 
activity, and would be consistent with loss of function TNFAIP3 mutation. 
 
Regulation 
(fold 
change) 
Gene 
no. 
Gene no. 
(p<0.05) 
Up (>2) 40 31 
Down (<2) 4 4 
B 
A 
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3.1.5.9 IkBα analysis 
In view of these results, we examined NF-kB signalling specifically. IKK activation 
leads to phosphoralytion of IKBα and consequently rapid degradation of IKBα upon cell 
stimulation. We stimulated T cells with TNFα and examined IKBα expression by flow 
cytometry over a brief time-course. 
 
  
 
 
 
 
 
 
 
Figure 3.30 IkBα expression after TNFα stimulation. PBMCs were thawed and incubated at 37oC for 2 
hours prior to the stimulation. Cells were then incubated with TNFα (50ng/ml) for various time points. 
CD3+ cells were analysed for IkBα expression by intracellular staining. A. Histogram of IkBα expression 
at 0, 20, and 60 minutes after the stimulation. B. Comparison of IkBα expression between A.II.1 and 
controls without stimulation. C. MFI of IKBα expression in time course stimulation with TNFα. 
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We observed that IkBα expression decreased at 20 minutes and its expression increased 
back to baseline at 60 minutes after stimulation in A.II.1 and one of the controls (Figure 
3.30). Changes in IKBα expression were similar in A.II.1 and controls. We did observe, 
however, that 50% of T cells from A.II.1 lacked IKBα even in the absence of 
stimulation (compared with less than 15% in controls), consistent with constitutive NF-
kB activation. 
 
3.1.6 A20 interacting gene search 
It has been reported that mutations in NF-kB genes including CARD11, MALT1, 
IKBKA, and IKBKB cause defects in T and B cell differentiation, activation and/or 
proliferation (Lahtela, Nousiainen et al. 2010; Snow, Xiao et al. 2012; McKinnon, 
Rozmus et al. 2014; Nielsen, Jakobsen et al. 2014; Turvey, Durandy et al. 2014; Brohl, 
Stinson et al. 2015). A.II.1 showed defects in activation of T cells and B cells, 
proliferation of T cell and B cell, and plasmablast differentiation. The cellular 
phenotype of A.II.1 is similar to one from primary immune deficiency patients with 
CARD11 mutations. Furthermore, a mouse model, which carries a constitutively active 
form of IKKβ shows a very similar phenotype including a high percentage of effector T 
cells, irresponsive T cell activation, spontaneous naïve T cell activation, abnormal T cell 
proliferation, high PD1 expression and poor survival (Krishna, 2012). This suggests that 
the cellular phenotype of A.II.1 is caused by activated NF-kB resulting from defects in 
negative regulation of NF-kB and A20 S254R. On the other hand, the cellular and 
functional changes observed in kindred B, and indeed in other carriers within kindred A, 
are far less significant than those observed in the proband from kindred A. We therefore 
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investigated A.II.1 for a second genetic variant that might modify A20 to cause a more 
severe NF-kB signalling defect, and explain this function and phenotypic discrepancy.  
 
 
 
Figure 3.31 Schematic diagram for mutation selection 
 
First, we examined lymphocytes from A.II.1 for a somatically acquired second mutation 
in TNFAIP3. RNA was isolated from PBMCs, from which we generated cDNA. We 
analysed transcripts for splice variants, and for sequence variation by Sanger 
sequencing. No somatic variants in TNFAIP3 were identified, although we found a 
previously unreported splice variant of TNFAIP3 (between exon 7 and exon8), which 
was present in A.II.1 and several healthy controls) .  
 
Second, we interrogated the A.II.1 genome for variants in TNFAIP3 interacting genes. 
Using the String and BioGrid software tools, we identified 89 interacting genes (listed 
Exome sequenced mutations  
Non synonymous or splicing site  
mutations   
A20 interacting genes 
Seen in only A.II.1 not the other A20 
S254R carriers.  
Candidate mutations 
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in Appendix III). We identified 13 nonsynonymous or splice site mutations of these 
genes in A.II.1’s exome. We excluded variants found in other A20S254R carriers, since 
we had shown through exhaustive analysis that other carriers are phenotypically 
distinct. This left us with just one variant, a heterozygous missense SNP in TAX1BP1 
(L307I). We confirmed the TAX1BP1 polymorphism by Sanger sequencing from 
lymphocytes and saliva and also confirmed that among all S254R carriers, only A.II.1 
caries the TAX1BP1 variant, which was transmitted paternally (A.I.1). TAX1BP1L307I is 
not novel. According to dbSNP, the MAF is 0.069. Analysis by Polyphen2 and SIFT 
tests showed 0.278 and 0.78 scores, respectively, scores consistent with possible 
damage. 
 
3.1.6.1 TAX1BP1L307I 
 
 
 
                       
                                                                    
 
 
 
 
 
 
Figure 3.32 L307I TAX1BP1 mutation. A. Sanger sequencing of TAX1BP1 showing heterozygous 
mutation (*). B. Schematic representation of human TAX1BP1 structure showing SKICH domain, three 
coiled coil (CC) domains and two ubiquitin binding zone (UBZ) domains. The mutation encoding L307I 
is next to the first coiled-coil domain (star). C. Summary of the mutation  
 
cDNA Protein 
Position Allele change Position Residue change 
1007 TTA ⇒ ATA 307 L [Leu] ⇒  I [Ile] 
A B 
C 
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TAX1BP1 is a scaffolding protein that is crucial for assembly of the macromolecular 
complex containing A20, ITCH, RNF11, and RIP1. We investigated TAX1BP1 as a 
potential modifier of A20 to explain the severe NF-kB phenotype of A.II.1. Since L307 
is located in a coiled coil region of TAX1BP1, which is responsible for protein 
interactions (Figure 3.32), we hypothesized that this mutation might affect interaction 
between A20 and TAX1BP1. 
 
3.1.7 Biochemical analysis 
3.1.7.1 NF-kB activation 
To investigate the effects of both A20 and TAX1BP1 variants in the absence of 
endogenous normal genes, we generated a TAX1BP1 and TNFAIP3 double-deficient 
RAJI cell line (A20-/-, TAX1BP1-/-) by CRISPR/Cas9. The deletion of two nucleotides 
(GT) at g.8910 in TNFAIP3, and the insertion of one nucleotide (T) at g.48154 in 
TAX1BP1 were confirmed by Sanger sequencing and frameshifts were predicted to 
result in premature termination of expression due to the appearance of a stop codon 
(TGA) at 252 in TNFAIP3 and at 331 in TAX1BP1. Absence of endogenous protein 
expression was confirmed by western blot. 
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Figure 3.33. TNFAIP3-/- TAX1BP1-/- Raji cells were generated by CRISPR/CAS9. A. Sanger sequencing 
of TNFAIP3 and TAX1BP1 germline DNA. Amino acids changed are shown in red. B. A20 and 
TAX1BP1 expression was analysed by western blot. T6BP, TAX1BP1; Wt, Wildtype, LAC, lymphocyte 
activation cocktail 
 
Wildtype or mutant TNFAIP3 vectors were co transfected into double knockout Raji 
cell line (TNFAIP3 -/-, TAX1BP1-/-) with wild type or mutant type TAX1BP1 and an 
mCherry vector. The positively transfected cells were isolated using by FACS 
according to mCherry expression and sorted cells were then activated with various 
stimuli for 24 hours and 48 hours and cells were analysed for  CD69  expression. 
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Figure 3.34 The expression of B cell activation markers in knockout cell lines created by CRISPR 
CAS9 system. Mean fluorescence intensities (MFI) of CD83, CD86 and CD69 expressions were 
obtained. Three experiments were conducted. 
 
Before transfection, CD69 expression was increased in Raji cells deficient in 
TAX1BP1, and expressed at even higher levels when rendered doubly deficient in 
TNFAIP3 and TAX1BP1, when compared with WT cells (Figure 3.34). 
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Figure 3.35 Analysis of CD69 expression. Constructs encoding either wildtype or S254R A20 and 
wildtype or L307I TAX1BP1 were transfected into TNFAIP3-/- TAX1BP1-/- Raji cells. A. Histogram of 
CD69 expression from cultures incubated with CD40L(1ug/ml) for 24h and 48h B. Bar graphs  of CD69 
expression at 24 hours and 48 hours. 
 
Next, we examined the action of genetic complementation of double-deficient Raji cells 
with either mutant or wild type alleles of TAX1BP and TNFAIP3, either together, or 
with their wildtype interacting partners. CD69 expression was determined by flow 
cytometry. Wild type or mutant A20 mammalian vectors were cotransfected with 
wildtype or mutant TAX1BP1 mammalian vectors into Raji TNFAIP3-/- TAX1BP1-/- 
cells by electroporation using the NEON system. 
 
mCherry vectors were used for selecting transfectants and mCherry positive cells were 
sorted and activated with CD40L, TNFα or anti-Ig for 24 hours or 48 hours. CD69 
expression was measured by flow cytometry. TNFAIP3S254R and TAX1BP1L307I 
transfection resulted in increased CD69 expression, relative to cells transfected with 
wildtype constructs. Significantly, transfection of either mutant TAX1BP1 or TNFAIP3 
with wild type interacting partner resulted in phenotypes intermediate between those 
found after transfection of mutant versions of both TAX1BP1 and TNFAIP3, although 
cells containing the mutant allele of TNFAIP3 and those homozygous for both mutant 
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genes exhibited similar phenotypes. Mutant TAX1BP1 cells expressed less CD69. 
CD40L stimulation induced enhanced CD69 expression in all cultures however TNFα 
and anti Ig did not significantly stimulate the expression levels. Nonetheless, this was 
shown in all stimulations and the difference between wildtype and mutant types was 
more pronounced after 48 hours. 
 
3.1.7.2 Co-immunoprecipitation 
A20 and TAX1BP1 are known to form a macromolecular complex in order for A20 to 
perform its normal catalytic function. We investigated the possibility of physical 
interaction between mutant A20 and TAX1BP1 to explain the putative epistatic 
interaction between TAX1BP1 and TNFAIP3. We generated constructs of wildtype and 
point mutants of each gene with tag proteins. A20 was conjugated with a C-terminal 
cMyc and TAX1BP1 was FLAG-tagged at its N terminal. 
 
HEK293T cells were transiently co-transfected with wild type A20 and wild type 
TAX1BP1 or A20S254R and TAX1BP1L307I expressing vectors. After 36 hours, cells 
were stimulated with TNFα to induce A20 complex formation and cells were harvested 
and lysed. 
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Figure 3.36 Co-immunoprecipitation of A20 and TAX1BP1. Wildtype A20 and wild type TAX1BP1 
or A20S254R and TAX1BP1L307I cell lyates were precipitated with anti-Flag, anti-cMyc or isotype control 
antibodies. A. Immunoblotting with anti c-Myc  B. Immunoblotting with anti FLAG antibodies. A20-
cMyc fusion; TAX1BP1-Flag fusion. 
 
A20 was immunoprecipitated with anti-cMyc and the interaction was analysed by 
immunoblotting with anti-Flag for TAX1BP1. We also analysed cells after 
immunoprecipitaion of TAX1BP1 followed by immunoblot analysis with anti cMyc. 
 
Anti-cMyc (A20) precipitated a small amount of anti FLAG (TAX1BP1)-containing 
complex in cells transfected with A20WT and TAX1BP1WT. By contrast, we observed 
B 
A 
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more FLAG (TAX1BP1)-containing complexes after anti-cMyc (A20) precipitation of 
cells transfected with A20S254R and TAX1BP1L307I (Figure 3.36A). Similar results were 
obtained with the converse strategy, in which we precipitated protein complexes with 
anti cMyc (A20) (Figure 3.36B).  
 
These findings suggested preferential assembly of mutant TAX1BP1 and A20, and this 
would be consistent with the observed severe phenotype in A.II.1. In the absence of any 
interaction, we would expect approximately 50% of A20-containing molecular 
complexes to contain mutant A20. In the presence of this perturbed interaction, greater 
that 50% would contain the A20 with reduced function. These findings potentially 
explain why simple TNFAIP3 heterozygosity confers a mild phenotype, but combined 
TNFAIP3 and TAX1BP1 mutations confer a severe phenotype. In other words, our 
results are consistent with non-allelic non complementation, in which two mutations 
within separate genes, combine to cause a phenotype that might be expected with 
damaging homozygous mutations of either gene alone.  
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3.2 Discussion 
We discovered a novel mutation in TNFAIP3 (g.8910C>A) by whole exome 
sequencing, from two unrelated patients with common variable immune deficiency 
(CVID) recruited to the Australian and New Zealand Antibody Deficiency Allele 
(ANZADA) study. By genotyping their family members we found three additional 
carriers of the mutation.  
 
A20 is an important negative regulator that terminates signalling via the canonical NF-
kB pathway. In most cells, A20 expression is maintained at very low levels in resting 
cells, but its expression is induced when cells are activated by canonical NF-kB stimuli. 
This is thought to providea negative feedback loop for regulating NF-kB signalling 
(Catrysse, Vereecke et al. 2014). The mutation we report here is located at S254 
proximal to an active site, H256, and it was predicted to alter the conformation of the 
A20 structure to perturb catalytic activity by crystallization and in silico tests.Indeed, 
the deubiquitination experiment reveals that the mutation TNFAIP3S254R impairs 
deubiquitination. Consistent with previous reports we also found that the OTU domain 
cleaves K48 linked ubiquitin chains rather than K63-linked ubiquitin chains in vitro. 
While the wildtype OTU domain was able to generate dimeric or monomeric ubiquitin 
chains within 30 minutes of activation, S254R attenuated DUB activity to generate di- 
or mono-meric ubiquitin chains. This biochemical defect was, however, not as severe as 
that observed with an OTU harbouring a H256R substitution.   
 
Our NF-kB activation experiment reveals a substantial effect of A20S254R on NF-kB 
activity (Figure 3.6). A20S254R exhibits robust and prolonged NF-kB activity compared 
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to its wildtype. Two distinct domains of A20 function in a stepwise manner so DUB 
function facilitates the E3 ligase function of A20 (Wertz, O'Rourke et al. 2004), and 
therefore, the S254R mutation may influence not only DUB activity but also E3 ligase 
of A20.  
 
Lu and colleagues generated Tnfaip3 OTU/OTU mice, which carry a cysteine to alanine 
mutation at amino acid residue 103, and demonstrated that the OTU domain accounts 
for some of A20 functions (Lu, Onizawa et al. 2013), although the phenotypes of these 
mutant mice were less severe than that of Tnfaip3-/- mice, which die prematurely from 
multi-organ inflammation and cachexia (Lee, Boone et al. 2000; Lu, Onizawa et al. 
2013)(Lee et al., 2000 Lu, 2013).  
Interestingly, mice carrying mutations in the OTU domain do not exhibit defects at birth 
but exhibit splenomegaly and dextran sulphate sodium (DSS) induced colitis by 6 
months of age (Lu, Onizawa et al. 2013). These abnormalities are similar to those 
observed in proband A.II.1.  
 
TNFAIP3S254R/+ carriers have various defects in immune function, but both probands, 
from two independent kindreds, exhibit primary antibody deficiency. Proband from 
kindred A (A.II.1) presented with severe haematological autoimmunity. Detailed 
immunological phenotyping revealed increased numbers of T cells but a normal number 
of B cells. Further analysis of the B cell compartment, however, revealed a high 
proportion of transitional B cells and a deficiency of memory B cells. We found no 
evidence of plasma cell formation either in vivo or in vitro.  
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We found evidence of constitutive cellular activation, based on analysis of cell surface 
phenotype, an increase of propensity to apoptosis. Consistent with this, biochemical 
analysis revealed enhanced IKBa activity. Furthermore, global gene analysis revealed 
an active NF-kB signature, that was remarkably concordant between T and B cells. 
Taken together, these findings are consistent with a defect in termination of NF-kB 
signalling as a result of the A20 S254R mutation (Figure 3.5-6, 3.30).  
 
Several individuals who presented with persistent B cell lymphocytosis have been found 
to harbour gain of function mutations in CARD11 (Snow, Xiao et al. 2012). While our 
proband had normal total B lymphocyte numbers, the defects in lymphocyte activation, 
and proliferation were very similar. The mutations in CARD11 may be associated with 
regulating A20 functions. MALT1 has been reported to have a specific proteolytic 
activity that cleaves A20 upon TCR activation (Coornaert, Baens et al. 2008). CARD11 
mutations confer activation of MALT1 and consequently lead to inactivation of A20. 
This could explain the similarity between the patient with A20 S254R and patients with 
CARD11 mutations. 
 
The mutant CARD11 and A20 S254R both result in activation of IKKβ. Remarkably, 
the phenotype of our patient is very similar to one of the constitutively active IKKβ 
mice (caIKKβ) which carry a gain of function mutation in Ikbkb (Krishna, Xie et al. 
2012). Analysis of circulating CD4+ T cells revealed that the majority adopted an 
effector memory type (TEM), with very few naïve T cells in either CD4 or CD8 
compartments. A similar defect in T cell differentiation, with increased formation of 
TEM cells was also observed in caIKKβ mice.  
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Since A20 is constitutively expressed to inhibit activation of NF-kB in lymphocytes, 
any defect in A20 would be expected to enhance activation of lymphocytes. In the 
absence of stimulation, lymphocytes from caIKKβ mice express increased CD69. 
Similarly, we observed spontaneous activation in T cells from proband A.II.1.  
Chronic activation is thought to impair responsiveness to repeated stimulation of 
lymphocytes. In caIKKβ mice, there is a reduced response to TCR stimulation. We 
reported impaired upregulation of both CD69 and CD25 after T cell stimulation of cells 
from A.II.1. A similar result was reported in patients CARD11 gain-of-function 
mutations. Absence of responsiveness may reflect cloncal exhaustion, and consistent 
with this, we observed high expression of exhaustion marker PD1 was seen in A.II.1, 
and similar findings were reported in T cells from caIKKβ mice (Krishna, Xie et al. 
2012).  
 
Activation and proliferation experiments both showed that the majority of the patient's 
cells failed to survive. Apoptosis experiments confirmed that cells from A.II.1 were 
prone to apoptosis after stimulation with PMA and ionomysin, or TNFa. Remarkably, 
global gene expression showed that both T and B cells expressed very high levels of IL-
8 and CCL2. They chemokines are known to facilitate phagocytosis. In 2013, Cullen 
and colleagues discovered that TNFα or CD95 induced apoptotic cells secreted various 
signals, particularly IL-8 and CCL2 to induce phagocytosis (Cullen, Henry et al. 2013).  
A20 is physically associated with the DISC complex, and inhibits the DISC formation 
by removing ubiquitin chains of caspase 8 through DUB activity (Jin 2009). Thus, 
impaired DUB function may result in an enhanced propensity to apoptosis.  
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Increased cell death was observed in caIKKβ mice, as well as high levels of expression 
of both active caspase 8 and active caspase 3. Intriguingly, patients with gain-of-
function mutations in CARD11 did not show cell apoptosis. Although CARD11 is 
crucial for lymphocyte activation, CARD11 is restricted to lymphocytes. By contrast, 
A20 and IKKβact more broadly to regulate canonical NF-kB pathways such as TNF or 
TLR-induced NF-kB, which might explain why A20 S254R more closely resembles the 
phenotype of caIKKb mice than CARD11 patients. 
 
We observed a severe phenotype in A.II.1, with evidence of increased cell activation, 
enhanced apoptosis, and clinical features of autoimmunity and immune deficiency. 
Other carriers of the TNFAIP3 mutation were phenotypically normal. Recent evidence 
has emerged that truncated mutations in TNFAIP3 resulting in A20 haploinsufficiency is 
sufficient to cause a florid inflammatory phenotype (Zhou, Wang et al. 2016). The 
discrepancy could be explained because A20 S254R still contains a functional E3 ligase 
domain and haploinsufficient DUB activity may be compensated by E3 ligase domain.  
 
The severe phenotype observed in the proband from kindred A, however, appears to be 
due to the combined action of the A20 variant, and a variant in its interacting partner, 
TAX1BP1. A20 forms macromolecular complexes that function in NF-kB inhibition 
and apoptosis (Shembade, Harhaj et al. 2008; Shembade, Parvatiyar et al. 2009). The 
discovery of an increasing number of A20 interacting partners indicates that A20 is 
involved in a broad range of immune regulation. We hypothesized that an additional 
mutation in interacting partners would alter A20-containing complexes to impair A20 
functions. We identified 13 nonsynonymous or splicing mutations from A20 interacting 
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genes in the A.II.1 genome. Among them a mutation in TAX1BP1 was the only unique 
mutation that was found in A.II.1 but not in the other A20S254R carriers.  
 
TAX1BP1 was discovered in a yeast two–hybrid screen for A20 binding partners (De 
Valck et al., 1999). TAX1BP1 is also an essential regulator. TAX1BP1-deficiency in 
mice results in premature death due to age-dependent hypertrophic cardiac valvulitis. 
These mice also exhibit hypersensitivity to sublethal doses of TNF and IL-1, which had 
also been observed in A20-/- mice (Iha, Peloponese et al. 2008). Inhibition of NF-kB is 
attenuated in Tax1bp1 deficient cells, due to impaired ubiquitin editing, although 
TAX1BP1 does not possess the ubiquitin editing activity. Therefore TAX1BP1 is 
thought to be a scaffolding protein that recruits A20 to ubiquitinated substrates, 
enabling A20 to perform its ubiquitin editing function to terminate NF-kB signalling 
(Verstrepen, Verhelst et al. 2011). Recently, it has been reported that phosphorylation of 
TAX1BP1 is required to form A20 editing complexes, and mutations in active sites of 
TAX1BP1 impair the formation (Shembade, Pujari et al. 2011). This observation 
confirms that functional TAX1BP1 is important for the normal operation of the A20 
editing complex, and that mutations on TAX1BP1 could impair the A20 ubiquitin 
editing functions. 
 
We went on to confirm both the functional consequence of TAX1BP1 deficiency, and 
the defect on function conferred by combined mutations in TAX1BP1 and TNFAIP3. In 
order to exclude endogenous gene expression, we generated RAJI A20-/- TAX1BP1-/- and 
RAJI TAX1BP1 -/- were by CRISPR/cas genetic engineering. We observed high level 
expression of CD69 in RAJI A20-/- TAX1BP1-/- and RAJI TAX1BP1 -/- cells, confirming that 
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TAX1BP1 and A20 inhibit NF-kB activation. RAJI A20-/- TAX1BP1-/- showed enhanced 
CD69 expression compared with RAJI TAX1BP1-/-. Consistent with previous reports, this 
suggests that A20 has additional functions independent of TAX1BP1. The effect of 
A20S254R and TAX1BP1L307I was tested in RAJI A20-/-, TAX1BP1-/-. As expected, A20S254R 
and TAX1BP1L307I cells exhibited more persistent and stronger NF-kB activity 
compared to wild type or single mutant cells. The cells with three different stimuli 
showed the same results in both 24 hour and 48 hour stimulation.  
 
We investigated the possibility of biochemical interaction between both mutant proteins 
by co immunoprecipitation experiments. Our initial hypothesis was that A20 S254R or 
TAX1BP1 L307I may interrupt the formation of molecular complexes involving these 
two proteins, possibly as a result of conformational changes. The results were in 
contrast to this prediction, and revealed that the interaction between A20 S254R and 
TAX1BP1 L307I is enhanced relative to that between wildtype proteins. We observed a 
relatively weak the interaction between wildtype A20 and TAX1BP1 possibly due to 
stringent immunoprecipitation buffer. By contrast, we observed a robust 
coimmunoprecipitation of mutant proteins, suggesting a higher affinity interaction 
between the mutant proteins. Preferential interaction of mutant proteins, resulting in 
greater than expected incorporation of mutant A20, would therefore amplify the 
phenotypic consequences of mutant A20, which we showed exhibits defect 
deubiquitination.  
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Figure 3.37  A theory of nonallelic noncomplementation discovered in this study 
 
In conclusion, we report a novel mutant allele of A20 S254R that segregates with 
primary antibody deficiency. In vitro, A20S254R impairs DUB and inhibition of NF-kB. 
The mutation in TNFAIP3 appears to be in epistasis with a polymorphism of 
TAX1BP1, as the phenotypic consequences of the mutant A20 protein are accentutated 
by TAX1BP1 polymorphism. We present biochemical evidence of a preferential 
interaction between the two mutant proteins, consistent with the phenomenon of 
nonallelic noncomplementation, in which two different recessive mutations confer a 
phenotype because they encode proteins that act in the same pathway, or contribute to  
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the same macromolecular complex. In this particular case, the mutations increase the 
affinity of interaction between A20 and TAX1BP1 to amplify the consequences of a 
hypomorphic TNFAIP3 allele.  
 
 
Table 3.1 Summary of immunogical phenotype 
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T1 B cells  
(CD24+++ CD38+++) 2.23 1.91 17.5 2.81 4.07 2.66 1.78 8.72 0.79-6.06 
T2 B cells 
(CD24++ CD38++) 6.31 7.36 18.5 4.72 12.7 8.09 6.05 15.3 2.87-11.5 
Naïve B cells 
(CD24+ CD38+) 57.1 55.4 18.8 43.3 72.8 47.7 76.8 54.7 41.3-68.7 
Memory B cells 
(CD24++CD38+) 21.3 22.8 5.98 26.7 8.41 36.1 13.6 17.7 7.47-39.3 
Plasma cells 
(CD24-CD38+++) 0.25 0.47 0.079 1.09 0.011 0.16 0.017 0.25 0.018-0.48 
Anergic B cells 
(CD24- CD38-) 0.67 0.76 13.7 1.6 0.047 0.24 0.02 0.083 0.14-2.24 
CD21 low 14.57 13.54 46.61 18.18 9.31 6.6 7.13 7.67 3.7-17.6 
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 CD4+ TEMRA  
(CD4+ CCR7- CD45RA+) 11.2 24.1 12.3 17.7 8.45 7.78 17.8 20.5 3.27-11.4 
CD4+ Naïve 
(CD4+ CCR7+ CD45RA+) 15.5 47.2 1.48 37 32.5 23.8 44.6 58.4 8.47-55.4 
CD4+ TCM 
(CD4+ CCR7+ CD45RA-) 15.1 10.3 6.72 14.3 33.4 14.5 9.33 5.67 14.7-31.1 
CD4+ TEM 
(CD4+ CCR7- CD45RA-) 58.2 18.3 79.5 31 25.7 54 28.4 15.4 18.9-45.3 
Treg  
(CD4+ CD25+ CD127- 
FOXP3+) 
3.86 4.29 0.58 3.35 3.2 3.63 2.9 3.65 4.13-7.47 
cTFH 
(CD4+ CXCR5+ CD45RA-) 13.7 7.23 3.96 9.41 15.6 8.29 5.51 4.46 7.5-14 
TH1 
(CD4+ CCR6- CXCR3+) 11.7 10.7 4.09 24.6 26.8 28.7 28.2 20.9 9.57-45.3 
TH2 
(CD4+ CCR6- CXCR3-) 26.8 48.8 54.3 52.3 26.2 17.4 15.7 27.9 28.3-67.2 
TH17 
(CD4+ CCR6+ CXCR3-) 33.7 30.4 36.2 11.2 24.3 20.9 24.6 33.6 17.2-39.2 
CD57+ 1.69 1.03 19.08 9.99 7.116 2.491 0.553 0.338 0.39-2.3 
PD1+ 31.33 14.25 80.2 24.44 46.72 58.35 38.577 33.565 18.8-45.62 
CD57+ PD1+ 0.83 0.45 14.7 5.44 6.22 2.35 0.477 0.265 0.22-1.62 
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4 Pedigree II 
4.1 Results 
4.1.1 Clinical history of our proband 
 
Table 4.1 Clinical history of TCH128 family 
 
We identified an individual (I.1) with complete B-cell deficiency from within a larger 
cohort of patients with primary immune deficiencies. She was not diagnosed with CVID 
until the age of 40 but had a long history of chronic sinusitis, bacterial pneumonia, 
recurrent intestinal giardiasis, and periodontitis. She also had alopecia areata at age 14 
years. At the time of investigation, she was receiving intravenous immunoglobulin 
(IVIG) replacement. Further investigation of the kindred revealed 2 of 3 offspring with 
 
 
 
  
I.1 
 II.1  II.2  II.3 
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hypogammaglobulinemia, 1 diagnosed at age 20 years (II.2) and the other in infancy  
(II.3) (Table 4.1). Both sons have a history of chronic sinusitis from childhood and 
remarkably, both have a history of childhood alopecia totalis. One is receiving IVIG, 
and the other remains healthy despite refusing immunoglobulin replacement therapy.  
 
4.1.2 The cellular phenotype 
 
 
 
Figure 4.1 Analysis of circulating B cells and summary of B cell numbers relative to other CVID 
affected patients and healthy control CD19+CD27- cells represent naïve B cells CD19+ CD27+ cells 
indicate memory B cells. 
 
Analysis of peripheral blood samples from A.I and all 3 offspring revealed severe B-cell 
deficiency (Figure 4.1). In all cases, B cells represented less than 2% of total 
lymphocytes, which is exception not only in healthy controls but also unrelated patients 
with hypogammaglobulinemia, where the average proportion of B cells was 
approximately 15% (Figure 4.1). 
0.1 0.1 25.3 3.5 1.
4 
0.2 0.2 0.2 
I.1 II.1 II.2 II.3 
CD27 
C
D
1
9
 
Novel NF-kB mutations in common variable immunodeficiency (CVID)  
148 
 
 
 
Figure 4.2 Analysis of transitional B cells in family members. They are CD19+ cells and 
CD24+++CD38++ cells represent transitional stage 2 B cells and CD24++ CD38 ++ cells represent 
transitional stage 1 B cells. 
 
Each patient was also found to have severe deficiency of transitional stage 1 and 2 B 
cells (defined according to CD19, CD24 and CD38 expression) in the peripheral blood 
(Figure 4.2).  
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Figure 4.3 Distribution of CD24loand CD10hi cells A. Analysis of CVID patients and healthy controls 
B. summary of the population C. Analysis of the population from Cord blood, Tonsile or ribuximab from 
patient with rituximab treatment. 
 
Careful analysis of the few remaining CD19+ cells revealed a relative expansion in 
CD10hi CD24lo cells and this population, which is rare in cord blood and tonsil as well 
as adult peripheral blood, but is relatively prominent in patients who have received 
rituximab (anti-CD20) (Figure 4.3). 
                         
 
Figure 4.4 Analysis of bone marrow samples A. Pro B cells (CD10+ CD34+) and Pre B cells (CD10+ 
CD34-) were analysed B. Expression of indicated transcripts from I.1 relative to their expressions in two 
normal control marrows. Ctrl, control 
 
Consistent with these findings, reanalysis of an archival bone marrow biopsy obtained a 
decade earlier from I.1 revealed an arrest in early B cell ontogeny (pro-B cells) (Figure 
4.4).  
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Despite profound B cell deficiency, serum Ig was measurable. Furthermore, antibodies 
to specific antigens were also detected (tetanus toxoid and 7/14 pnemococcal 
polysaccharides, Table 4.1). Consistent with this finding, analysis of transcripts 
prepared form the aspirate are consistent with the presence of plasma cells (Figure 4.1).  
 
In order to investigate abnormalities in plasmablast induction, B cells were stimulated 
with CD40L and IL-21, or CpG and IL-21 for 4 days in vitro. Remarkably, we observed 
a 4-12 fold increase in plasmablast (CD27 + CD38++) induction with CpG, IL-21 or 
CD40L, IL-21 in I.1 relative to controls (Figure 4.5). Thus, despite the profound B cell 
deficiency, plasmablast formation is preserved a finding consistent with the discordance 
between the observed B cell count and immunoglobulin levels. 
 
 
Figure 4.5 Flow cytometric analysis of plasmablast induction in vitro A. PBMCs were cultured with 
CD40L (1µg/ml) and IL-21 (50ng/ml) or CpG (2µM) and IL-21(50ng/ml) for 4 days. Then plasmablasts 
(CD27++ CD38+++) were enumerated. Ctrl, healthy control; I.1, proband 
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Figure 4.6 Flow cytometric analysis of circulating T lymphocytes Enumeration of memory and 
effector T cells. Representative profiles and summary data. TCM, central memory T cells; TEM, effector 
memory T cells; TEMRA, CD45RA+ effector memory T cells.  
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All family members had normal numbers of circulating T cells (Figure 4.6).  Analysis 
of the T-cell compartment revealed an inversion of the normal CD4/8 ratio in patients 
and the affected individuals seems to have more naïve T cells in CD4 compartment 
however, we found no substantial abnormality of T-cell differentiation to memory cells 
or CD4 effector cells (Figure 4.6). 
 
 
 
 
 
Figure 4.7 T cell activation and proliferation Either naive CD4+ T cells separated by negative selection 
with magnetic beads or CD4+ T cells with PBMC were analysed by dilution of cell trace violet after 
simulation with CD3 CD28. Cells were harvested and analysed by flow cytometry on day 4 (blue) and 
day 6 (red). Histograms were gated on CD3 and CD4. Unstimulated control cells are shown (grey). In the 
same experiment, naïve CD4+ T cells were analysed for activation based on induction of CD69. The 
percentage of CD69+ cells at each division was determined and plotted (control2, open blue; I.1, black 
filled). CTV, cell trace violet  
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To test for abnormalities of T-cell activation, PBMCs and purified naive T cells were 
isolated from both proband and controls and activated with anti CD3 and CD28. 
Activation according to CD69 and CD25 induction and proliferation appeared similar in 
patients and controls (Figure 4.7).  
 
   
 
Figure 4.8. cTfh A. Peripheral blood flow cytometric analyses, gated on CD4+ T cells and analyzed for 
Tfh-like cells (boxed as CXCR5+ CD45RA-). B. Frequencies of and circulating Tfh-like cells among 
CD4 T cells from healthy controls (open circles); healthy sibling (black-filled circles ), ***P < 0.0001.  
 
We did, however, identify a consistent reduction by approximately 20% in circulating 
CXCR5+ CD45RA- CD4+ T cells (P=0.0001; Figure4.8). This population is related to 
follicular helper T cells (Tfh), which are largely confined to secondary lymphoid organs 
here they provide crucial helper signals for B cells and antibody production. The mean 
frequency of natural regulatory T cells (FoxP3+) among CD4 cells was decreased to 
approximately 30% of normal in those affected (P=0.03; Figure 4.9).  
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Figure 4.9 Regulatory T cells (boxed CD127low, CD25high) A. Percentage of CD4 T cells within the 
gated subsets is shown. B. Histograms show intracellular staining for Foxp3 expression in cells within the 
CD127low, CD25high gate (red histogram) and within the cells excluded from this gate (blue histogram). 
(C) Frequencies of and Tregs among CD4 T cells from healthy controls (open circles); healthy sibling 
(black-filled circles), *P=0.03 
 
    
 
 
 
Figure 4.10 Recent thymic emigrants A. Flow cytometric analysis of peripheral blood mononuclear 
cells for recent thymic emigrants CD31+ CD45RA+). B. Frequencies of CD31+ CD4+ recent thymic 
emigrants among CD4 T cells from healthy controls (open circles); healthy sibling (black-filled circles); 
NFKB2 mutant siblings and parent (black-filled squares). (E)  
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We observed an increase in recent thymic emigrants, as determined by 
CD31+andCD45RA+cell expression (Figure 4.10), which raises the possibility of an 
abnormality in thymic function.  
 
 
4.1.3 Mutation discovery 
 
 
 
 
 
 
 
 
 
 
 
131 
18513 
ns8619 
 
human  852 TRDKLPSTAEVKEDSAYGSQSVEQE 
mouse  852 TRDKLPSTAEVKEDSAYGSQSVEQE 
wolf  852 ARDKLPST-EVKEDSAYGSQSVEQE 
cow   853 TQEKLPST-EVKEDSAYGSQSVEQE 
chicken  859 PLEKLQST-EVKEDSAYGSESVEEE 
zebrafish 870 PREDKQSS-DSTEDSGFGSQSIGEE 
Xenopus   917       SPAEGKNDSAYESQSMEVDQS 
Fugu    841      HNT–EATVDSGFSSQPMEEE 
Elegans   no homologue        
Drosophila  no alignment     
A B 
C 
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Figure 4.11 NFKB2 mutation. A. Frequency histogram of novel alleles according to filter based on 
tissue expression, phenotype of mice with mutations in orthologs, disease association, GO, and PolyPhen-
2 scores (NFKB2 in red circle). B. Sanger sequencing of  NFKB2 (according to pedigree in 4.1.1 ). C. 
Conservation of mutated residue of NF-kB2. D. Summary of p100 processing. Amino acid D in red 
indicates the location of D865G mutation, which is adjacent to one of the N-terminal phosphorylation 
sites (S866). Rel homology domain (green), ankyrin repeat domains (Jain, Ma et al.),  death domain 
(Belot, Kasher et al.).  
 
 
Table 4.2 Summary of the mutation 
 
NFKB2 
Variant  Chr10; 104162024A>G 
 g.2594 A>G; c.2594A>G; 
Protein  D865G 
Mutation taster  Disease causing P=0.999979076300663 
SIFT  Damaging (0.04) 
Poly Phen-2  Probably damaging 1.0   
 (sensitivity 0, Specificity 1.0) 
 
 
 
Whole exome sequencing of the proband identified 131 novel mutations, which were 
then filtered according to pattern of tissue expression, GO pathways, phenotypes of 
mice harboring genetic mutations in orthologs, disease association (OMIM), and 
PolyPhen-2 score (Figure 4.11). From this analysis, 3 clear candidates emerged: 
TNFRSF10A, TNFRSF1A, and NFKB2. All 3 mutations were confirmed by Sanger 
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sequencing, but only the NFKB2 mutation segregated with CVID phenotype and the B-
cell phenotype. Furthermore, during the course of the project, 2 other kindreds with 
dominant antibody deficiency were described. 
 
Members of the kindred described here have a heterozygous missense mutation 
encoding an amino acid substitution of aspartate to glycine at position 865 
(NFKB2D865G) (Figure 4.11, Table 4.2). Based on interrogation of dbSNP, 1000 
Genomes Project, Human Genome Mutation Database, and ClinVar databases as well as 
other CVID kindreds within our cohort, this appears to be a novel mutation. Aspartate 
865 is located in the NF-kB–inducing kinase (NIK)- responsive domain of the p100 
protein product of NFKB2 and is absolutely conserved in vertebrates from humans to 
fish (Figure 4.11). The substitution with glycine is predicted to be damaging by 3 
different in silico tests (Table 4.2). 
 
4.1.4 Effect of NFKB2 D865G on P100 processing 
Signaling via the noncannoical NF-kB pathway depends on accumulation of NIK 
(MAP3K14), a serine/threonine protein kinase that becomes stabilized after engagement 
of several TNF super family receptors including lymphotoxin α1β2, BAFF and CD40.  
NIK cooperates with another serine kinase, IkB kinase α (IKKα), to bind the full-length 
NF-kB2 (p100) protein and phosphorylate it on 2  
 
A 
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Figure 4.12 Effect of D865 > G mutation on NIK induced p100 processing HEK293 cells were co-
transfected with expression vectors encoding wild-type (WT) or D865 . G mutant NFKB2 together with 
varying amounts of MAP3K14 expression vector encoding NIK. A. p100 and p52 detection by western 
blot B. Summary of relative expression of p100 and p52 determined as determined in (A). 
 
critical serines, S866 and S870, in the C-terminal processing inhibitory domain. 
Phosphorylation of these sites allows binding of the ubiquitin ligase SCFbTrCP and 
polyubiquitination of lysine 855, tagging the p100 protein for limited proteasomal 
processing to yield the transcriptionally active p52 subunit of NF-kB2.The D865G 
mutation is located immediately adjacent to the critical S866 phosphorylation site. We 
investigated the effect of the D865G animo acid substitution on p100 processing. First, 
we transfected HEK293 cells with vectors expressing either wild-type or D865G mutant 
NFKB2 alleles. Analysis of cell lysates demonstrated dose-dependent processing of 
NFKB2 NFKB2
D86
5G
 
NFKB2
+/D86
5G
 
0.5 1 2 0 NIK 0.5 1 2 0 
 
1 
NFKB2 NFKB2
D865
G
 
  
NIK 
p100 
p52 
NIK 
 
NFKB2
+/D86
5G
 
 
 
 
B 
Novel NF-kB mutations in common variable immunodeficiency (CVID)  
159 
 
normal p100 stimulated by co-transfected NIK.  By contrast, NFkB2D865G exhibited 
near-absence of p100 processing after NIK co-transfection (Figure 4.12). Only a small 
residual p52 band was detected, which is probably accounted for by endogenous NF-
kB2 in the cell line. Co-transfection of mutant and normal alleles (NFKB2+/D865G) 
resulted in approximately 50% of normal processing to p52. The defect in 
NFKB2D865Gp100 processing was not corrected by stimulation with lymphotoxin-α. 
Processing of wild type p100 was blocked by MG132, a prteasome inhibitor, 
confirming its dependence on the proteasome (AppendixVI).  
 
Next, we demonstrated that the D865G substitution affects p100 phosphorylation 
(Figure 4.13), even though this mutation does not involve a serine residue. This would 
appear to account for the loss of p100 processing.  
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Figure 4.13 Effect of D865>G mutation on NIK induced p100 phosphorylation. HEK293 cells were 
co-transfected with expression vectors encoding wild-type (WT) or D865G mutant NFKB2 together with 
varying amounts of MAP3K14 expression vector encoding NIK. A phosphorylation of serines 867 and 
870 in response to increasing dose of NIK B. Summary of relative expression of phosphor-NFKB2 as 
determined in (A). 
 
 
 
Finally, we examined p100 processing in patient cells. B cells are too few in affected 
patients to examine for a biochemical defect in response to CD40L. Instead, we 
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generated dendritic cells in vitro from donor monocytes (DCMC). DCMC were then 
stimulated with CD40L; this revealed a similar defect in p100 processing as we had 
observed in transfectants (Figure 4.14). 
 
Figure 4.14 p100 processing in response to CD40L in monocyte derived dendritic cells (MDDC) 
Monocytes from I.1 or a healthy control were incubated with IL-4, GM-CSF and β-mecaptoethanol for 7 
days to induce dendritic cells in vitro (MDDC). MDDCs were stimulated with CD40L (1ug/ml) for 3 
days and p52 and p100 expression were measured by western blot. pIKKα and β-actin were used for non 
canonical activation and loading control, respectively  
 
4.1.5 Effect of NFKB2 D865G on canonical NF-kB activity 
 
p100 is thought to exert an IkB-like action on the canonical pathway, which prompted 
us to investigate whether the accumulation of p100 exerts a dominant negative action 
that contributes to the severity of the B-cell phenotype in this syndrome.  
 
To directly test the effect of the mutation on both canonical and noncanonical pathways, 
we compared the actions of CD40L, which is considered a noncanonical stimulus, but 
also activates the canonical pathway, and anti-Ig (a canonical stimulus) for their abilities 
to activate rare peripheral B cells from an affected individual (Figure 4.15), according to 
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expression of surface antigens generally considered to be NF-kB–responsive (CD86, 
CD69, andCD83). B cells 
                                                  
     
Figure 4.15 B cell activation Analysis of B cells from II.2 relative to controls for expression of CD86, 
CD69, and CD83 after 24 hours of treatment with indicated stimuli. 
 
 
from patient II.2 exhibit much less CD86 induction but preserved CD69 expression 
withCD40L compared with healthy controls; the difference was more pronounced with 
CD40L and anti-Ig  stimulation. These findings are consistent with defects in both 
canonical and noncanonical pathways. Activation of the canonical pathway results in 
translocation of p65 to the nucleus, where it regulates gene transcription. To further 
explore the possible action of p100 on canonical pathway signaling, we examined the 
location of p65 in cells transfected with NIK plus either wild-type or wild-type and 
D865G NFKB2. NIK alone results in activation of the noncanonical pathway and 
processing of p100, which causes abundant nuclear translocation of p65 in response to a 
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canonical stimulus (TNF). A similar response is observed in the presence of NF-kB2 
with NIK, whereas D865G NF-kB2 with NIK results in cytoplasmic retention of p65. 
 
 
Figure 4.16 Inhibition of canonical NFKB pathway by investigation of p65 translocation Dapi is 
used for nuclei staining. TNFα (50ng/ml) was used for 1 hour to stimulate canonical NF-kB pathway 
Nuclear translocation of p65(red) in HEK293 cells transfected with the indicatedconstructs after 
stimulation with TNF. A 4,6 diamidino-2-phenylindole counterstain identifies cell nuclei. A. Image and B. 
Summary of p65 translocation of immunofluorescence confocal. 
 
 
To determine the effect of our mutation on the canonical pathway, we looked at p65 
translocation (Figure 4.16). We transfected HEK293 with vectors expressing either 
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wildtype or D865G mutant alleles of NFKB2 with NIK. After 48 hours post transfection 
cells were stimulated with TNF alpha for 1 hour. p65 and nuclei were stained for 
translocation. This first column in Figure 4,16 shows that most of the p65 was 
cytoplasmic after mock stimulation. In cells transfected with NFKB2 and stimulated 
with TNF alone, p65 was distributed in both the cytoplasm and nuclei, as expected if 
p100 partially blocks the canonical pathway. In cells transfected with NIK alone, the 
majority of p65 translocated to the nucleus. In cells transfected with NFKB2 + NIK the 
majority of p65 was also found in the nucleus, although the effect was less pronounced 
compared to NIK alone. This is because in the absence of transfected NIK, transfected 
p100 may not have been completely processed, and may have bound to p65. Since the 
mutation described in the kindred is heterozygous mutation, we also investigated a 
possible dominant negative action. We transfected cells with wildtype and mutant 
NFKB2 expressing vectors together with NIK. We observed that inhibition of p65 
translocation was much more pronounced in heterozygous mutant culture compared to 
wildtype. 
 
Next, we investigated how these changes in NFKB2 signalling would affect B cell 
activation. This experiment was made difficult by the severe B cell deficiency exhibited 
by patients. B cells were stimulated B cells with CD40L or CD40L+anti Ig. We found 
that II.2 showed much less CD86 induction with CD40L compared with healthy 
controls, and the effect was pronounced with CD40L and anti Ig stimulation. This result 
was similar to the p65 translocation in the heterozygous transfectant experiment. By 
contrast, we found no abnormalities CD83 or CD69 expression. This is consistent with 
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other evidence that CD86, Cd83 and CD69 responses can be discordant in the presence 
of defects in the canonical NF-kB pathway (Snow, Xiao et al. 2012).  
 
4.2 Discussion  
Our findings reveal the importance of D865 for NF-kB2 (p100) phosphorylation and 
processing to p52 for maintaining both integrity of noncanonical NF-kB signaling and 
efficiency of canonical NF-kB signaling for maintaining normal numbers of human B 
cells. Several previous lines of evidence have identified the importance of the 
noncanonical NF-kB pathway for human B-cell survival. NF-kB2 is known to be 
activated by signals from TNFRSF members lymphotoxin-b receptor, BAFFR, RANKL 
(receptor activator of NF-kB), and CD40 (Claudio, Brown et al. 2002; Coope, Atkinson 
et al. 2002; Kayagaki, Yan et al. 2002; Derudder, Dejardin et al. 2003; Novack, Yin et 
al. 2003). Of these, CD40 and BAFFR are thought to provide B-cell survival signals 
(Locksley, Killeen et al. 2001; Schiemann, Gommerman et al. 2001). Mutations in 
CD40 and CD40LG both confer a phenotype of hyper-IgM, with absent germinal 
centers and absence of class switch recombination (DiSanto, Bonnefoy et al. 1993; 
Conley, Larche et al. 1994; Morrison, Reiley et al. 2005). BAFF acts relatively 
selectively on the noncanonical NF-kB pathway (Morrison, Reiley et al. 2005). BAFFR 
deficiency has been reported to cause a primary antibody deficiency syndrome, based 
on the phenotypes of 2 siblings, both of whom presented relatively late in life (CVID4, 
OMIM 606269) (Warnatz, Salzer et al. 2009). In one of these individuals, there was an 
arrest of peripheral B-cell development at the transitional stage of B-cell ontogeny, and 
a significant deficiency of IgG. In the other sibling, the defect appeared to be milder 
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with detectable mature B cells. Similarly, antibody-mediated blockade of BAFF in 
humans is an approved therapy but induces a surprisingly gradual decrease in naive 
circulating B cells (Wallace, Stohl et al. 2009). 
 
 Finally, truncation mutations of NFKB2 have been reported to cause antibody 
deficiency but normal levels of circulating B cells.20 The phenotype of 
NFKB2D865G/1 is significantly different from that described for human mutations in 
CD40, CD40LG, and TNFRSF13C (BAFFR), and indeed for truncation mutations 
ofNFKB2.20 NFKB2D865G missense mutation results in unprocessable p100 and 
consistent and severe B-cell deficiency. Chen et al reported small reductions inBcells in 
2 of 4 patients with truncation mutations (855X or 853X), but the mean reduction in 
total B-cell count is 30-fold greater in patients with the missense mutation described 
here (5.23% vs 0.16% of PBMCs). We demonstrate defects in B-cell activation via the 
canonical pathway and reduced nuclear translocation of p65 (Figure 4.16); we propose 
that the profound reduction in B cells conferred by NFKB2D865G mutation could be 
accounted for by the combined effects of reduced noncanonical signaling plus inhibition 
of the canonical pathway by unprocessed p100. 
 
p100 exhibits IkB-like activity, which serves to inhibit assembly of the p50/RelA 
complex of the canonical NF-kB pathway as well as RelB/p52 itself and sequester the 
complexes in the cytoplasm (Basak, Kim et al. 2007; Tucker, O'Donnell et al. 2007). In 
other words, unprocessable p100 acts in a dominant negative manner to impair 
canonical signaling, while simultaneously compromising noncanonical signaling by 
haploinsufficiency. Consistentwith this possibility, mice deficient for both NFKB1 and  
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NFKB2 have more severe B-cell deficiency and profound maturation arrest than mice 
with either single deficiency, (Franzoso, Carlson et al. 1998; Claudio, Saret et al. 2009) 
although not as severe as the human deficiency observed here. By contrast, Nfkb2-/-mice 
exhibit subtle reductions in B-cell numbers, normal Ig apart  from IgA, but abnormal 
splenic white pulp architecture with failure of germinal center formation (Caamano, 
Rizzo et al. 1998).  
 
Consistent with the dominant negative action proposed for the human mutation reported 
here, mice with an Nfkb2 truncating mutation 2 residues distal to D865 exhibit failure 
of p100 processing but have a relatively mild decrease in mature B cells even in 
homozygous state, although they have a deficit in lymph node development (Miosge, 
Blasioli et al. 2002; Tucker, O'Donnell et al. 2007). Defects in B-cell survival and 
differentiation have been reported in patients with mutations affecting BAFFR, NEMO, 
CD40, and CD40L as well as truncationmutations ofNFKB2, but none of these cause B-
cell deficiency as severe as we report here. (DiSanto, Bonnefoy et al. 1993; Conley, 
Larche et al. 1994; Caamano, Rizzo et al. 1998; Warnatz, Salzer et al. 2009; Chen, 
Coonrod et al. 2013). This is likely because NFKB2D865G disrupts noncanonical 
signaling normally activated by several ligands, and because the mutation results in 
impaired canonical NF-kB signaling as well.  
 
The noncanonical defect in p52 production is a defect in response to the combined 
actions of CD40L, CD27, and BAFF—all ligands that normally signal via the 
noncanonical pathway to maintain B-cell homeostasis. p100 not only functions as a 
precursor of p52, but also as the fourth IkB protein (along with IkBa, b, and g 
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[NEMO]), which inhibits nuclear translocation of RelA/p50 by the canonical pathway 
(Basak, Kim et al. 2007). Thus, noncanonical stimuli result in p100 processing to reduce 
the restraint on canonical signaling as well. Accumulation ofp100 conferred by 
NFKB2D865G appears to result in enhanced IkB activity, based on dampened response 
to canonical stimuli (anti-Ig) and reduced nuclear translocation of p65. As in mice, in 
which combined Nfkb1 and Nfkb2 defects cause much more severe defects than either 
defect alone, the combined effects on both canonical and noncanonical pathways are 
likely to explain the comparative severity of the B-cell phenotype. Two possible 
explanations emerge to account for differences in B-cell phenotype between truncation 
and missense mutations. 
 
 First, D865G results in more profound inhibition of the noncanonical pathway than the 
truncation mutant. For example, p100 protein translated from the missense mutation 
fails to undergo either phosphorylation or processing and might sequester IKKa, thereby 
reducing phosphorylation and processing of the protein product of the normal allele. 
Second, the full-length nonprocessable D865G p100 inhibits canonical signaling more 
effectively than the truncated protein. Our data favor the latter possibility. Co-
transfection of normal and mutant alleles into HEK293 cells resulted in approximately 
50% reduction in p52, arguing against a dominant negative action on the noncanonical 
pathway (Figure 4.12). Although the most obvious phenotype of the NFKB2 mutation 
described here is B-cell deficiency, all 3 affected individuals exhibited alopecia areata, 
with no other evidence of other autoimmunity. Taken together with findings reported by 
Chen et al, we confirm the autosomal-dominant syndrome of antibody deficiency and 
alopecia arising from NFKB2 mutation. We found no evidence for other autoimmunity 
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(including no ACTH deficiency). This independent confirmation would appear to 
substantiate an autosomal-dominant syndrome of antibody deficiency and alopecia 
areata as a consequence of NFKB2 mutation. Further studies will be necessary to 
delineate the cause for alopecia.Mouse models have established that NF-kB2 is 
important for central T-cell tolerancemediated by negative selection and Treg induction 
(Zhu, Chin et al. 2006; Venanzi, Gray et al. 2007; Seach, Ueno et al. 2008).  
 
Noncanonical NF-kB signaling downstream of RANK and LTbR is necessary for 
normal maturation of the thymic medullary epithelial cells that express AIRE. We 
observed a significant reduction in natural Tregs. Consistent with this postulate, 
mutations in AIRE are the most penetrant genetic defects associated with alopecia so far 
(Wengraf, McDonagh et al. 2008). Either way, abnormalities in the noncanonical 
signaling provide a new mechanism to account for the curious and well-established 
coincidence of autoimmunity and primary antibody deficiency, and the occurrence of 
Treg deficiency in some cases of CVID. NF-kB2 is also important for cell migration by 
transactivating genes encoding chemokines and their ligands, including CCL19, 
andCCL21, which are important for thymic retention of T cells. This pathway could 
account for the increase in recent thymic emigrants in the peripheral blood. We also 
observed a deficiency of CXCR51 T cells in the periphery. Although the precise 
ontogeny of this T-cell subset remains uncertain, there is evidence that they have an 
enhanced capacity to provide help to B cells when compared with CXCR5- memory T-
cell counterparts, (Morita, Schmitt et al. 2011) and mouse studies have shown their 
dependence on Nfkb2. It is also plausible, however, that this Tfh defect reflects the 
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absence of peripheral blood B cells because B cells are known to provide important 
trophic signals for this T-cell compartment (Martini, Enright et al. 2011). 
 
Finally, this phenotype of the patients reported here is remarkable for the discordance 
between B-cell deficiency and antibody deficiency. Other examples of late-onset B-cell 
deficiency have been described in which the phenotype is more consistent with XLA. In 
XLA, however, there is usually a good correlation between the B-cell deficiency and the 
severity of the antibody deficiency. By contrast, the D865G NFKB2 mutation appears 
to cause profound B-cell deficiency, in which Ig levels including antigen-specific 
antibodies, remain detectable. The persistence of specific antibody in the absence of B 
cells raises the possibility that medium to long-livedplasma cells can form 
independently of NF-kB2. It is also possible that mimicking the effect of this mutation 
to obtain a partial reduction in NF-kB2 might offer therapeutic approaches for B-cell– 
and antibody-mediated disease, in which the objective is to eliminate ongoing aberrant 
immune responses while preserving protective immunity already established. 
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6 Appendex 
Appendex I. DNA sequences 
A20 cDNA 
     1 TGCCTTGACCAGGACTTGGGACTTTGCGAAAGGATCGCGGGGCCCGGAGAGGTGTTGGAG 
    61 AGCACAATGGCTGAACAAGTCCTTCCTCAGGCTTTGTATTTGAGCAATATGCGGAAAGCT 
   121 GTGAAGATACGGGAGAGAACTCCAGAAGACATTTTTAAACCTACTAATGGGATCATTCAT 
   181 CATTTTAAAACCATGCACCGATACACACTGGAAATGTTCAGAACTTGCCAGTTTTGTCCT 
   241 CAGTTTCGGGAGATCATCCACAAAGCCCTCATCGACAGAAACATCCAGGCCACCCTGGAA 
   301 AGCCAGAAGAAACTCAACTGGTGTCGAGAAGTCCGGAAGCTTGTGGCGCTGAAAACGAAC 
   361 GGTGACGGCAATTGCCTCATGCATGCCACTTCTCAGTACATGTGGGGCGTTCAGGACACA 
   421 GACTTGGTACTGAGGAAGGCGCTGTTCAGCACGCTCAAGGAAACAGACACACGCAACTTT 
   481 AAATTCCGCTGGCAACTGGAGTCTCTCAAATCTCAGGAATTTGTTGAAACGGGGCTTTGC 
   541 TATGATACTCGGAACTGGAATGATGAATGGGACAATCTTATCAAAATGGCTTCCACAGAC 
   601 ACACCCATGGCCCGAAGTGGACTTCAGTACAACTCACTGGAAGAAATACACATATTTGTC 
   661 CTTTGCAACATCCTCAGAAGGCCAATCATTGTCATTTCAGACAAAATGCTAAGAAGTTTG 
   721 GAATCAGGTTCCAATTTCGCCCCTTTGAAAGTGGGTGGAATTTACTTGCCTCTCCACTGG 
   781 CCTGCCCAGGAATGCTACAGATACCCCATTGTTCTCGGCTATGACAGCCATCATTTTGTA 
   841 CCCTTGGTGACCCTGAAGGACAGTGGGCCTGAAATCCGAGCTGTTCCACTTGTTAACAGA 
   901 GACCGGGGAAGATTTGAAGACTTAAAAGTTCACTTTTTGACAGATCCTGAAAATGAGATG 
   961 AAGGAGAAGCTCTTAAAAGAGTACTTAATGGTGATAGAAATCCCCGTCCAAGGCTGGGAC 
  1021 CATGGCACAACTCATCTCATCAATGCCGCAAAGTTGGATGAAGCTAACTTACCAAAAGAA 
  1081 ATCAATCTGGTAGATGATTACTTTGAACTTGTTCAGCATGAGTACAAGAAATGGCAGGAA 
  1141 AACAGCGAGCAGGGGAGGAGAGAGGGGCACGCCCAGAATCCCATGGAACCTTCCGTGCCC 
  1201 CAGCTTTCTCTCATGGATGTAAAATGTGAAACGCCCAACTGCCCCTTCTTCATGTCTGTG 
  1261 AACACCCAGCCTTTATGCCATGAGTGCTCAGAGAGGCGGCAAAAGAATCAAAACAAACTC 
  1321 CCAAAGCTGAACTCCAAGCCGGGCCCTGAGGGGCTCCCTGGCATGGCGCTCGGGGCCTCT 
  1381 CGGGGAGAAGCCTATGAGCCCTTGGCGTGGAACCCTGAGGAGTCCACTGGGGGGCCTCAT 
  1441 TCGGCCCCACCGACAGCACCCAGCCCTTTTCTGTTCAGTGAGACCACTGCCATGAAGTGC 
  1501 AGGAGCCCCGGCTGCCCCTTCACACTGAATGTGCAGCACAACGGATTTTGTGAACGTTGC 
  1561 CACAACGCCCGGCAACTTCACGCCAGCCACGCCCCAGACCACACAAGGCACTTGGATCCC 
  1621 GGGAAGTGCCAAGCCTGCCTCCAGGATGTTACCAGGACATTTAATGGGATCTGCAGTACT 
  1681 TGCTTCAAAAGGACTACAGCAGAGGCCTCCTCCAGCCTCAGCACCAGCCTCCCTCCTTCC 
  1741 TGTCACCAGCGTTCCAAGTCAGATCCCTCGCGGCTCGTCCGGAGCCCCTCCCCGCATTCT 
  1801 TGCCACAGAGCTGGAAACGACGCCCCTGCTGGCTGCCTGTCTCAAGCTGCACGGACTCCT 
  1861 GGGGACAGGACGGGGACGAGCAAGTGCAGAAAAGCCGGCTGCGTGTATTTTGGGACTCCA 
  1921 GAAAACAAGGGCTTTTGCACACTGTGTTTCATCGAGTACAGAGAAAACAAACATTTTGCT 
  1981 GCTGCCTCAGGGAAAGTCAGTCCCACAGCGTCCAGGTTCCAGAACACCATTCCGTGCCTG 
  2041 GGGAGGGAATGCGGCACCCTTGGAAGCACCATGTTTGAAGGATACTGCCAGAAGTGTTTC 
  2101 ATTGAAGCTCAGAATCAGAGATTTCATGAGGCCAAAAGGACAGAAGAGCAACTGAGATCG 
  2161 AGCCAGCGCAGAGATGTGCCTCGAACCACACAAAGCACCTCAAGGCCCAAGTGCGCCCGG 
  2221 GCCTCCTGCAAGAACATCCTGGCCTGCCGCAGCGAGGAGCTCTGCATGGAGTGTCAGCAT 
  2281 CCCAACCAGAGGATGGGCCCTGGGGCCCACCGGGGTGAGCCTGCCCCCGAAGACCCCCCC 
  2341 AAGCAGCGTTGCCGGGCCCCCGCCTGTGATCATTTTGGCAATGCCAAGTGCAACGGCTAC 
  2401 TGCAACGAATGCTTTCAGTTCAAGCAGATGTATGGCTAACCGGAAACAGGTGGGTCACCT 
  2461 CCTGCAAGAAGTGGGGCCTCGAGCTGTCAGTCATCATGGTGCTATCCTCTGAACCCCTCA 
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TAX1BP1cDNA 
 
 
     1 GGAAGAGACCGCCCCGTGGGCGGAAGTGACGCAAGGCCTACTGTCGGCTGGGAGGGGAGG 
    61 TGTAGCCGGTCTTTGGGGGTAGGCGGTAGTGGCGGAAGAGGTTCGGCGGCTGATGGCGGA 
   121 TCAGGATCGGAAGCCTGCGTAACTTTCTCCCTTGATCCGGGAGTCTTTCCACTGGATTCA 
   181 CAATGACATCCTTTCAAGAAGTCCCATTGCAGACTTCCAACTTTGCCCATGTCATCTTTC 
   241 AAAATGTGGCCAAGAGTTACCTTCCTAATGCACACCTGGAATGTCATTACACCTTAACTC 
   301 CATATATTCATCCACATCCAAAAGATTGGGTTGGTATATTCAAGGTTGGATGGAGTACTG 
   361 CTCGTGATTATTACACGTTTTTATGGTCCCCTATGCCTGAACATTATGTGGAAGGATCAA 
   421 CAGTCAATTGTGTACTAGCATTCCAAGGATATTACCTTCCAAATGATGATGGAGAATTTT 
   481 ATCAGTTCTGTTACGTTACCCATAAGGGTGAAATTCGTGGAGCAAGTACACCTTTCCAGT 
   541 TTCGAGCTTCTTCTCCAGTTGAAGAGCTGCTTACTATGGAAGATGAAGGAAATTCTGACA 
   601 TGTTAGTGGTGACCACAAAAGCAGGCCTTCTTGAGTTGAAAATTGAGAAAACCATGAAAG 
   661 AAAAAGAAGAACTGTTAAAGTTAATTGCCGTTCTGGAAAAAGAAACAGCACAACTTCGAG 
   721 AACAAGTTGGGAGAATGGAAAGAGAACTTAACCATGAGAAAGAAAGATGTGACCAACTGC 
   781 AAGCAGAACAAAAGGGTCTTACTGAAGTAACACAAAGCTTAAAAATGGAAAATGAAGAGT 
   841 TTAAGAAGAGGTTCAGTGATGCTACATCCAAAGCCCATCAGCTTGAGGAAGATATTGTGT 
   901 CAGTAACACATAAAGCAATTGAAAAAGAAACCGAATTAGACAGTTTAAAGGACAAACTCA 
   961 AGAAGGCACAACATGAAAGAGAACAACTTGAATGTCAGTTGAAGACAGAGAAGGATGAAA 
  1021 AGGAACTTTATAAGGTACATTTGAAGAATACAGAAATAGAAAATACCAAGCTTATGTCAG 
  1081 AGGTCCAGACTTTAAAAAATTTAGATGGGAACAAAGAAAGCGTGATTACTCATTTCAAAG 
  1141 AAGAGATTGGCAGGCTGCAGTTATGTTTGGCTGAAAAGGAAAATCTGCAAAGAACTTTCC 
  1201 TGCTTACAACCTCAAGTAAAGAAGATACTTGTTTTTTAAAGGAGCAACTTCGTAAAGCAG 
  1261 AGGAACAGGTTCAGGCAACTCGGCAAGAAGTTGTCTTTCTGGCTAAAGAACTCAGTGATG 
  1321 CTGTCAACGTACGAGACAGAACGATGGCAGACCTGCATACTGCACGCTTGGAAAACGAGA 
  1381 AAGTGAAAAAGCAGTTAGCTGATGCAGTGGCAGAACTTAAACTAAATGCTATGAAAAAAG 
  1441 ATCAGGACAAGACTGATACACTGGAACACGAACTAAGAAGAGAAGTTGAAGATCTGAAAC 
  1501 TCCGTCTTCAGATGGCTGCAGACCATTATAAAGAAAAATTTAAGGAATGCCAAAGGCTCC 
  1561 AAAAACAAATAAACAAACTTTCAGATCAATCAGCTAATAATAATAATGTCTTCACAAAGA 
  1621 AAACGGGGAATCAGCAGAAAGTGAATGATGCTTCAGTAAACACAGACCCAGCCACTTCTG 
  1681 CCTCTACTGTAGATGTAAAGCCATCACCTTCTGCAGCAGAGGCAGATTTTGACATAGTAA 
  1741 CAAAGGGGCAAGTCTGTGAAATGACCAAAGAAATTGCTGACAAAACAGAAAAGTATAATA 
  1801 AATGTAAACAACTCTTGCAGGATGAGAAAGCAAAATGCAATAAATATGCTGATGAACTTG 
  1861 CAAAAATGGAGCTGAAATGGAAAGAACAAGTGAAAATTGCTGAAAATGTAAAACTTGAAC 
  1921 TAGCTGAAGTACAGGACAATTATAAAGAACTTAAAAGGAGTCTAGAAAATCCAGCAGAAA 
  1981 GGAAAATGGAAGATGGAGCAGATGGTGCTTTTTACCCAGATGAAATACAAAGGCCACCTG 
  2041 TCAGAGTCCCCTCTTGGGGACTGGAAGACAATGTTGTCTGCAGCCAGCCTGCTCGAAACT 
  2101 TTAGTCGGCCTGATGGCTTAGAGGACTCTGAGGATAGCAAAGAAGATGAGAATGTGCCTA 
  2161 CTGCTCCTGATCCTCCAAGTCAACATTTACGTGGGCATGGGACAGGCTTTTGCTTTGATT 
  2221 CCAGCTTTGATGTTCACAAGAAGTGTCCCCTCTGTGAGTTAATGTTTCCTCCTAACTATG 
  2281 ATCAGAGCAAATTTGAAGAACATGTTGAAAGTCACTGGAAGGTGTGCCCGATGTGCAGCG 
  2341 AGCAGTTCCCTCCTGACTATGACCAGCAGGTGTTTGAAAGGCATGTGCAGACCCATTTTG 
  2401 ATCAGAATGTTCTAAATTTTGACTAGTTACTTTTTATTATGAGTTAATATAGTTTAGCAG 
  2461 TAAAAAAAAAAAAAAAAA 
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       ATGAGCACAAGCCTGGGAGATGGCAGTGAT                                                                  
   121 GGAAATGGCCTGCCCAGGTGCCCCTGGCTCAGCAGTGGGGCAGCAGAAGGAACTCCCCAA 
   181 AGCCAAGGAGAAGACGCCGCCACTGGGGAAGAAACAGAGCTCCGTCTACAAGCTTGAGGC 
   241 CGTGGAGAAGAGCCCTGTGTTCTGCGGAAAGTGGGAGATCCTGAATGACGTGATTACCAA 
   301 GGGCACAGCCAAGGAAGGCTCCGAGGCAGGGCCAGCTGCCATCTCTATCATCGCCCAGGC 
   361 TGAGTGTGAGAATAGCCAAGAGTTCAGCCCCACCTTTTCAGAACGCATTTTCATCGCTGG 
   421 GTCCAAACAGTACAGCCAGTCCGAGAGTCTTGATCAGATCCCCAACAATGTGGCCCATGC 
   481 TACAGAGGGCAAAATGGCCCGTGTGTGTTGGAAGGGAAAGCGTCGCAGCAAAGCCCGGAA 
   541 GAAACGGAAGAAGAAGAGCTCAAAGTCCCTGGCTCATGCAGGAGTGGCCTTGGCCAAACC 
   601 CCTCCCCAGGACCCCTGAGCAGGAGAGCTGCACCATCCCAGTGCAGGAGGATGAGTCTCC 
   661 ACTCGGCGCCCCATATGTTAGAAACACCCCGCAGTTCACCAAGCCTCTGAAGGAACCAGG 
   721 CCTTGGGCAACTCTGTTTTAAGCAGCTTGGCGAGGGCCTACGGGCTCTGCCTCGATCAGA 
   781 ACTCCACAAACTGATCAGCCCCTTGCAATGTCTGAACCACGTGTGGAAACTGCACCACCC 
   841 CCAGGACGGAGGCCCCCTGCCCCTGCCCACGCACCCCTTCCCCTATAGCAGACTGCCTCA 
   901 TCCCTTCCCATTCCACCCTCTCCAGCCCTGGAAACCTCACCCTCTGGAGTCCTTCCTGGG 
   961 CAAACTGGCCTGTGTAGACAGCCAGAAACCCTTGCCTGACCCACACCTGAGCAAACTGGC 
  1021 CTGTGTAGACAGTCCAAAGCCCCTGCCTGGCCCACACCTGGAGCCCAGCTGCCTGTCTCG 
  1081 TGGTGCCCATGAGAAGTTTTCTGTGGAGGAATACCTAGTGCATGCTCTGCAAGGCAGCGT 
  1141 GAGCTCAGGCCAGGCCCACAGCCTGACCAGCCTGGCCAAGACCTGGGCAGCAAGGGGCTC 
  1201 CAGATCCCGGGAGCCCAGCCCCAAAACTGAGGACAACGAGGGTGTCCTGCTCACTGAGAA 
  1261 ACTCAAGCCAGTGGATTATGAGTACCGAGAAGAAGTCCACTGGGCCACGCACCAGCTCCG 
  1321 CCTGGGCAGAGGCTCCTTCGGAGAGGTGCACAGGATGGAGGACAAGCAGACTGGCTTCCA 
  1381 GTGCGCTGTCAAAAAGGTGCGGCTGGAAGTATTTCGGGCAGAGGAGCTGATGGCATGTGC 
  1441 AGGATTGACCTCACCCAGAATTGTCCCTTTGTATGGAGCTGTGAGAGAAGGGCCTTGGGT 
  1501 CAACATCTTCATGGAGCTGCTGGAAGGTGGCTCCCTGGGCCAGCTGGTCAAGGAGCAGGG 
  1561 CTGTCTCCCAGAGGACCGGGCCCTGTACTACCTGGGCCAGGCCCTGGAGGGTCTGGAATA 
  1621 CCTCCACTCACGAAGGATTCTGCATGGGGACGTCAAAGCTGACAACGTGCTCCTGTCCAG 
  1681 CGATGGGAGCCACGCAGCCCTCTGTGACTTTGGCCATGCTGTGTGTCTTCAACCTGATGG 
  1741 CCTGGGAAAGTCCTTGCTCACAGGGGACTACATCCCTGGCACAGAGACCCACATGGCTCC 
  1801 GGAGGTGGTGCTGGGCAGGAGCTGCGACGCCAAGGTGGATGTCTGGAGCAGCTGCTGTAT 
  1861 GATGCTGCACATGCTCAACGGCTGCCACCCCTGGACTCAGTTCTTCCGAGGGCCGCTCTG 
  1921 CCTCAAGATTGCCAGCGAGCCTCCGCCTGTGAGGGAGATCCCACCCTCCTGCGCCCCTCT 
  1981 CACAGCCCAGGCCATCCAAGAGGGGCTGAGGAAAGAGCCCATCCACCGCGTGTCTGCAGC 
  2041 GGAGCTGGGAGGGAAGGTGAACCGGGCACTACAGCAAGTGGGAGGTCTGAAGAGCCCTTG 
  2101 GAGGGGAGAATATAAAGAACCAAGACATCCACCGCCAAATCAAGCCAATTACCACCAGAC 
  2161 CCTCCATGCCCAGCCGAGAGAGCTTTCGCCAAGGGCCCCAGGGCCCCGGCCAGCTGAGGA 
  2221 GACAACAGGCAGAGCCCCTAAGCTCCAGCCTCCTCTCCCACCAGAGCCCCCAGAGCCAAA 
  2281 CAAGTCTCCTCCCTTGACTTTGAGCAAGGAGGAGTCTGGGATGTGGGAACCCTTACCTCT 
  2341 GTCCTCCCTGGAGCCAGCCCCTGCCAGAAACCCCAGCTCACCAGAGCGGAAAGCAACCGT 
  2401 CCCGGAGCAGGAACTGCAGCAGCTGGAAATAGAATTATTCCTCAACAGCCTGTCCCAGCC 
  2461 ATTTTCTCTGGAGGAGCAGGAGCAAATTCTCTCGTGCCTCAGCATCGACAGCCTCTCCCT 
  2521 GTCGGATGACAGTGAGAAGAACCCATCAAAGGCCTCTCAAAGCTCGCGGGACACCCTGAG 
  2581 CTCAGGCGTACACTCCTGGAGCAGCCAGGCCGAGGCTCGAAGCTCCAGCTGGAACATGGT 
  2641 GCTGGCCCGGGGGCGGCCCACCGACACCCCAAGCTATTTCAATGGTGTGAAAGTCCAAAT 
  2701 ACAGTCTCTTAATGGTGAACACCTGCACATCCGGGAGTTCCACCGGGTCAAAGTGGGAGA 
  2761 CATCGCCACTGGCATCAGCAGCCAGATCCCAGCTGCAGCCTTCAGCTTGGTCACCAAAGA 
  2821 CGGGCAGCCTGTTCGCTACGACATGGAGGTGCCAGACTCGGGCATCGACCTGCAGTGCAC 
  2881 ACTGGCCCCTGATGGCAGCTTCGCCTGGAGCTGGAGGGTCAAGCATGGCCAGCTGGAGAA 
  2941 CAGGCCCTAACCCTGCCCTCCACCGCCGGCTCCAC    
 
NFKB2 from BIOMATIK 
gctagcATGGAGAGTTGCTACAACCCAGGTCTGGATGGTATTATTGAATATGATGATTTCAAATTGAACTCCTC
CATTGTGGAACCCAAGGAGCCAGCCCCAGAAACAGCTGATGGCCCCTACCTGGTGATCGTGGAACAGCCTAAGC
AGAGAGGCTTCCGATTTCGATATGGCTGTGAAGGCCCCTCCCATGGAGGACTGCCCGGTGCCTCCAGTGAGAAG
GGCCGAAAGACCTATCCCACTGTCAAGATCTGTAACTACGAGGGACCAGCCAAGATCGAGGTGGACCTGGTAAC
ACACAGTGACCCACCTCGTGCTCATGCCCACAGTCTGGTGGGCAAGCAATGCTCGGAGCTGGGGATCTGCGCCG
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TTTCTGTGGGGCCCAAGGACATGACTGCCCAATTTAACAACCTGGGTGTCCTGCATGTGACTAAGAAGAACATG
ATGGGGACTATGATACAAAAACTTCAGAGGCAGCGGCTCCGCTCTAGGCCCCAGGGCCTTACGGAGGCCGAGCA
GCGGGAGCTGGAGCAAGAGGCCAAAGAACTGAAGAAGGTGATGGATCTGAGTATAGTGCGGCTGCGCTTCTCTG
CCTTCCTTAGAGCCAGTGATGGCTCCTTCTCCCTGCCCCTGAAGCCAGTCATCTCCCAGCCCATCCATGACAGC
AAATCTCCGGGGGCATCAAACCTGAAGATTTCTCGAATGGACAAGACAGCAGGCTCTGTGCGGGGTGGAGATGA
AGTTTATCTGCTTTGTGACAAGGTGCAGAAAGATGACATTGAGGTTCGGTTCTATGAGGATGATGAGAATGGAT
GGCAGGCCTTTGGGGACTTCTCTCCCACAGATGTGCATAAACAGTATGCCATTGTGTTCCGGACACCCCCCTAT
CACAAGATGAAGATTGAGCGGCCTGTAACAGTGTTTCTGCAACTGAAACGCAAGCGAGGAGGGGACGTGTCTGA
TTCCAAACAGTTCACCTATTACCCTCTGGTGGAAGACAAGGAAGAGGTGCAGCGGAAGCGGAGGAAGGCCTTGC
CCACCTTCTCCCAGCCCTTCGGGGGTGGCTCCCACATGGGTGGAGGCTCTGGGGGTGCAGCCGGGGGCTACGGA
GGAGCTGGAGGAGGTGGCAGCCTCGGTTTCTTCCCCTCCTCCCTGGCCTACAGCCCCTACCAGTCCGGCGCGGG
CCCCATGGGCTGCTACCCGGGAGGCGGGGGCGGGGCGCAGATGGCCGCCACGGTGCCCAGCAGGGACTCCGGGG
AGGAAGCCGCGGAGCCAAGCGCCCCCTCCAGGACCCCCCAGTGCGAGCCGCAGGCCCCGGAGATGCTGCAGCGA
GCTCGAGAGTACAACGCGCGCCTGTTCGGCCTGGCGCAGCGCAGCGCCCGAGCCCTACTCGACTACGGCGTCAC
CGCGGACGCGCGCGCGCTGCTGGCGGGACAGCGCCACCTGCTGACGGCGCAGGACGAGAACGGAGACACACCAC
TGCACCTAGCCATCATCCACGGGCAGACCAGTGTCATTGAGCAGATAGTCTATGTCATCCACCACGCCCAGGAC
CTCGGCGTTGTCAACCTCACCAACCACCTGCACCAGACGCCCCTGCACCTGGCGGTGATCACGGGGCAGACGAG
TGTGGTGAGCTTTCTGCTGCGGGTAGGTGCAGACCCAGCTCTGCTGGATCGGCATGGAGACTCAGCCATGCATC
TGGCGCTGCGGGCAGGCGCTGGTGCTCCTGAGCTGCTGCGTGCACTGCTTCAGAGTGGAGCTCCTGCTGTGCCC
CAGCTGTTGCATATGCCTGACTTTGAGGGACTGTATCCAGTACACCTGGCAGTCCGAGCCCGAAGCCCTGAGTG
CCTGGATCTGCTGGTGGACAGTGGGGCTGAAGTGGAGGCCACAGAGCGGCAGGGGGGACGAACAGCCTTGCATC
TAGCCACAGAGATGGAGGAGCTGGGGTTGGTCACCCATCTGGTCACCAAGCTCCGGGCCAACGTGAACGCTCGC
ACCTTTGCGGGAAACACACCCCTGCACCTGGCAGCTGGACTGGGGTACCCGACCCTCACCCGCCTCCTTCTGAA
GGCTGGTGCTGACATCCATGCTGAAAACGAGGAGCCCCTGTGCCCACTGCCTTCACCCCCTACCTCTGATAGCG
ACTCGGACTCTGAAGGGCCTGAGAAGGACACCCGAAGCAGCTTCCGGGGCCACACGCCTCTTGACCTCACTTGC
AGCACCAAGGTGAAGACCTTGCTGCTAAATGCTGCTCAGAACACCATGGAGCCACCCCTGACCCCGCCCAGCCC
AGCAGGGCCGGGACTGTCACTTGGTGATACAGCTCTGCAGAACCTGGAGCAGCTGCTAGACGGGCCAGAAGCCC
AGGGCAGCTGGGCAGAGCTGGCAGAGCGTCTGGGGCTGCGCAGCCTGGTAGACACGTACCGACAGACAACCTCA
CCCAGTGGCAGCCTCCTGCGCAGCTACGAGCTGGCTGGCGGGGACCTGGCAGGTCTACTGGAGGCCCTGTCTGA
CATGGGCCTAGAGGAGGGAGTGAGGCTGCTGAGGGGTCCAGAAACCCGAGACAAGCTGCCCAGCACAGCAGAGG
TGAAGGAAGACAGTGCGTACGGGAGCCAGTCAGTGGAGCAGGAGGCAGAGAAGCTGGGCCCACCCCCTGAGCCA
CCAGGAGGGCTCTGCCACGGGCACCCCCAGCCTCAGGTGCACTGAggatcc 
 
Appendix II. Antibody cocktail mix 
1. B cells 
Marker Fluorescent Ratio volume 
CD19 Pecy7 1:80 12.5 
CD3 APC 1:10 100 
CD27 FITC 1:20 50 
CD38 V450 1:300 3.3 
FACS wash   834.2 
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2. 10 colour B cells 
 Marker Fluorescent Ratio volume 
1st staining CD19 Pecy7 1:80 12.5 
CD3 AF700 1:50 20 
CD27 APC 1:80 12.5 
CD21 PerCP Cy5.5 1:100 10 
CD38 V450 1:160 6.25 
CD24 CF594 1:20 50 
IgM FITC 1:120 8.3 
IgD PE 1:80 12.5 
IgA Biotin 1:320 3.1 
FACS wash   864.8 
2nd staining Streptavidin V500 1:1600 0.63 
FACS wash   999.4 
 
3. Transitional B cells 
Marker Fluorescent Ratio volume 
CD19 Pecy7 1:80 12.5 
CD3 FITC 1:100 10 
CD27 APC 1:80 12.5 
CD21 PeCy5 1:100 10 
CD10 PE 1:20 50 
FACS wash   905 
 
4. T cell distribution 
Marker Fluorescent Ratio volume 
CD3 FITC 1:100 10 
CD4 PerCP 1:20 50 
CD8 PE 1:200 5 
CD45RA Pacific Blue 1:300 3.3 
CCR7 Pecy7 1:20 50 
FACS wash   876.7 
 
5. Tfh and Effector T cells 
Marker Fluorescent Ratio volume 
CD3 APC 1:10 100 
CD4 PerCP 1:20 50 
CD45RA FITC 1:10 100 
CXCR3 BV510 1:40 25 
CCR6 PE 1:20 50 
CCR7 Pecy7 1:20 50 
FACS wash   625 
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6. Treg 
 Marker Fluorescent Ratio volume 
Surface CD4 PerCP 1:50 20 
CD25 APC 1:6 167 
CD127 FITC 1:20 50 
FACS wash   763 
intercellular FoxP3 PE 1:6 167 
FACS wash   833 
 
Appendix III Gene lists 
 
NF-kB target genes 
AHR, BANK1, BATF, BCL2, BCL2A1, BCL2L1, BIRC2, BIRC3, BUB1B, CCL2, 
CCL22, CCL3, CCL4, CCND2, CCR4, CCR7, CD36, CD40, CD40LG, CD44, CD69, 
CD82, CD83, CFLAR, CISH, CSF2, CX3CL1, CXCL1, CXCL10, CXCL13, CXCL2, 
CXCL9, CXCR7, DUSP1, DUSP2, EBI3, EGR1, ELL2, EMR1, FAS, FGF12, FNDC3A, 
GADD45B, HLA-F, HSPA1L, ICAM1, ID2, IER2, IER3, IL10, IL15RA, IL1B, IL2, 
IL2RA, IL32, IL6, IL8, IRF1, IRF4, JUNB, KLF10, LSP1, LTA, LYN, MAP3K1, 
MAP3K8, MYB, NCL, NFKB1, NFKB2, NFKBIA, NFKBIE, PASK, PIM1, PIM2, PLEK, 
PRKCD, PRPF4B, PTGS2, PTPN1, PTPN3, RASGRP1, REL, RELB, RET, RFTN1, 
RGS1, RRAS2, SDC4, SELL, SLAMF7, SLC2A5, SMAD7, SMARCA2, SOCS2, SOD2, 
SPI1, STAT1, STAT5A, STX4, TNF, TNFAIP3, TNIP2, TPMT, TRAF1, VIM, WTAP, 
ZFP36L1 
 
BLK pathway genes 
ABL1, B4GALT1, CL2L1, BCL2L11, BLK, BLNK, BMX, BTK, CBL, CBLB, CD19, 
CD72,CD79A, CD79B, DAPP1, DCLRE1C, ECSIT, EPO, FADD, FASLG, FCER1A, 
FCER1G, FGR, FOS, FYN, GAPDH, GP6, GRAP2, GRB2, GTF2I, HCK, HRAS, IBTK, 
IGHE, INPP5D, IRAK1, IRAK2, IRAK3, IRAK4, ITK, ITPR3, JAK1, JAK2, JUN, 
KHDRBS1, KIT, LCK, LYN, MAP3K1, MYD88, NCK1, PIK3AP1, PIK3CA, PIK3CB, 
PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5, PIP4K2A, PLCG1, PLCG2, 
PLCG2, PLEK, PRKCA, PRKCB, PRKCE, PRKCQ, PRKCZ, PRKD1, PTPN6, RAC1, 
RELA, RPS6KB1, SH3BP5, SH3KBP1, SIGIRR, SOS1, SRC, STAT5A, SYK, TEC, 
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TIRAP, TLR4, TLR6, TLR8, TLR9, TNFRSF11A, TP53, TRAF6, TREM2, TYROBP, 
VAV1, VAV2, VAV3, WAS, ,YES1, ZAP70 
 
A20 interacting gene list from BioGrid and string 
ALDH9A1, ARRDC3, AXIN1, BECN1,BioGRid A20, BioGRid A20, BIRC2, BIRC3, 
CASP8, CCDC50, CHUK, CNKSR2, FADD, FBXO3, GIT2, GLDC, HSP90AA1, 
IKBKB, IKBKE, IKBKG, IL17A, IL17RA, IRAK1, IRAK2, IRF7, ITCH, KIF11, LAMP1, 
LAPTM5, LMP1, LRRC47, MALT1, MAP3K5, MCM6, NAF1, NDUFS1, NFKB1, 
NFKB2, NFKBIA, NXF1, OCLN, OLIG3, PPP2R1B, PPP6R3, PTPN22, RARRES3, 
RBCK1, RELA, RIPK1, RIPK2, RLIM, RNF11, RNF114, RNF31, RNF5, RNH1, 
RPS27A, SHARPIN, STAT4, TAX1BP1, TBK1, TICAM1, TNF, TNFAIP3, TNFRSF10B, 
TNFRSF1A, TNFSF10, TNIP1, TNIP2, TNIP3, TP53, TRADD, TRAF1, TRAF2, TRAF6, 
TRIM2, TRIM23, TRIM3, TRIM8, UBC, UBE2D1, UBE2N, YWHAB, YWHAE, 
YWHAG, YWHAH, YWHAQ, YWHAZ 
 
Appendix VI Supplementary experiments 
 
 
 
Supplementary Figure 1 Analysis of transitional B cells in A.II.1 and his family members. CD21 and 
CD10 were gated on CD19+ cells and CD21+ CD10+ cells represent transitional B cells 
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Supplementary Figure 2 Effect of D865>G mutation on NIK induced p100 processing with 
lympotoxin α1β2 stimulation. HEK293 cells were co-transfected with expression vectors encoding wild-
type (WT) or D865 . G mutant NFKB2 together with varying amounts of MAP3K14 expression vector 
encoding NIK and after 24hours cells were simulated with lympotoxin α1β2 or PBS. Six hours prior to 
the stimulation MG132 was added and p100 and p52 detection by western blot  
 
